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Abstract 
Development of reductive aldol cyclisation methodologies in the Lam group led to 
the point where it was possible to initiate a total synthesis using this highly valuable 
transformation. Upon analysis of possible synthetic targets a salinosporamide A (1) 
was chosen. This molecule was recently isolated from marine micro-organisms and 
attracted a lot of attention in scientific community because of its highly bioactive 
properties. 
Scheme 1: Structure of salinosporamide A 
Application of a reductive aldol cyclisation in the formal synthesis of salinospo-
ramide A led to a concise synthetic pathway. A nickel-catalysed reductive aldol cy-
clisation with a sequential lactonisation step was employed in the construction of the 
7-lactaln core of 1. In the key step of synthesis we installed the C2 side-chain of the 'y-
lactam core, the C5 oxygen was protected for later modification and a ready to reduce 
7-lactone ring was prepared for a reduction in a late stage of formal synthesis. 
Upon completion of salinospormaide A (formal synthesis) a new methodology was 
devised. A copper-catalysed asymmetric reduction of 2-alkenylhet.eroarenes was based 
on published procedures for enantioselective reduction of alkenes activated with strong 
electron-withdrawing substituents. We questioned whether a much less electron with-
drawing groups could be used in a similar fashion. A selection of nitrogen based hete-
rocycles have been successfully employed for activation of alkenes. Extensive screening 
of reaction conditions afforded a high yielding and selective catalyst system for the 
asymmetric reduction of conjugated 2-alkenylheteroarenes. 
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°C degrees celsius 
Ac acetyl 
acac acetyl acetonate 
AIBN 2,2-azobis (isobutyronitrile) 
Aq aqueous 
Ar aromatic group 
Atm atmosphere(s) 
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CAN Cerium (IV) ammonium nitrate 
Cat catalytic; catalyst 
COD cyclooctadiene 
Cp cyclopentadiene 





DCC N, N-dicyclohexylcarbodiimide 
VI 
dd doublet of doublets 
DEPT distortionless enhancement by polarization transfer 
DIBAL-H diisobutylaluminium hydride 
DIG N, N-diisopropylcarbodiimide 




DMS dimethyl sulfide 
DMSO dimethylsulfoxide 
DPPB 1, 2- bis (diphenyl-phosphino) but ane 
DPPE 1 ,2-bis(diphenylphosphino)ethane 
DPPF 1,1 -bis(diphenylphosphino)ferrocene 
dr diastereorneric ratio 
(S,S)-Et-DuPhos (+)- 1, 2-bis((2S, 5S)-2,5-diethylphospholano) benzene 
EDC 1- [3- (dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride 
ee enantiomeric excess 
El electron ionization 
EtOAc ethyl acetate 
equiv equivalents 
ESI electrospray ionisation 
Et ethyl 
FAB fast atom bombardment 
g 	 gram 
h 	 hour 
HMPA 	 hexametylphosphoramide 
HOBt 	 1-hydroxybenzotriazole 
HPLC 	 high performance liquid chromatography 




JR infra red spectroscopy 
J coupling constant 
KHMDS potassium bis-(trimethylsilyl)amide 
L litre 
LDA lithium diisopropylamide 
LHMDS lithium bis- (trirnethylsilyl) amide 
LRMS low resolution mass spectrometry 
MAO inethylaluminoxane 
M Molar 










MsCl methanesulfonyl chloride 
NaHMDS sodium bis- (trimethylsilyl) amide 
NBS N-bromosuccinimide 
NIS N-iodosuccinimide 
NMR nuclear magnetic resonance 




PMHS poly methyihydrosiloxane 
ppm parts per million 
Pr propyl 
p-TsOH p-toluenesulfonic acid 
pybox 2,6-bis(oxazolinyl) pyridine 
q quartet 
rac-BINAP racemic 2,2 -bis(diphenylphosphino)- 1,1 -binaphthyl 
rt room temperature 
sal salicylaldehydate 




TfOH trifluoromethanesulfonic acid 
THE' tetrahydrofuran 
Thr threonine 
TLC thin layer chromatography 
TBAF tetrabutylammonium fluoride 





Formal Synthesis of 
Salinosporamide A 
The synthesis of naturally occurring compounds has been the foundation of organic 
chemistry. The first synthesis of this kind was the synthesis of urea [CO(NH2 )2] by 
Woehier in 1828.' It was followed by the synthesis of acetic acid  (Kolbe, 1845), 
glucose' (Fischer, 1890), camphor (Komppa, 1903) and many others. Modern chemists 
consider these compounds as building blocks (because of their simplicity) and not 
synthetic targets. Several generations of chemists have provided us with the tools and 
skills that allow the synthesis of almost any desired molecule. However, despite this 
long history and over 20 Nobel Prizes awarded for related fields organic synthesis is 
still full of challenges. 
Advances in transition metal-catalysed cyclisation reactions have provided the means 
to access increasingly diverse carbocyclic and heterocyclic compounds from relatively 
simple starting materials, often with impressive levels of diastereo- and enantioselec-
tivity.4 '6 Reductive cyclisations, where the reaction is promoted by stoichiometric 
reductants such as molecular hydrogen, silanes, formic acid, stannanes, borohydrides 
or main group organometallic reagents, represent an important class of these transfor-
mations.'0 '6 Many of these reactions have been developed to a level of utility that 
enable their application in natural product synthesis.' 7 25 
1 
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Scheme 1.1: Example of reductive aldol cyclisation 
Previous research in the Lam group has led to the development of a series of metal-
catalysed reductive aldol cyclisation reactions that form /3-hydroxylactones and 3-
hydroxylactams in a highly diastereoselective fashion .26-2'  A notable result is the 
cyclisation of 2 using Ni(acac)2 as the precatalyst and Et2 Zn as the stoichiometric 
reductant, which provided 3-hydroxy-'y-lactam 3 as a single diastereomer.29' 3° This 
outcome was of interest to us because examination of the structure of 3 revealed 
similarities with the core of salinosporarnide A (1) (Scheme 1.2), a secondary metabolite 
isolated by Fenical.3' A full discussion of nickel catalysed reductive aldol reactions will 
be provided in section 1.3. 
Scheme 1.2: Structure of Salinosporamide A 
1.1 Biological background 
Salinosporamide A (1) is structurally related to omuralide 5 (isolated in 1991 by 
Omura 32,33)  Omuralide was one of the first 20S proteasome inhibitors. This complex 
regulates protein degradation and can be an important target for anti-cancer drugs. 
2 






 Scheme 1.3: Analogues of Salinosporamide A 
Ubiquit in-mediated proteolysis 
A large part of protein degradation is mediated through the ubiquitin pathway. Ubiq-
uitin is a highly conserved 76 amino acid protein capable of being covalently linked 
to lysine residues in protein targets. A cascade of enzymatic events that covalently 
tag substrates with polyubiquitin chains most commonly trigger regulated intracellu-
lar protein degradation by a multisubunit protease known as the proteasome. 
Protein degradation is a commonly employed mechanism for the control of protein 
abundance. It is a particularly effective method for promoting unidirectional cell cycle 
transitions because of its rapidity and irreversibility. Major cell cycle transitions require 
the degradation of specific proteins via the ubiquitin-26S proteasome pathway. The 
formation of ubiquitin-protein conjugates involves three components that participate 
in a cascade of ubiquitin transfer reactions. Ubiquitin is activated as a thiol-ester on El 
in an ATP dependent reaction, transferred to an E2 as a thiol ester and, in conjunction 
with an E3, which functions in substrate recognition and also serves as a thiol-ubiquitin 
carrier. Together, these enzymes polyubiquitinate lysine residues in target proteins 
through formation of isopeptide bonds with ubiquitin, leading to recognition by the 
26S proteasome and protein destruction. 
20S Proteasome inhibition 
The 26S proteasome (a 2 MDa complex) is made up of two subcomplexes: the 20S 
proteasome and the regulatory complex. The former is a 700 kDa cylindrical protease 
complex consisting of four stacks of heptameric rings with 28 subunits with molecular 
masses of about 20-35 kDa, whereas the latter is a 700-1000 kDa complex consisting 
3 
Dihydroeponemycin 
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of at least 18 subunits with molecular masses of 28-110 kDa. 
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Scheme 1.4: Examples of proteasorne inhibitors 
Enzyme-specific inhibitors of proteases are usually short peptides linked to a phar-
macophore (Scheme 1.4). The pharmacophore interacts with a catalytic residue result-
ing in the formation of a reversible or an irreversible covalent adduct, while the peptide 
portion specifically associates with the enzyme substrate binding pocket at the active 
site. Although the proteasome has multiple active sites, inhibition of all of them is not 
required to significantly reduce protein breakdown. 34-36 
Examples of non-peptide inhibitors are lactacystin and omuralide. Lactacystin 6 
is a Streptomyces metabolite, which was discovered by Omura and was later synthe-
sised by Corey and co-workers.37 Subsequent studies demonstrated that 6 itself is not 
active against proteasomes in vitro but, undergoes spontaneous transition to clasto-
1actacystin-3-lactone,38 for which the name "omuralide" (5 was suggested (Scheme 
Kinetic analysis demonstrated that this 3-lactone, but not lactacystin, re-
acts with the proteasome's active site threonines,38 resulting in the opening of the 
/3-lactone ring and acylation of the proteasome's catalytic hydroxyl. The structure of 
the lactacystin-proteasome complex was determined by X-ray diffraction, and provided 
strong evidence that an acyl enzyme conjugate is indeed an intermediate in catalysis 
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by the proteasome. 39 
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Scheme 1.5: New class of proteasome inhibitors 
Discovery of salinosporamide A 
In 2003, Fenical and co-workers isolated salinosporaniide A (Scheme 1.2) from marine 
actinornycete bacteria of Salinospora strain CNB-392.3' This compound has attracted 
significant attention because of its impressive biological activity.3' Salinosporamide A 
(1) inhibits proteasomal proteolytic activity with an IC50 value of 1.3 nM. In a paral-
lel assay, the IC50 of 5 was 49 nM. Structurally, 1 shares its fused 7-lactam-3-lactone 
bicyclic core with omuralide (5), Although omuralide (5) is also an effective 20S protea-
some inhibitor, differences between 1 and 5 at C2, C3 and C5 render 1 approximately 
35 times more potent than 531  Moreover, 1 has potent in vitro cytotoxicity (LC50 
10 nM), and it also exhibits promising potential as an anti-cancer therapeutic agent. 
Indeed, 1 is currently in clinical trials for this purpose. 40-42  X-ray crystallographic 
CI 	 NH 	CI NH 	 NH 
	
Enz 	 Enz 
1 	 7 	 8 
Scheme 1.6: Irreversible binding of Salinosporamide A to proteasome 
studies revealed that 1 binds to the same threonine residue of the proteasome that 
is acylated by 	Higher activity of 1 compared to 6 is attributed to irreversible 
proteasome inhibition by 1 (Scheme 1.6). 
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1.2 Previous syntheses of salinosporamide A 
Salinosporamide A (1) has elicited significant interest from a synthetic perspective, 
with a number of total and partial syntheses having been reported .4453 However, this 
molecule is only a single member of a large family of highly potent drug candidates 
possessing a densely functionalised 'y-lactam-/3-lactone fused ring system. Total syn-
thesis of these compounds is needed to fully understand structure-activity relationships 
and further improve anti-cancer potency. 
1.2.1 Corey's synthesis 
Corey and co-workers were the first group to accomplish an enantioselective total syn-
thesis of salinosporainide A in 2004 .4' Their synthesis was based on previous work by 
Corey on lactacystine and omuralide several years before. 54-57 
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Conditions: (a) p-TsOH, toluene, reflux, 12 h, 80%; (b) LDA, THF-HMPA, 78 °C then C1CH2OBn, 
4 h, 69%; (c) NaCNBH3, AcOH, 40 °C, 12 h, 90%; (d) TMSCI, Et20, 23 °C, 12 h; (e) Acryloyl 
Chloride, iPr2NEt, CH2 C12 , 1 h, 0 °C then H, Et2 0, 23 °C, 1 h, 96%; (f) Dess-Martin periodinane, 
23 °C, 1 h, 96%; (g) Quinuclidine, DME, 0 °C, 7 d, 90%; (h) BrCH2Si(CH3)2C1, Et3N, DMAP, 
CH2 C12, 0 °C, 30 mm, 95%; 
Scheme 1.7: Corey's synthesis 
N-Acylation of (S)-Threonine methyl ester with 4-methoxybenzoyl chloride in DCM 
at 23 °C produced 9 (71%). Cyclisation of 9 to oxazoline 10 (80%) was achieved 
by refluxing in toluene with p-TsOH. Oxazoline 10 was deprotonated with lithium 
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diisopropylamide in a mixture of THF and HMPA at -78 °C and the resultant anion 
was reacted with chloromethyl benzyl ether to selectively form the required quaternary 
stereocentre of 11 in 69% yield. The selective reduction of 11 with NaBH3CN gave the 
N-protected amino alcohol 12 (90%). The successful acylation of secondary amine 12 
required a sequence of protection and deprotection steps. Reaction of 12 with TMSC1 
and Et3N gave the TMS ether, that was acylated with acryloyl chloride at 0 °C, and a 
subsequent work up with HClaq removed the TMS protection to give 13 in 96% overall 
yield. Alcohol 13 was oxidised with Dess-Martin periodinane58' 59 to produce the keto 
amide ester 14 in 96% yield. 
The key transformation of Corey's synthesis of salinosporamide A was intramolecu- 
lar Baylis—Hillman-aldo16164 reaction of 14 using quinuclidine as a catalyst in dimethoxyethane 
at 0 °C for 7 d. The 'y-lactam 15 was obtained in 90% yield and 9:1 diastereoselectiv-
ity, it was demonstrated that this reaction can proceed much faster at 20 °C (only 9 h 
as compared to 7 days). However, the ratio of diastereomers at the higher temperature 
was reduced to 4:1. Silylation of 15 with bromomethyldimethylsilyl chloride afforded 
16 in 95% yield. At this stage the diastereoisomers produced in the Baylis—Hillman 
cyclisation were easily separated by silica gel column chromatography. 
Reaction of 16 with tri-n-butyltin hydride and catalytic AIBN in refluxing benzene 
allowed the formation of the required stereocenters at C2 and C3 through radical-chain 
cyclisation to give 17 in 89% yield. Removal of the benzyl ether and subsequent oxida- 
tion with Dess-Martin periodinane provided 18 in 90%. Alkylation of the aldehyde 18 
with 21 established the last two remaining stereocenters of 19 in 88% yield and with 
an impressive 20:1 diastereomeric ratio. The 2-cyclohexenylzinc chloride (21) reagent 
can be easily obtained from 1 ,2-cyclohexadiene by palladium catalysed 1,2-addition of 
tributyltin hydride and then transmetallation with n-butyllithium and zinc chloride. 
Tamao-Fleming oxidation 65-67  of 19 produced triol 20 in 92% yield. Compound 20 
was transformed in four steps to salinosporamide A (1). Firstly the PMB and methyl 
ester protecting groups were removed using Ce(IV)-driven oxidative cleavage (83%) 
and lithium hydroxide catalysed ester hydrolysis to give the corresponding 'y-lactam- 
7 
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Conditions: (a) Bu3SnH, AIBN, Benzene, reflux, 8 h, 89%; (b) Pd-C, EtOH, H2 (1 atm), 18 h, 95%; 
(c) Dess-Martin periodinane, 23 °C, 1 h, 95%; (d) 21, THF, 78 °C, 5 h, 88%; (e) KF, KHCO3 , H202 , 
THF-MeOH (1:1), 23 °C, 18 h, 92%; (f) CAN, MeCN-H20; (3:1), 0 °C, 1 h, 83%; (g) 3N LiOH-THF 
(3:1), 5 °C, 4 d; (h) BOPC1, pyridine, DCM, 23 °C, 1 h; (i) Ph3PC12 , MeCN, pyridine, 23 °C, 1 h, 
65% (over 3 steps). 
Scheme 1.8: Corey's synthesis 
carboxylic acid. The crude product was converted to fi-lactone-y-1actam with BOPC1 
and chlorination of the primary alcohol afforded salinosporamide A (1) in 65% yield 
over three steps. 
Modifications 
0 	 22 
/-PrO. 
IPMB 


















Conditions: (a) Ti(Oi-Pr)4 (4 equiv), c-05H9MgCI (7 equiv), t-BuOMe, 40 °C, 30 mm, 12 (5 equiv), 
-40 °C, 2 h then 0 °C, 2 h; (b) Et3N, DCM, 30 mm, 83%. 
Scheme 1.9: Corey's synthesis 
The same group reported improved conditions for the cyclisation of 14 in the fol-
lowing year. This time compound 14 was treated with Kulinkovich reagent (22 )68,69 
formed from Ti(Oi-Pr)4 and a large excess of cyclopentylmagnesium chloride, to pro- 
duce 23 after quenching with iodine cm-iodoniethyl-y-lactam, that was transformed into 
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15 by addition of triethylamine in 83% yield. The new conditions provided 15 with 
complete diastereoselectivity (>99:1).46,53 
Alongside the new methodology Corey published a synthesis of 3-methyl-2-epi-
omuralide70 (Scheme 1.10 26). The cyclisation precursor 24 was treated with Kulinkovich 
reagent to give a titanium intermediate that was hydrolysed with 1 M HC1 to produce 
'y-lactam 25 in 95% yield. 
0 	 o 	 o 
	
a





I__I_<L  Me 	 Me' 	 Me / A OTBS 
Me 	 HO CO2Me 	 0 bH 
Me OTBS 	
0 
24 	 25 	 26 
Conditions: (a) Ti(Oi-Pr)4 (4 equiv), c-05H9MgC1 (7 equiv), t-BuOMe, -40 °C, 30 mm, then 1 M 
aq HCl 95%. 
Scheme 1.10: Corey's synthesis 
To further improve his approach, an innovative methodology was published by 
Corey that facilitated methyl ester cleavage, /l-lactone formation, and primary alcohol 
chlorination procedure in one pot.46' 53 Hydrolysis of the methyl ester was particularly 
difficult as 27 can go through a series of undesired reactions including retroaldol cleav-
age. Steric hindrance of this methyl ester makes it difficult to find a strong and yet 
selective agent for hydrolysis. To overcome these issues a new tellurium based reagent 
was developed (Me2 TeA1Me)2. It can be easily formed by warming tellurium powder 
and trimethylaluminum in toluene for 6 h.7' This reagent can accomplish methyl es-
ter hydrolysis under mild conditions by selectively attacking the methyl substituent of 
the methyl ester rather then the carbonyl center. 
0 	 0 	 0 
HO 	 Me 	 CI 	




Me Me Me"" 	
"ODMIPS 	
c 
ODMIPS OH HO CO2Me 
27 28 	 29 
Conditions: (a) [Me2TeA1Me]2 Toluene, 23 °C, 12 h; (b) PPh3C12, DCM, pyridine, 12 h, 89%; (c) 
Et3NHF, THF, 23 °C, 4 h, 92%. 
Scheme 1.11: Corey's synthesis 
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The carboxylic acid obtained after tellurium-induced hydrolysis was, without added 
purification, reacted with P113PC12 in a 1:1 mixture of dry MeCN-pyridine to directly 
deliver 28 in 89% yield. This valuable operation allowed the new method of /3-lactone 
formation and the side chain chlorination procedure to take place in one-pot. Sub-
sequently, desilylation of 28 gave the salinosporamide-omuralide hybrid 29 in 92% 
yield. 
In his approach to salinosporamide A, Corey took advantage of the fact that the 
target molecule has five continuous stereocentres. He started with the formation of 
the synthetically most difficult tetrasubstituted stereocentre (at C4) that was neatly 
formed with assistance of the oxazoline ring derived from threonine. This chirality was 
then used to control the construction of neighbouring stereocentres in almost text-book 
fashion. The Baylis-Hillman cyclisation (later Kulinkovich) did deliver the required 
configuration at C3 in the y-lactam ring with a high diastereomeric ratio. However, 
it took Corey and co-workers several steps including a tin hydride-mediated radical 
cyclisation to transform the exomethylene group of 15 into the chloroethyl functionality 
with the appropriate configuration at C2. It seems more than likely that initialy Corey 
envisaged a different approach involving Michael type addition to the o-/3-unsaturated 
amide 15 that proved to be unsuccessful and so an alternative route involving a radical 
cyclisation was devised. It is worth mentioning that the procedure for the /3-lactone 
formation and chlorination of primary alcohol developed in this study have been applied 
by several different groups in their total synthesis of 1. 
Salinosporamide A was synthesised by Corey in 18 steps and 8.7% overall yield 
through Baylis-Hillman cyclisation, which was later increased to 9.1% yield using 
Kulinkovich reagent. 
1.2.2 Danishefsky's synthesis 
Danishefsky and co-workers reported the second approach to salinosporamide A in 
2005 .47  Their synthesis started with a known procedure to convert L-glutamic acid 
to pyroglutamate 30.7274  This compound possesses a substantial facial bias of bicy- 
10 
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clo[3.3.0] ring system, that was used to facilitate the formation of the C3 stereocentre. 
Addition of vinylmagnesium bromide in the presence of CuT gave the product of a-face 
attack of the vinyl duprate in 75% yield as a single diastereomer. Deprotonation of this 
intermediate with LDA and addition of 3-benzyloxy iodoethane, that mostly attacked 
the preformed enolate from the a-face, yielded 31 as a 14:1 mixture of diastereomers 
(77%). 
.Ph a,b BnO 	























iki 	 BnO—/__-~LN 
CO 	








Conditions: (a) vinylmagnesium bromide, TMSC1, Cul, 78 °C, 75%; (b) [(2-
iodoethoxy) methyl] benzene, LDA, THF, rt, 77%, di' = 14:1; (c) 03, DCM-MeOH (3:1), -78 
°C then NaBH4, 0 °C, 86%; (d) CICO2Et, pyridine, rt, 96%; (e) TfOH, THF-H20 (9:1), rt, 100%; 
(f) Jones reagent, acetone, rt; (g) Me2NCH(Ot-Bu)2, toluene, reflux, 72% over 2 steps; (h) Et30BF4, 
K2CO3, DCM, rt, 88%; (i) LHMDS, THF, -20 °C, 82%; (j) 1 M HC1 aq, THF, 0 °C, 90%; (k) 
PMBC1, NaH, DMF, rt, 61%; (1) Pd(OH)2 on carbon, H2, EtOH, rt, 100% 
Scheme 1.12: D anishefsky 's synthesis 
The terminal olefin present in 31 was converted to the primary alcohol 32 in 86% 
yield by first ozonolysis and reductive quenching with sodium borohydride. The alcohol 
32 was reacted with ethyl chioroformate in pyridine to form a mono-ethyl carbonate 
(96%) and this intermediate was treated with triflic acid to produce the amino alcohol 
33 in 100% yield. The primary hydroxyl group in 33 was converted to a carboxylic 
acid with Jones reagent and then directly esterified with Me2 NCH(Ot-Bu)2 (72% over 
two steps). The use of Et30BF4 (Meerwein's reagent) afforded the imidate product 34 
in 88% yield. 
The imidate 34 concealed 'y-lactam character and facilitated acylation at C4. De-
protonation of 34 with LHMDS and intramolecular trapping of the enolate by the 
carbonate substituent gave 35 in 82% yield as a single diastereoisomer. At this stage 
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Danishefsky shuffles protecting groups. Firstly the 'y-lactam was unmasked using aq 
1 M HC1 (90%) and then PMB protection was introduced on to nitrogen with NaH 
and PMBC1 (61%). Cleavage of the benzyl ether protection from the primary hydroxyl 
group was achieved by palladium-catalysed hydrogenation to give 36 in quantitative 
yield. 
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Conditions: (a) PhSeSePh, NaBH4, EtOH, 60 °C; (b) BnBr, K2CO3, DMF, rt, 72% over 2 steps; (c) 
30% H202 aq, THF, rt; (d) toluene, 100 °C, 72% + 22% over 2 steps; (e) Dess-Martin periodinane, 
DCM, rt, 92% (f) PhSeBr, AgBF4, BnOH, DCM, 20 to 0 °C, 74% (12:1); (g) AIBN, nBu3SnH, 
toluene, 100 °C, 98%; (h) NaBH4, THF-EtOH (3:1), rt, 85%; (i) Dess-Martin periodinane, DCM, rt, 
95%; 
Scheme 1.13: Danishefsky's synthesis 
The 'y-lactone ring of 36 was then opened by a nucleophilic attack of a phenylse-
lenium anion (pregenerated from (PhSe)2 and NaBH4) and subsequent esterification 
with benzyl bromide afforded 37 in 72% yield over two steps. Oxidation of the phenyl 
selenium substituent of 37 produced the corresponding selenoxide that was eliminated 
at 100 °C in toluene to give alcohol 38 (72%) as the major product together with 
the unexpected aldehyde 39 (22%) which was a one-step advancement in the synthetic 
route. The alcohol 38 was oxidized to aldehyde 39 with Dess-Martin periodinane to 
produce aldehyde 39 in 89% yield (over three steps) 
The formation of acetal 40 was facilitated by the addition of phenylselenium bro-
mide and AgBF4 to aldehyde 39 in the presence of benzyl alcohol. This transformation 
set up the required stereocentres at C2 and C3 positions. The phenylselenium sub-
stitution of 40 was removed under radical conditions to give compound 41 in 98% 
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yield. The benzyl ester of 41 was selectively cleaved in the presence of tert-butyl ester 
with sodium borohydride in a mixture of THF and ethanol. Oxidation of the resultant 
alcohol gave the desired aldehyde 42 in 95% yield. 
N - PMB 	
a 
BnO\0)c 
Me CO2t-Bu 	a ZnCI 	 Me CO2t-Bu 42 	 43 
21 
lb,c,d 
CI 	 HO 
	
N H 	 NH e,f,g
Me Co OH 
0 	 44 
Conditions: (a) cyclohexenyl zinc chloride 21, THF, 78 °C; (b) CAN, DCM-1-120, 0 °C, 90%; (c) 
Na, liq NH3, 78 °C; (d) NaBH4, THF-H20 (2:1), rt, 97% over two steps; (e) BCI3, DCM, 0 °C; (f) 
BOPC1, Et3N, DCM, rt; (g) PPh3C12, pyridine, DCM, rt, 51% over 3 steps. 
Scheme 1.14: Danishefsky's synthesis 
Danishefsky and co-workers employed Corey's procedure for the introduction of the 
last two remaining stereocentres.45 Addition of cyclohexenyl zinc chloride reagent 21 
to the aldehyde 42 afforded 43 with 88% yield and excellent diastereoselectivity. The 
same procedure was also attempted on an aldehyde derived from compound 35 but 
this yielded only 78% of 4:3 mixture of diastereoisomers. It was speculated that PMB 
protection of the 'y-lactam ring plays a crucial role in controlling the diastereoselectivity 
of this transformation. After the successful addition of cyclohexenyl zinc chloride, the 
PMB protection of 43 was removed with CAN. The benzyl glycoside moiety of the 
corresponding intermediate was reduced with sodium and sodium borohydride in liquid 
ammonia to give the triol 44 (97% over two steps). Hydrolysis of tert-butyl ester was 
performed using BC13 and the crude acid was transformed to salinosporamide A using 
Corey's lactonisation-chlorination procedure. 
The total synthesis of salinosporamide A by Danishefsky and co-workers was achieved 
in 28 steps and 1.8% overall yield. In his synthesis Danishefsky is almost constantly 
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changing protecting groups, oxidation steps and configuration of stereocenteres. For 
these reasons this is the longest approach to salinosporamide A and it is also difficult 
to point out a key transformation. However, formation of the C4 stereocentre by in-
tramolecular cyclisation of an enolate onto the mono-ethyl substituent is an important 
point in the synthesis. Surprisingly Danishefsky does not use this stereocentre to con-
trol the configuration at the C3 position. Instead, the stereocentre at C2, constructed 
very early in synthesis, is employed to control the substituents around C3. 
1.2.3 Pattenden racemic synthesis 
A short approach to racemic salinosporamide A was published by Pattenden in 200648  
(Scheme 1.15). Starting from compound 45 (synthesis of which was previously re-
ported 15  a high yielding synthesis was obtained. Firstly, the ketone group in 45 was 
protected using ethylene glycol in the presence of a catalytic amount of p-TsOH to 
give an acetal derivative that was subsequently treated with a solution of NaOH to hy-
drolyse the methyl ester. The resultant acid was coupled to dimethyl 2-aminomalonate 


















Conditions: (a) ethylene glycol, p-TsOH, benzene, 110 °C, 14 h; (b) 2M NaOH, EtOH, 70 °C, 3 
h; (c) dimethyl aminomalonate, HOBt, EDCI, DCM, NMM, 0 °C to rt (82% over 3 steps); (d) 4:1 
AcOH-H20, 65 °C, 4 d (71%); 
Scheme 1.15: Pattenden synthesis 
Compound 46 was then treated with diluted acetic acid at 65 °C for 4 days to 
give the 'y-lactam 47 in 71% by initial hydrolysis of the acetal followed by a highly 
diastereoselective intramolecular cyclisation. This transformation was a key step in 
Pattenden synthesis, it delivered a single diastereomer of the desired product in good 
yield. Intermediate 47 possesses a 'y-lactam backbone with the desired functionality 
in place making it relatively straight forward to transform it to salinosporamide A. 
14 
Chapter 1. Formal Synthesis of Salinosporamide A 
Protection of the hydroxyl group in 47 with a silyl ether and the lactam nitrogen 
using a p-methoxybenzyl group afforded 48 in 75% yield over two steps. Selective 
reduction of one of the methyl esters (positioned anti to the silyl ether) with LiEt3BH 
gave the aldehyde 49 in 78% yield. Addition of cyclohexenyl zinc (21) to aldehyde 49 
was done following Corey's protocol.45 Compound 50 was formed in 78% yield with 
very high levels of diastereoselectivity and this intermediate posseses all stereocentres 
in place. 
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C11  HO 	 PMB VH ` i-n 	 BnO NH 	 -k 	 N'
OH Me 





Conditions: (e) TMSOTf, 2,6-lutidine, DCM, 78 °C to 0 °C, then 1 M HCI (91%); (f) PMBBr, 
NaH, DMF, 0 °C to rt, 14 h (82%); (g) LiEt3BH (1.0 M in THF), DCM, 78 °C, (78%); (h) 2-
cyclohexenyizinc chloride 21, THF, 78 °C (87%); (i) Me2 SBC13, DCM, 24 h, 0 °C to rt; (j) 48% 
HF in H20-MeCN (1:9), rt, 22 h; (k) CAN, MeCN, H20 (3:1), 0 °C, 1 h (87% over 3 steps); (1) 
MeTeA1Me2 1 2 , toluene, rt, 24 h; (m) BOPC1, DCM, pyridine, rt, 3 h; (n) PPh3C12, MeCN, pyridine, 
rt, 4 h (45% over 3 steps). 
Scheme 1.16: Pattenden synthesis 
Subsequent deprotection of the benzyl ether with BC13, TMS ether with HF and p-
methoxybenzyl with CAN produced Corey's intermediate 5145  in 87% over three steps. 
The triol 51 was transformed according to previously reported procedures 46,53,71  to 
salinosporamide A (1). The total synthesis of racemic salinosporamide A was achieved 
in 14 steps and an impressive 11.5 % overall yield. 
1.2.4 Langlois's formal synthesis 
Langlois and co-workers published two separate approaches to salinosporamide A.49' 50 
The first report described a racemic synthesis of 52 which is a derivative of Corey's 
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key intermediate 15 (Scheme 1.17). In their approach a highly stereoselective nitrone 















Scheme 1.17: Langlois's synthesis 
Deprotonation of 'y-lactam 53 with LHMDS followed by addition of chioromethyl-
benzylether gave the alkylated intermediate in 53% yield, which was later BOC pro-
tected on nitrogen to give 54 (quantitative yield). The BOC protection in 54 allowed 
the deprotonation at the ce-carbon (to the lactam carbonyl) and the formation of a sele-
nium intermediate that was subsequently reacted with H202 in the presence of pyridine 
to give the o-unsaturated lactam 55. Addition of methylcuprate to 55 gave an alky-
lated product that was once more subjected to the previous condition to reform the 
carbon-carbon double bond in compound 56. 
A key step in the Langlois synthesis was a 1,3-dipolar cycloaddition. Treatment of 
55 with N-methylnitrone in refiuxing toluene gave 56 in 57% yield. This highly regio-
and stereoselective reaction installed the relative configuration at the C3 carbon. In 
this step Langlois used Pearlman's catalyst to selectively break the nitrogen-oxygen 
bond (through hydrogenolysis, 72% yield) without deprotection of the benzyl ether. 
Addition of excess iodomethane and triethylamine gave the methylation product 52 in 
65% yield. 
In Langlois's second report an enantioselective version of the previous approach 
to salinosporamide A (1) is described. An enantiopure bicyclic nitrile 5876,77  was 
hydrolysed in the presence of 6 M HCl to give 59 in 98% yield. Treatment of this 
intermediate with diazomethane in ether afforded 7-lactam 60 in 67%, which was 
selectively benzylated using 2-benzyloxy-1-methylpyridinium trifiate 61 to produce 62 
in 75% yield. Using 62 as a chiral precursor and Langlois previously reported synthesis, 
compound 52 was made without lost of enantioenrichment from 62. 
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Conditions: (a) LHMDS, THF, BnOCH2C1 (53%); (b) (Boc)2 0, DMAP, MeCN (100%); (c) LHMDS, 
THF, PhSeC1; H202, DCM, pyridine (89%); (d) Me2CuLi, THF, TMSC1 (83%); (e) LHMDS, THF, 
PhSeC1; H202 , DCM, pyridine (75%); (f) N-methylnitrone, toluene, reflux (57%); (g) H2, Pd(OH)2 , 
EtOAc-MeOH (72%); Mel, THF, Et3N (65%). 




CI 	 0- 












Conditions: (a) 6M HC1, reflux (98%); (b) diazornethane, Et20 (67%); (c) 61, MgO, PhCF3, reflux 
(75%). 
Scheme 1.19: Langlois's synthesis 
Synthesis of Corey's intermediate 15 was achieved through the initial substitution 
of N-BOC protection in 52 to PMB in 64 (two steps, 57% yield). However, 1,3-
dipolar cycloaddition of N-methylnitrone to compound 64 gave lower than expected 
stereoselectivity (4:1) and product 66 was isolated in 54% yield. Cleavage of the 
nitrogen-oxygen bond with hydrogenolysis and formation of the exo-methylene group 
proceeded as previously giving -methylenelactam 15. 
The formal synthesis of salinosporamide A was achieved in 18 steps (from 60) in 
4% overall yield. 
- 
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Conditions: (a) CF3CO2H, DCM (100%); (b) Cs2CO3, PMBBr, DMF (57%); (c) N-methylnitrone, 
toluene, reflux (14% for 65, 54% for 66); (d) H2, Pd(OH)2, EtOAc-MeOH (64%); (e) Mel, MeOH; 
Na2CO3, DCM (90%). 
Scheme 1.20: Langlois's synthesis 
1.2.5 Romo's racemic synthesis 
Romo and co-workers reported a racernic synthesis of salinosporamide A using a novel 
methodology to form the /3-lactone ring.5' Sequential formation of the carbon-carbon 
and carbon-oxygen bonds during intramolecular cyclisation (Scheme 1.21) allowed ef-
ficient synthesis of the 'y-lactone--lactam ring system and a very short synthesis of 
racemic 1 (9 steps). Romo observed that A,,3 strain78 present in 69 allowed the stereos-
elective formation of 68 without a the risk that the highly acidic /3-ketoamide hydrogen 
could effect a racemisation at C2 carbon upon deprotonation. 
0 	 0 
PMB 	I' bis- 	PMB _H 






con formationally 	H 	Me 
68 controlled acidity 69 
(A' 3 strain) 
Scheme 1.21: Romo's synthesis 
A benzyl ether serine derivative 70 was functionalised with p-methoxybenzyl and 
allyl protecting groups to give 71 in 74% over two steps. Addition of 73 to 71 
provided the intermediate 74 in 80% yield. Deprotection of the allyl ester with 
tetrakis(triphenylphosphine)palladium and morpholine afforded the acid 75 (75% yield). 
A key step in Romo's synthesis was the cyclisation of 75 to form epimers of 'y- 
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Conditions: (a) p-anisaldehyde, MeOH, NaBH4; (b) p-TsOH, ally! alcohol (74%, 2 steps); (c) THF, 
60 °C, 36 h (80%); (d) Pcl(PPh3)4 , morpholine (75%) 
Scheme 1.22: Romo's synthesis 
1actone--lactam (77 and 78) in 25-35% yield. The major product (dr 2-3:1) con-
tained the appropriate configuration of stereocentres required for the synthesis of sali-
nosporamide A. However, a much higher total yield was expected based on previous 
experiments. These results were explained by significant steric hindrance caused by 
substituents at the C4 carbon that were not present in model studies. 
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0 
0  


















Conditions: (a) DIPEA, PPY, Dclvi, 10 °C, 6 h (25-35 %, dr 2-3:1); (b) H2, Pd/C, THF, 25 °C 
(98%); (c) EDCI, DMSO, C12CHCOOH; (d) 2-cyclohexenylzinc chloride 24, THF, 78 °C(33%, 2 steps, 
dr 3.5:1); (e) CAN, MeCN/H20 (49%, major diast.). 
Scheme 1.23: Romo's synthesis 
Hydrogenation of 78 mediated by Pd/C afforded debenzylated intermediate 79 in 
quantitative yield. Alcohol 78 was oxidized using Moffat" protocol and the aldehyde 
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product was reacted with cyclohexenyl zinc chloride to give 80 in 33% as a 3.5:1 mixture 
of diastereoisomers. Removal of the PMB protective group in 80 with CAN furnished 
salinosporamide A (1) in 49% yield. 
The total synthesis of raceinic salinosporamide A was achieved in only 9 steps with 
1.2% overall yield. 
1.2.6 Macherela's total synthesis 
Macherela and co-workers reported the enantioselective total synthesis of salinospo-
ramide A in 2007.52  Formation of an amide bond between 81 and 82 using MsCl and 
triethylamine gave amide 83. Cleavage of acetal protection in 83 gave the 3-ketoamide 
84 as a mixture of diastereoisomers. A key step in Macharela's synthesis was a novel in-
tramolecular aldol cyclisation, treatment of 84 with t-BuOK produced 85 in 64% yield 
and 70% de. This new transformation allowed the self-regeneration of stereocentres8°  
to subsequently forin the desired configurations around C2 and C3. 
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Conditions: (a) MsC1, Et3N, DCM, 0 °C to rt, o/n (66%); (b) CeC13, Nal, MeCN, 60 °C, 4 h (84%); 
(c) t-BuOK, THF, rt, 15 mm (64%, 70% de); (d) 0s04, NMO, H20/THF, 3 h then Na104, 2 h, 
(99%); (e) BnBr, t-BuOK, THF, 6 h, 76%; (f) LiBH4, THF, 24 h (94%); (g) TPAP (cat.), NMO, 
DCM, 18 h (79%); (h) THF, 78 °C to rt, 11.5 h (80%) 
Scheme 1.24: Macherela's synthesis 
The obtained mixture of diastereoisomers of 85 was reacted with 0s04 /NMO and 
followed by addition of Na104 and then BnBr to give 86. This methyl ester was then 
reduced with LiBH4 and subsequently oxidised to aldehyde 87. The cyclohexenyl moi-
ety was introduced via the addition of B-2-cyclohexen-1-yl-9-BBN (88) to aldehyde 87 
20 
Chapter 1. Formal Synthesis of Salinosporamide A 
which gave 89 in 80% yield. As predicted, a syn addition product 89 was obtained 
that contained the required configuration at C6. However, the orientation of the hy-
droxyl group at C5 was incorrect for the final product and would have to be reversed 
at a later stage in the synthesis. 
The ring opening of benzyl acetal moiety in 89 was achieved by acid hydrolysis fol-
lowed by reduction with NaBH4. Benzoyl protection of the obtained intermediate gave 
90 in 70% yield over three steps. This protection step allowed the use of relatively harsh 
conditions for the hydrolysis of oxazoline. Treatment of 90 with 1 ,3-propanedithiol, 
HCl and trifluoro-ethanol afforded the desired product that was subsequently protected 
with TMS ether at the C5 hydroxyl to give intermediate 91. The primary hydroxyl 
group in 91 was then oxidized to a carboxylic acid by a two-step procedure giving 92 in 
63% yield overall. Hydrolysis of the benzoyl protective group of 92 was followed with 
a BOPC1-mediated -1actone formation. A subsequent chlorination of the primary al-
cohol using P113PC12 gave 93 that is a C5 epilner of salinosporamide A. In an attempt 
to obtain the desired configuration at C5, the secondary hydroxyl group in 93 was 
oxidized using Dess—Martin periodinane81'82 and the resulting ketone was selectively 
reduced with ketoreductase enzyme to produce salinosporamide A 1. 
Although Macherela managed to successfully apply an enantioselective intramolec-
ular aldol cyclisation, a lot of synthetic steps were needed for protecting group manip-
ulations. Salinosporamide A was synthesised in 24 steps with 0.2% overall yield. 
1.2.7 Hatakeyama's total synthesis 
In 2008 Hatakeyama and co-workers applied their indium-catalysed conia-ene reaction 
in the total synthesis of salinsoporamide A (Scheme 1.26).83  The synthesis began with 
the stereoselective preparation of 97 that was a precursor for a key In(OTf)3-catalysed 
cyclisation. A chiral propargyl alcohol 94 was converted to the mesylate derivative and 
then treated with (tert-butyldimethylsilyloxy) acet aldehyde via the allenylzinc species 
to afford 95 as a 90:10 mixture of epimers. Removal of the PMB and silyl protecting 
groups and a selective acylation of one of the hydroxyls gave 96. Treatment with Cr03  
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Conditions: (a) HC1, THF, 60 °C, 10 h; (b) NaBH4, THF/1-120, 30 mm (81%, 2 steps); (c) BzC1, 
Et3N, DCM, 10 h (87%); (d) 1,3-propanedithiol, HC1, CF3CH20H, 60 °C, 4 h (94%); (e) TMSC1, 
Et3N, DCM, 12 h (53%); (f) Dess-Martin periodinane, DCM, 2 h; (g) NaH2 PO4, NaC102, 2-methyl-
2-butene, t-BuOH/H20, 0 °C, 1.5 h (63%, 2 steps); (ii) K2CO3, Me0H, 15 h; (i) B0PC1, pyridine, 
MeCN, 2 h (60%, 2 steps); (j) Ph3PC12, pyridine, MeCN, 18 h (57%); (k) Dess-Martin periodinane, 
DCM, 2 h (60%); (1) KRED-EXP-B1Y, NAD+, GDH-103, glucose, pH 6.9, 37-39 °C, 40 mm (56%). 
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Conditions: (a) MsC1, Et3N, DMAP, DCM, 0°C, 95%; (b) Pd(OAc)2, PPh3, Et2 Zn; then 
TBSOCH2CH0, THF, -78 to -20 °C, 63%; (c) DDQ, DCM / H2 0 (10:1), 0 °C, 87%; (d) AcC1, 
2,4,6-collidine, DCM, -78 °C, quant.; (e) TBAF, THF, 0 °C, 92%; (f) Cr03, H104, acetone, H20, 
0 °C; (g) (COC1)2, DMF, DMF, 0 °C; then PMBNHCH(CO2 Me)2, toluene, 75%; (h) In(OTf)3 (5 
mol%), toluene, 110 °C, 96%; (i) Lipase PS, phosphate buffer, acetone, 35 °C, 89%; (j) Dess-Martin 
periodinane, DCM, 88%; (k) PhSeBr, AgBF4, PhCH20H, DCM, -20 to 0 °C, 85%; 
Scheme 1.26: Hatakeyama's formal synthesis 
and H104 in a mixture of acetone and water afforded the corresponding carboxylic 
acid. Condensation with dimethyl 2- (4- met hoxyb enzylamino) malonate gave 97. Upon 
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97 and 98. This mixture was reacted with catalytic amount of In(OTf)3 in refiuxing 
toluene and gave complete conversion to 98. A very mild hydrolysis of the acetoxy 
group using a lipase-catalysed reaction afforded 99. Oxidation of 99 with Dess-Martin 
periodinane provided the aldehyde 100. The quaternary centre have been assembled 
using Danishefsky's acetal-mediated cationic cyclisation.47 Treatment of 100 with 
phenylselenyl bromide, AgBF4 and benzyl alcohol afforded 101 with 93:7 dr at C3. 
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Conditions: (a) AIBN, n-Bu3SnH, toluene, 100 °C, 83%; (b) NaBH4, THF / EtOH, 88%; (c) Dess-
Martin periodinane, DCM, 94%; (d) cyclohex-2-enylzinc chloride, THF, -78 °C, 88%; (e) CAN, aq 
MeCN, 0 °C, 83%; (f) Na, liq. NH3 , THF, -78 °C; (g) NaBH4, aq THF, 71% (over 2 steps); (h) 
(Me2 A1TeMe)2, toluene; (i) BOP-CI, pyridine, DCM, 54% (over 2 steps); (j) Ph:3PC12, pyridine, 77%. 
Scheme 1.27: Hatakeyama's formal synthesis 
Removal of phenylselenium with tin hydride under radical conditions produced 102 
(Scheme 1.27). Selective reduction of one of the methyl esters with NaBH4 and sub-
sequent reoxidation with Dess-Martin periodinane gave aldehyde 103. Using Corey's 
procedure, addition of cyclohex2-enylzinc chloride to aldehyde 103 produced 104 as 
a single stereoisomer. The PMB group of 104 was removed with CAN to yield 105. 
Using sodium in liquid ammonia and NaBH4 in THF a reductive opening of the cyclic 
acetal gave intermediate 106. A cleavage of the methyl ester with (Me2AlTeMe)2 , /3-
lactonisation with BOP-Cl in pyridine and a final chlorination completed the synthesis 
of salinosporamide A 1. 
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1.2.8 Omura's formal synthesis 
A lengthy total synthesis of salinospormiade A was published by Omura and co-workers 
in 2008.84  Several aspects of this synthesis were particularly interesting. A lipase-
catalysed desymmetrisation of the diol 108 afforded an optically active acetate that 
was protected with TBDPS to give 109 in 97% ee (Scheme 1.28). This stereocentre is 
then gradually converted into the quaternary chiral centre of salinosporarnide A. 
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Conditions: (a) Ph3 CH3Br, NaHMDS, THF, rt, 97%; (b) p-TsOH, MeOH, rt, 82%; (c) Lipase, 
vinyl acetate, i-Pr2 0, rt; (d) TBDPSC1, imidazole, DMF, rt, 94%, 97% ee (over 2 steps); (e) K2CO3, 
MeOH, rt; (f) MEMC1, i-Pr2NEt, DCM, rt, 94% (over 2 steps); (g) TBAF, THF, rt; (h) NaH, THF 
/ DMF, then PMBC1, rt, 97% (over 2 steps); (i) 0504, NMO, acetone / H20, rt; (j) Na104, MeOH 
/ H20, rt, 92% (over 2 steps); (k) LDA, cyclohexanone, THF, -78 °C; (1) BzC1, 79% 
Scheme 1.28: Omura's formal synthesis 
Installation of the C5 and C6 stereocentres using Corey's protocol of stereoselective 
addition of cyclohexenylzinc chloride only gave limited selectivity when aldehyde 112 
was used. Instead Omura optimised conditions for a chelation- controlled aldol addition 
of cyclohexanon that upon quenching with BzCl, afforded the desired product 114 in 
79% yield and 20:1 dr. 
The conversion of the cyclohexanone group in 114 to the cyclohexene moiety in 
salinosporamide A appeared quite difficult (Scheme 1.29). Six synthetic steps were 
required involving a cyclic sulfate 116 as a key intermediate that upon exposure to 
DBU at 100 °C and subsequent treatment with TsOH produced 117. 
A 'y-lactain ring was afforded by N-acylation of 119 and a subsequent intramolecular 
aldol reaction using LHMDS and chloroacetyl chloride. The desired compound 120 was 
Im 
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produced as a single isomer. This procedure also constructed a C3 stereocentre. 
PMB 
















MEMO 	 MEMO 




Conditions: (a) NaBH4, CeC13, MeOH, rt; (b) K2CO3,  MeOH, rt, 95% (over 2 steps); (c) SOC12, 
pyridine, DCM, rt; (d) RuC13, Na104, MeCN / CC14 / H2 0, rt, 94% (over 2 steps); (e) DBU, toluene, 
100 °C; (f) TsOH, dioxane, rt, 97% (over 2 steps); (g) NaH, THF / EtOH, rt; (h) (COd)2 , DMSO, 
Et3N, DCM, -78 °C, 92% (over 2 steps); (i) MeMgBr, THF, -78 °C; (j) Dess-Martin periodinane, 
DCM, rt, 100% (over 2 steps); (k) CAN, MeCN / H20, 0 °C, 92% 
Scheme 1.29: Omura's formal synthesis 
To install the C2 side chain a Reformatsky-type reaction of 120 with benzyloxy 
acetaldehyde gave 121 (Scheme 1.30). For a successful deoxygenation step, it was 
necessary to convert 121 into a inesylate derivative. Subsequent alkaline hydrolysis af-
forded 122 that was chemoselectively reduced with LiEt3BH to produce a 4.2:1 mixture 
of diastereoisomers of 123. 
After a shuffle of protecting groups, a sequence of 5 synthetic steps have been 
applied. Oxidation of the primary alcohol, deprotection of the benzyl group using 
a Birch reduction, BOP-Cl mediated /-lactonisation and chlorination with Ph3 PC12 
afforded the 7-lactam-/3-lactone 125. Deprotection of the TES ether with HF-pyridine 
gave salinospormiade A (1) as the final product. 
1.2.9 Bode's formal synthesis 
A recent publication by Bode describes a formal synthesis of salinosporamide A.85 
A novel NHC-catalysed intramolecular lactonisation was developed and successfully 
25 
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Conditions: (a) LHMDS, THF, -78 °C, chioroacetyl chloride, 63%; (b) Sm12, LiC1, benzyloxyacetaled-
hyde, THF, -78 °C, 83%; (c) MsC1, Et3N, Me3NHC1, toluene, rt; (d) NaOH, MeOH / H20, 0 °C, 
81% (over 2 steps); (e) LiEt3BH, THF, 0 °C, 77%; (f) TESC1, NaT, MeCN, 0 °C, 100%; (g) TESOTf, 
2,6-lutidine, DCM, -78 °C, 48%; (h) HF-pyridine, THF, 0 °C, 90%; (i) Dess-Martin periodinane, 
DCM, rt; (j) NaC102, 2-methyl-2-butene, Na2HPO4, t-BuOH / H20, rt; (k) Li, NH3, t-BuOH, THF, 
-78 °C; (1) BOPC1, pyridine / DCM, rt; (m) PH3PC12 , pyridine / MeCN, rt, 48% (over 5 steps); (n) 
HF-pyridine, THF, rt, 84% 
Scheme 1.30: Omura's formal synthesis 
applied albeit with limited selectivity (Scheme 1.31). Compound 126 was prepared 
following Corey's procedure. 45  Although the initial plan to obtain 129 was a two 
step procedure involving acylation of 126 using an oj3-unsaturated acid containing an 
aldehyde functionality masked as an acetal and then an acid catalysed hydrolysis to 
reveal the aldehyde has failed (similar difficulties in acylation have been encountered 
in our formal synthesis of salinosporamide A), a longer route was developed. 
N-Acylation of 126 with sorbyl chloride was followed by TMS ether deprotection 
and Dess-Martin oxidation to give 127. A regioselective Sharpless dihydroxylation 
afforded 128 as a single diastereomer that was subsequently treated with sodium pe-
riodate to give the product of the diol cleavage 129. 
Cyclisation of 129 was achieved using N-heterocyclic carbene 130 as a catalyst. 
The products were obtained as a 1:1.1 mixture of diastereomers (in favour of the 
undesired isomer). Compound 131 was identical to the one obtained in this study.86 
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132 	 129 
Conditions: (a) sorbyl chloride, DIPEA, DCM, 0 °C to rt, 28 h; (h) 6 N HCI(aq) , rt, 1 h; (c) 
Dess-Martin perioclinane, DCM, rt, 16 h, 60% over 3 steps; (d) AD-mix a, (DHQ)2 PHAL, OSO4, 
MeS02NH2 , NaHCO3, 3:2 H20:t-BuOH, rt, 24h, 40%; (e) Na104, sat. NaHCO3(aq) , DCM, rt, 20 
h, quant. (f) 130 (15 mol%), DBU (10 mol%), 10:1 THF:t-BuOH (0.05M), 40 °C, 3 h, 88% (di' = 
1:1.1) 
Scheme 1.31: Bode's formal synthesis 
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1.3 Reductive aldol cyclisations in the Lam group 
The synthesis of salinosporamide A was initiated in our group after an extensive de-
velopment of reductive aldol cyclisation methodology. Our plan was to prove the ap-
plicability of our reductive aldol cyclisation methodology in a synthesis of a valuable 
natural product. Using experience gained during the development of our reductive al-
dol cyclisations we managed to apply this methodology as a key step in the formal 
synthesis of salinosporamide A. A short overview of the research leading to this project 
is presented below. 
1.3.1 Copper-catalysed reductive aldol cyclisation 
Our first target was a reductive aldol cyclisation of oj-unsaturated esters contain-
ing ketone acceptors. In 2005 Lain and co-workers reported a highly stereoselective 
copper-catalysed process that allowed the formation of five- and six-membered 3-
hydroxylactones.26 Similar reactions of this type had been carried out utilising Stryker's 
reagent with stoichiomnetric amounts of silanes.87' 88 Our initial study was to optimise 
reaction conditions with easier to handle sources of copper precatalyst. It was also 
crucial to fine tune the reactivity of copper hydride with phosphine ligands. 
Initial screening of copper salts and bisphosphine ligands proved to be fruitful, and 
a highly reactive catalyst system consisting of Cu(OAc)2 , TMDS and either DPPF or 
rac-BINAP, in THF was found. These conditions allowed the formation of five- and 
six-membered lactones with good yields and exceptionally high diastereoselectivities 
(>20:1). 
The application of enantiopure chiral ligands allowed the formation of products with 
good levels of enantioselectivity. It was observed that MeO-BIPHEP and SEGPHOS 
ligands delivered better selectivity in final product as compared to BINAP. 
We have proposed a catalytic cycle for these reactions (Scheme 1.33). A copper(II) 
precatalyst is initially reduced to a copper(I) hydride species 143 with TMDS. A 
nucleophilic 1,4-conjugate addition of 143 to the starting material 144 forms a copper 
12 
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PPh2 
	






5 mol% Cu(OAc)2 H20 
1 eq TMDS 
133 	o 	THFrt 	 HO 135 
Entry 	Substrate R Product 	Yield 






3 a a 	2-furyl 	R 	063 
4 	Me 	 i-Bu 
Me 
HO 	 73 





me Me)15 	 62 
Me 
Me A'—)HO  
7 R 	0 	 H 	 a 	71 
8 	 Me 50 
Ph 	
Ph 	 Ph 
HO 	
47 
10 	 0 	 H 	 a 	69 
11 R-O 	 Me 72
65 12 	 Ph 
)J 
i-Bu 	 Ph 
13 0 	 PhCH2CH2 HO 	 60 
Table 1.1: Copper-catalysed reductive aldol cyclisations 
PPh2 	MeO'r' PPh2 	MeO 	P(35-xyl)2 	MeO ' 	PAr2 	O i PPh2 01 5.PPh2 0öPPh2 
136 	 137 	 138 	 139 	 140 
Ar = 35-di-/-PrPh 
(S)-BINAP 	 (S)-Ph-MeO-BIPHEP 	(R)-35-xy1-Me0-BIPHEP (R)-3,5-d0-PrPh-Me0-BIPHEP (S)-SEGF'HOS 
Scheme 1.32: Chiral bisphosphines for asymmetric cyclisations 
enolate 145. Enolate 145 undergoes an intramolecular aldol reaction to generate the 
copper alkoxide 146 that reacts with a molecule of TMDS (a-bond metathesis) to 
regenerate the copper hydride and release silyl ether 147. During acidic work-up, the 
silyl ether is hydrolysed and alcohol products are isolated. 
It was observed that a,0-unsaturated amides can also be used in this process giving 
4- hydroxypiperidin- 2- ones with high levels of diastereoselectivity. Once more a broad 
scope of ketone acceptors was tolerated. However, only acryloyl and crotonyl amide 
29 
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0 
5 mol% ligand 	
o 
5 mol% Cu(OAc)2.H2 0 





Entry 	R 	Ligand 	Yield ee 
1 Ph 136 72 62 
2 Ph 137 73 73 
3 Ph 138 69 70 
4 Ph 139 64 77 
5 Ph 140 62 74 
6 4-C1Ph 136 79 73 
7 4-C1Ph 137 71 76 
8 4-C1Ph 138 71 83 
9 4-C1Ph 140 73 82 
10 PhCH2CH2 136 60 72 
11 PhCH2CH2 137 60 72 
12 PhCH2CH2 138 61 80 
13 PhCH2CH2 140 68 80 
Table 1.2: Copper-catalysed asymmetric reductive aldol cyclisations 
components were reactive enough to undergo the reaction under these conditions. In 






Q CUI _H 	R2 144 R3SiO 	
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P 	 0 
O 	o 0 
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Scheme 1.33: Proposed catalytic cycle of the copper-catalysed reductive aldol cycli-
sation 
The presence of a stereocentre at C5 or C6 delivered a strong 1,2- and 1,3-asymmetric 
induction and excellent levels of diastereoselectivities were observed in this class of 
starting materials (Table 1.4). 
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PPh2 
5moI% Fe 	 0 
0 	0 	
134 	—PPh2 	 _Ar 
R1 N''R2 	 N 
I 	 5 mol% Cu(OAc)2.H20 	 IIIJ 
Ar 
148 	 1eqTMDS 	 HO 149 
THE, rt 
Entry Substrate R Product Time Yield 
1 Me 2.5 66 
2 0 	0 Et 0 5.5 61 
z'-Bu Me.) J.PMP 24 64 
4 I Ph R 21 69 
5 
P MP 
4-MePh HO 24 64 
6 2-furyl 24 53 
O 	0 0 
7 Me N ' A Me Ft 22 55 I tN,Pmp  
8 Pi MP Et P 24 52 
HO 
0 
Me ) 	PMP 





Table 1.3: Copper-catalysed reductive aldol cyclisation to form 4-hydroxypiperidin-2-
ones 
1.3.2 Cobalt-catalysed reductive aldol cyclisation 
Although copper catalysis had proven to be highly successful in the formation of /3-
hydroxylactones, its efficiency in the formation of /3-hydroxylactams was diminished by 
the low electrophilicity of cj3-unsaturated amides. To counter the limitations of the 
copper-catalysed reductive aldol cyclisation reaction a new catalytic system had to be 
invented. 
The application of non-copper metal salts proved to be unsuccessful despite previous 
reports of similar processes involving Co(II) and silanes.899' Inspired by several articles 
in which organometallic reagents were used in place of silanes9296 we became interested 
in applying similar conditions for reductive aldol cyclisations. When a Co(acac)2 pre-
catalyst was used together with Et2 Zn as the stoichiometric reductant a high yielding 
reaction was observed.28 
Upon investigation of the reaction scope it was observed that this new catalyst 
system allowed a broad range of starting materials to undergo the reductive aldol cy- 
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Table 1.4: Formation of C5- and C6-substituted 4-hydroxypiperidin-2-ones 
clisation. It was possible to obtain five- and six-membered 3-hydroxy1actams contain-
ing a wide variety of substitutions that were previously unreactive under the copper-
catalysed procedure. Although Co(acac)2 was the most versatile precatalyst, CoC12 
together with electron-rich ligand (Cy2 PPh) was used for some starting materials 
Co (5 mol%) 	 o 
o 	ligand (5.5 mol%) 




THF, hexane 	 Me" PMP 154 	 O°Ctort HO 155 
	
0 	 0 	 OMe 	0 
Me 	- PMP 	 :)~N a M - PMP O'
N 
- 
PMP .7 . 
HO 	 HO 	 H 0 
158 	 157 	 156 
Co(acac)2 C0Cl2, Cy2PPh 	 CoCl2, Cy2PPh 
47% 9:1 dr 	 56% 8:1 dr 74% >14:1 dr 
Scheme 1.34: Cobalt-catalysed reductive aldol cyclisations to form five-membered 
lactams 
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Co (cat) 
0 	0 	 ligand (cat) 
R1 N R3 	
Et2Zn(2eq) 	RI N_R 





152 	 153 
Method A: Co(acac)2-2H20 (5 1,101%) 
Method B: C0Cl2 (5 mol%), Cy2PPh (5.5 mol%) 
Entry Substrate R Method Product dv Yield 
0 
1 Me A Ph ) JN _ MP 12:1 89 
2 I Et A A 9:1 79 
PMP 
HO 
3 H A 0 9:1 88 
A 	N Me 
i-Pr A RNBn  >19:1 >99 
Ph A 
Me.,. 
e' >19:1 97 
6 
Bn  
2-furyl A HO >19:1 >99 
0 
A 
Me A RY1iI JN Bfl  >19:1 94 






RN  H B 
0 
PMP 
A 	N 9:1 56 
10 Zb Me B HO >19:1 80 
11 Ph B \JCO2Et >19:1 88 
Table 1.5: Cobalt-catalysed reductive aldol cyclisations 
Although the formation of five-membered lactams was achieved with lower yields, 
these results were later to be of great importance in synthesis of salinosporamide A 
intermediates. 
Cobalt-catalysed reductive aldol reactions with diethylzinc were underperforming 
when starting materials containing phenyl ketone were used (<20% yield). This lim-
itation was partially overcome when Et3A1 was used instead of Et2Zn. In this case 
l-hydroxy-/l-phenyl-lactams were obtained in modest yields. 
0 
0 	 Co(acac)2 H20 (5 mol%)
Ph 
	
Me 	ll _R Et3AI (2 eq) 
THE, hexane 	Ph")' A 	0 	 O°Ctort 
HO 
159 	A = PMP 	 161 57% yield, >19:1 dr 
160 A = PMB 162 53% yield, 8:1 di 










42% 5:1 dr 
0 




70% 5:1 dr 
Chapter 1. Formal Synthesis of Salinosporamide A 
1.3.3 Nickel- catalysed reductive aldol cyclisations 
The improvements observed using the cobalt catalyst and diethylzinc inspired us to 
further extend the search for a catalyst for our reductive aldol reactions. At that time, 
nickel was rarely used as a catalyst for similar reactions, in one recent example Mont-
gomery applied Ni(COD)2 with Et3B.3° After thorough investigations it was demon-
strated that Ni(acac)2 in conjunction with Et2 Zn was a superb catalyst system for re-
ductive aldol cyclisations. The reactivity of the nickel catalyst towards c,/3-unsaturated 
amides not only improved previous results obtained with the cobalt catalyst but also 
allowed a much broader scope of starting materials then any other catalyst.29 
Interestingly, reactions of substrates with mono-ethyl esters of fumaric amides 
yielded bicyclic products in which the initial reductive aldol cyclisation to form the 
lactam ring was followed by a y-lactone formation (Table 1.6 entries 14 and 15). Most 
importantly these conditions allowed the preparation of a wide variety of 'y-lactams. 
These results initiated efforts in the total synthesis of salinosporamide A. 
0 
Ni(acac)2 (5 mol%) 
	
Et2Zn(2eq) 	A1 	N_PMP 
THE, hexane
Me~ 
0°Ctort 	 HO 166 
f 
OMe 	0 	 0 
'J N_PMF' N— PMP 
'.-....._'-- 
:)~ Et02C 
HO 	 HO 
169 170 
58% >19:1 dr 	 76% >19:1 dr 
Scheme 1.36: Nickel-catalysed cyclisations to form 'y-lactams 
Reactions of c3-unsaturated esters were also effective with the nickel catalyst. 
Upon comparison it was observed that many previously unreactive starting materials 
gave the reductive aldol products in high yields and excellent levels of diastereoselec-
tivity under the modified conditions. 
In an attempt to understand the superior reactivity of the nickel-catalysed reac-
tions, a mechanistic investigation was undertaken partially based on previous reports 
of coupling reactions with nickel catalysts.' It is widely accepted that Ni(acac)2 is re- 
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0 	0 	Ni(acac)2 (5 mol%) 	 0 
Et2Zn (2 eq) 
R'NR 
THE, hexane 
R2 I 	 OCtort 
	
163 HO 164 
Entry Substrate 	 R 	 Product dr Yield 
1 	 Me >19:1 97 
0 
2 0 	0 	 i-Pr 	 Bn 	12:1 	98 
3 	R 	N M e PhCH2CH2 R 	N > 19:1 95 
11  
I 	 M 
4 Bn Ph 	
e' 
HO 	 >19:1 	97 




N 	Me 	 j




PhNEt 	 PhN_PMP 	






Me 	N 	Ph 	
Et 	
N 





Bn 	9:1 	84 
N 
 __lL Ph 	Me 	R) JN - 
10 	 i-Bu 
 Ph. : 
h 	 12:1 84 Bn 
11 2-furyl 	HO > 19:1 	79 
0 	 0 
12 	 Me 	H 
CO2Et 	 _ 	PMP 	> 19:1 	62 
13 
RN 
Ph > 19:1 50 
CO2Et 
R'=PMP 	o 
14 	 R = Ph N 	> 19:1 	62 
R' = Bn 
A1  
15 	 R 2 = Me 	A2 	 > 19:1 	50 
Table 1.6: Nickel catalysed reductive aldol cyclisation to form 4-hydroxypiperidin-2-
ones 
duced with Et2 Zn to a nickel(0) species in situ and this intermediate acts as the active 
catalyst. Similarly cobalt(II) salts are also reduced with Et2Zn to cobalt(0). How-
ever, the mode of action of these two low valent metal catalysts are uncertain. We 
have proposed two mechanisms that can explain the reactivity patterns observed in 
our studies.27  
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Ni(acac)2 (5 mol%) 	
0 
	
0 	0 	 Et2Zn (2 eq) 
R1 O 
R1 OR2 	THE, hexane 
0 C tort 
171 	 HO 172 
Entry Substrate 	R 	Product dr Yield 
1 	 i-Bu 0 	 > 19:1 	77 
2 0 	0 PhCH2CH2 RO 	 > 19:1 85 
3 	RO Me 4-MeOPh 	Me 	 > 19:1 	76 
4 2-furyl HO > 19:1 81 
0 
5 	° ° i-Bu RKO 	 5.5:1 99 
6 RO Ph PhCH2 CH2 	Ph 	 > 19:1 	76 
HO 
0 	 0 
7 	
RO CO2Et 	
Me 	RO 	 > 19:1 	88 
8 i-Pr 
HO 	
> 19:1 74 
9 	 Ph 	\JCO2Et 	> 19:1 	73 
Table 1.7: Nickel-catalysed reductive aldol cyclisation to form /3-hydroxylactones 
A general mechanism for oxidative cyclisation with a low valent catalyst is shown 
on scheme 1.37. Initial coordination of the metal (nickel(0)) with two 7r-components 
is followed by oxidative cyclisation giving intermediate 174. Transmetallation of 174 
with a main group organometallic reagent gives 175. Reductive elimination of nickel 
from 175 releases the final product 176 and regenerates the low valent catalyst.5 
Ni°  
L L 	 LL 	
MR 	 I 	 M—A 	D—R 
A=B +C=D 	 Ni \ D 
	Ni 	 L _____ 
A/ , 	 A' 'D 	 M—A 	D—Ni—L 	 ' / I 	 B—C 
/ B—C R BC B  
173 	 174 	 175 	 176 
Scheme 1.37: Oxidative cyclisation of Ni(0) with two 7r-components 
The mechanism for the reductive aldol cyclisation with nickel and cobalt catalysts 
and diethyl zinc reductant is proposed based on an oxidative cyclisation mechanism 
(Scheme 1.38). Cyclisation between alkene, ketone and low valent metal catalyst is 
most likely facilitated by the diethylzinc reagent through Lewis acid-based activation. 
Possibly a three-center-two-electron intermediate is formed 178. 	Transmetallation 
of an ethyl group from zinc to nickel/cobalt yields intermediate 179. Upon /3-hydride 
elimination from an ethyl substituent a metal hydride 180 is formed which undergoes 
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reductive elimination to give the product in the form of alkoxide 181 and regenerates 
the metal catalyst. The alcohol product is isolated from reaction mixture upon acidic 
workup. 
0 
M(acac)2 	 0 
 
R' 	X 	
X R1  










R1 H H 0 	 R1  H 
H;M_&J 	
Et!( I X 
0 	 in-on 
EtZr( A2 
	
	 / 	R2 178 
Al H H 
Et - M' X 	
Zn to M 
3-hydride ethyl migration 
elimination 	 o 	 (transmetalation) 4n 
EtZn' A2 
179 
Scheme 1.38: First possible reaction mechanism: via formation of metallacycles 
In this mechanism, the control of the relative stereochemistry is achieved through 
formation of metallacycle 178 that contain a cis arrangement of rings producing mainly 
the syn diastereoisomer of the final product. 
Et 	 M(acac)2 
Zn 	 OZnEt 
- 	— 	











= Et\, Zn' 	---" Ri) 	R ' 
MO 
I 	II p2 
184 	0 
Scheme 1.39: Second possible reaction mechanism: via formation of a zinc enolate 
An alternative mechanism has also been proposed. In this scenario only the ci,/l-
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mediate 182 is preformed from the metal catalyst and diethyizinc. Coordination of 
182 to the starting material gives intermediate 184 that undergoes 3-hydride elimina-
tion from an ethyl group to produce 185. A concerted rearrangement of the 185 gives 
enolate 186 and regenerates the metal catalyst. Intermediate 186 undergoes aldol cy-
clisation through transition state 187 to produce the alkoxide 188. Acidic workup of 
the reaction mixture allows isolation of the desired aldol product. The stereoselectiv-
ity of this mechanism is the result of a preferential formation of a Z-enolate in 187 and 
a chelated Zimmerman-Traxler transition state. 
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1.4 Results and discussion 
Given the huge interest in salinosporamide A (1), and the resemblance of 3-hydroxy-
'y-lactam 3 to the core of 1, we became interested in the possibility of applying our 
nickel-catalysed reductive aldol methodology29 in a synthetic route towards this natural 
producO 
C11 	 NH 
0 	bOH 
Scheme 1.40: Structure of Salinosporamide A 
Reductive aldol cyclisation in the Lam group at that time was a well studied reac-
tion. We believed to have an extensive understanding of reaction conditions that would 
allow us to successfully apply our reductive aldol cyclisation to substrates significantly 
more difficult than those previously studied. Our motivation came from examples like 
those depicted in scheme 1.41. 
OMe 	0 	 OMe 	0 
- PM P 
Me1._J 	
Co(acac)2 (5moI% 
Et2Zn (2 eq), THF &M~e 
HO 0 
189 	 190 
74% >19:1 dr 
0 	 o 
	
EtO NPMB Ni(acac)2 (5 mol%) 	DO 	 _PMB 
0 Me (2 eq), THF 	 II 
Me 
0  HO 
191 	 192 
76% >19:1dr 
Scheme 1.41: Relevant examples of successful cyclisations to 5-membered ring -lactams 
Although the nickel-catalysed reductive aldol cyclisations proceeded smoothly to 
give /13-hyrdroxy-'y-lactams, the vast majority of starting materials did not contain large 
side chain substitutions and we were unsure how this would influence the key step in 
Work done in cooperation with Isabel Villanueva, t is used to mark experiments conducted by 
Isabel. 
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our synthesis. We were lucky to observe high levels of syn diastereoselectivity in most 
of the reactions but no control of enantioselectivity was known. Hence, we had to be 
sure that our cyclisation precursor in the synthesis of salinosporamide A contained a 
preformed stereocentre to efficiently direct our syn selective reductive aldol cyclisation 
towards one diastereoisomer. 
1.4.1 Retrosynthesis 
Employing a reductive aldol cyclisation as our key step in the total synthesis of sali-
nosporamide A placed a strong constraint on the possible synthetic pathway. Upon 
careful examination of previous total syntheses and difficulties that were observed by 


























194 11 Reductive 
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+ Me 
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coupling PGO)L N - PG 
Me 
195 
Scheme 1.42: Retrosynthetic analysis for the reductive aldol cyclisation approach 
Salinosporamide A is not a fully stable molecule due to its highly strained /-lactone 
ring that, upon opening, can form a cyclic ether by substitution of chlorine. For 
these reasons the /-lactone formation and chlorination were envisioned to be our last 
steps. It was also important to plan the introduction of the cyclohexene moiety at a 
later stage in the synthesis and these disconnections lead to intermediate 193. The 
aldehyde functionality in 193 has to be masked as group X (for example: silane, benzyl 
ether) during the reductive aldol cyclisation because of incompatibility with diethylzinc. 
Structure 194 represents an example of a reductive aldol cyclisation product that we 
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hoped to obtain from the cj3-unsaturated amide 195 that in turn can be constructed 
by peptide coupling between acid 197 and amino-ketone 196. 
Compound 196 can be seen as a /3-substituted derivative of amino acid. Trans-
formation of L-threonine to 196 is a relatively common process involving oxazoline 
intermediates for control of the stereochemistry of the tetrasubstituted stereocentre. 
1.4.2 Formal synthesis 
Using the retrosynthetic analysis as a guide we initiated studies towards the total 
synthesis of salinosporamide A. Surprisingly, because of unpredicted circumstances we 
managed to complete a formal synthesis by obtaining a different than expected product 
of the reductive aidol cyclisation. Our synthesis started with a relatively large scale 
preparation of basic starting materials. 
Preparation of oxazoline 
Esterification of L-threonine 198 gave the HC1 salt of the methyl ester 199 in a high 
yield although with minor difficulties. Our product of esterification was obtained as a 
slightly yellow highly viscous solid instead of white powder. As there were no impurities 
observed by means of spectral analysis we assumed that our source of HC1 (generated in 
situ from SOd 2 ) was impure or a side reaction was taking place giving small quantities 
of sulphur that inhibited the crystallisation process. Changing SOC12 to AcC1 did 
indeed help however, only a slight improvement was observed and the final product 
had to be washed several times in various solvents to achieve a nice white powder 
that was easier to handle then the viscous solid. After a search in scientific literature 
we found out that similar problems were observed by others and the only way to 
isolate L-threonine methyl ester as white powder is to conduct esterification in high 
purity methanol with HCl gas as a catalyst. Due to the of difficulties associated with 
handling large amounts of HC1 gas we decided to continue our synthesis using the 
previous protocol of pregeneration of HC1 in situ from methanol and thionyl chloride 
as depicted in scheme 1.43. 
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Following a known protocol98 4- met hoxyb enzonitrile 200 was smoothly transformed 
into 201 via an acid catalysed addition of methanol to nitrile. Product 201 was obtaine 
as a pure white solid on semi-industrial scale (up to 100g in one batch) and could 
be stored indefinitely in a fridge. Despite the use of AcC1, that caused difficulties 
in the crystallisation of ester 199, this time the desired white powder of 201 was 
spontaneously crashing out of solution. One drawback of this reaction was the need to 
maintain a slight overpressure of generated HCl inside the sealed reaction flask. That 
required a significant degree of caution during the addition of acetyl chloride and the 
reaction flask was sealed only after most of the HCl was released to ensure safety. 
H2N 	.0O2H 
HO1Me 











Scheme 1.43: Basic starting materials 
Condensation of imine 201 and the methyl ester of L-threonine 199 was initially 
achieved using 1 equiv of triethylamine in refluxing DCM. This process gave 40% of 
the desired oxazoline 202. However, upon scaling up, we found it to be a less reliable 
method because of difficulties with purification of the reaction mixture. Later we 
discovered that K2CO3 can be used instead of triethylamine and 65% yield of product 
was obtained. Oxazoline 202 is the same material that Corey obtained in his synthesis. 
Although our condensation approach with K2 CO3 was giving slightly lower yields than 
Corey's procedure (acylation of methyl ester 199 with 4-methoxybenzoyl chloride and 
subsequent acid catalysed cyclisation45), this process involved only one step and allowed 
grater reliability. 
Alkylation of oz-position in oxazoline 202 
Alkylation of oxazoline 202 was achieved by Corey using LDA in the presence of HMPA 
to form the enolate intermediate and followed by addition of chloromethyl benzyl ether 
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Scheme 1.44: Preparation of oxazoline 202 
to give the desired product 203 in 69% yield. We decided to try to optimise this 
reaction. 
Our desired product did not require the introduction of a benzyl ether substituent. 
It was enough to install any functional group that could be easily converted to an 
aldehyde. It was also desirable to avoid the use of unstable or toxic reagents. 
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Scheme 1.45: Optimisation of alkylation procedure 
Upon testing many different conditions we came to the conclusion that phase-
transfer catalysis is hopeless in this case (as expected) as only decomposition products 
were isolated. It was also not possible to exchange the chloromethyl benzyl ether 
with an iodomethyl silane reagent even when Corey's protocol of deprotonation was 
used. That can be explained due to the reduced electrophilicity and large steric bulk 
of iodomethyl silane in comparison to chloromethyl benzyl ether. Finally, we managed 
to improve Corey's yield using LHMDS instead of LDA to deprotonate the oxazoline 
202. This change of base also made it easier to conduct the alkylation steps because 
LHMDS is a stable commercial reagent as opposed to LDA that have to be preformed 
(Scheme 1.45 and Table 1.8). 
Preparation of a,0-unsaturated amide-ketone 212 
Oxazoline 203 was reductively opened with sodium cyanoborohydride in acetic acid 
(Scheme 1.46). The desired amino-alcohol 204 was obtained in a good yield, unfor-
tunately yields were variable between reaction runs (from 60 to 85%). Initially we 
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Entry Acceptor Base/Additive Solvent Results 
1 ICH2Si(Me)2 Ph KOH, BuNEt3C1 PhMe Decomp. 
2 C1CH2 OBn KOH, BuNEt3C1 PhMe Decomp. 
3 formaldehyde KOH, BuNEt3C1 PhMe Decomp. 
4 ICH2Si(Me)2 Ph LHMDS, HMPA THF Decomp. 
5 C1CH2 OBn LHMDS, HMPA THF 75% 
Table 1.8: Alkylation trials 
planned to protect the hydroxyl in 204 as a TMS ether, then perform a peptide cou-
pling of the amine to a desired oj-unsaturated acid. Deprotection of the TMS ether 
and oxidation of the alcohol to a ketone to afford compounds similar to 212. The rea-
son for this initial procedure was that reacting amino-alcohol 204 with Dess-Martin 
periodinane gave unidentified products of decomposition. Fortunately it was found 
that the same amino-alcohol can be readily oxidized with a good old Swern oxidation 
protocol. Using (COd)2 , DMSO and Et3N alcohol 204 was smoothly converted to the 
ketone 205 in 72% yield without the need for time consuming protection steps (con-
version from the amino-alcohol to the amide-ketone was done in two steps instead of 
four). 
CO2Me 	 HN _PMB 	 HN _PMB 
J." 
.
QBn NaBH3CN Me 
	
OBn (COC)2, DMSO Me 
	
I 	OBn 
MeO 	 AcOH 	r .- CO2Me 	Et3N,CH2Cl2 	 COMe 
OH 	 0 
203 	 204 205 
Scheme 1.46: Oxazoline reduction and Swern oxidation 
N-Acylation of 205 
Amine-ketone 205 was an important intermediate in the synthesis of salinosporamide 
A. We were able to form several different c,/3-unsaturated amides using this material 
and so test the efficiency of the reductive aldol cyclisation. Formation of an amide 
possessing the desired functionality was crucial in order to continue the synthesis of 
salinosporamide A because the side chain of the acid used would have to be converted 
in to the CH2CH20 side chain of final molecule at a later stage. We decided that the 
acid 210 with an OPMB protecting group would fulfil all the necessary requirements 
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for a late stage chlorination. The acid 210 was made via a three steps synthesis with 
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Scheme 1.47: Preparation of acid 210 
The formation of an amide bond between amine 205 and acid 210 proved to be 
more difficult than anticipated (Scheme 1.48). Initial trials concentrated on the in situ 
formation of an acid chloride 211 that was transferred to a solution of base and amine 
205 without prior isolation. We have used two protocols to generate the acid chloride 
211. In the first procedure, a solution of acid 210, oxalyl chloride and a catalytic 
amount of DMF was stirred until no further gas evolution was observed, that was a 
standard procedure used for amide coupling in our laboratory. In the second case, 
treatment of acid 210 with thionyl chloride for 3 h and vacuum distillation to remove 
the excess reagent was also tried. The solution of pregenerated acid chloride 211 was 
then added to a solution of amine 205 in the presence of a base (Et3N, i-Pr2 EtN, 
pyridine, 2,6-di-tert-butylpyridine, Na2CO3 aq ). Unfortunately, we were not able to 
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Scheme 1.48: Trials of peptide coupling 
Upon careful examination of our results we realized that PMB protecting group of 
the alcohol was susceptible to cleavage during acid chloride formation. This protecting 
group is known to be sensitive to acidic conditions. Additionally, the low nucleophilicity 
and steric hindrance of amine 205 made this amide coupling even more challenging. 
To avoid PMB cleavage we tried to use peptide coupling reagents to mediate this 
45 
Chapter 1. Formal Synthesis of Salinosporamide A 
difficult amide coupling. In theory, without the need to generate acid chloride deriva-
tives, there would be no problem of PMB cleavage. Several different peptide coupling 
reagents were trialled in the presence of various additives (Table 1.9). Unfortunately, 
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Entry Reagent, Additive/Base 	Solvent 
1 DCC, DMAP DCM 
2 DCC, HOBt DCM or DMF 
3 DIG, DMAP DCM or DMF 
4 EDC, HOBt DMF 
5 EDC, DMAP DCM or DMF 
Table 1.9: Peptide coupling reagents 
We speculated that the failure of peptide coupling reagents was caused by the low 
nucleophilicity and steric bulk of amine 205. A possible solution to this amide coupling 
would be to use the benzyl protected version of acid 210 to avoid the cleavage of the 
protecting group during acid chloride formation. However, benzyl protection would 
not be compatible for later steps in the synthesis of salinosporamide A as there was 
already one benzyl ether protected group in 205 that would have to be selectively 
hydrogenated after the reductive aldol cyclisation step. 
0-acylation and acyl transfer 
After the difficulties with the amide coupling we turned to a procedure of acyl transfer 
that has been used previously in the synthesis of natural products (Scheme 1.49). When 
amino-alcohol 204 was used with acid 210 under peptide coupling conditions an ester 
213 was smoothly isolated. This result confirmed our previous speculation concerning 
the large steric bulk of amine 205. We hoped that a Lewis acid activation of ester 
213 would facilitate an intramolecular attack of nitrogen onto the ester to yield amide 
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214. Upon examining several sets of conditions we obtained no product and only 
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Scheme 1.49: Esterification of 204 and acyl transfer trials 
Entry Conditions Results 
1 La(OTf)3 , DCM, Reflux SM 
2 DBU, PhMe, Reflux Isomerization 
3 MeAl, DCM, Reflux SM 
4 Me2A1C1, DCM, Reflux SM 
5 Me3A1, PhMe, Reflux SM 
6 EtOH, H2SO4,  Reflux Isornerization 
Table 1.10: Acyl transfer trials 
Mono-ethylfumaric amide 
A long series of unsuccessful amide coupling attempts motivated us to survey some 
different 8-unsaturated acids in an effort to at least verify that once we obtained the 
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Scheme 1.50: Preparation of 217 
Amide derived from mono-ethylfumaric acid 215 was a perfect candidate for such 
model studies. This acid was previously used during methodology studies giving good 
yields of five- and six-membered lactams. Pregeneration of the acid chloride 216 using 
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a standard procedure was followed by addition of the amine 205 in presence of a base. 
The desired mono-ethylester fumaric amide 217 was isolated in good yield (Scheme 
1.50). 
Compound 217 was considered as a suitable model for the reductive aldol cycli-
sation studies. The product of this cyclisation 218 was not suitable to continue the 
synthesis of salinosporamide A because of the ethyl ester substitution in a side chain. 
This ethyl ester would have to be selectively reduced in the presence of a methyl ester 
later in course of synthesis (Scheme 1.51). A more suitable group than an ethyl ester 
would be a PMB protected hydroxyl group that contains carbon atom at the oxida-
tion state of the final product (salinosporamide A) making it strategically much more 
valuable. 
selective 
ester 	 0 
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Scheme 1.51: Possible difficulties caused by ethyl ester 
Reductive aldol cyclisation of 217 
We planned to employ reductive aldol cyclisation methodology, developed in our group, 
to stereoselectively form the 'y-lactam ring of salinosporamide A. High levels of syn 
selectivity in reductive aldol cyclisations are accounted for by the preferential formation 
of Z-enolates together with Zimmerman-Traxler99 transition state.2629 For a successful 
synthesis of salinosporamide A it was desireable for the quaternary stereocentre to exert 
a strong effect on the face selectivity of syn cyclisation (Scheme 1.52). 
Possible influence of the quaternary stereocentre on the reaction outcome would be 
by additional binding of the catalyst to one of its substituents. A strong interaction 
between the catalyst and methyl ester of the quaternary center would yield the desired 
diastereomer 223. However, the benzyl ether group is also a suitable binding site and 
such binding would produce the undesired diastereomer 224, although this interaction 
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Scheme 1.52: Transition states that give two syn products of cyclisation 
should be weaker then catalyst-methyl ester (Scheme 1.53). 
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Scheme 1.53: Directing effect of quaternary stereocentre 
Ultimately, it was difficult to predict the diastereoselective outcome of this reductive 
aldol cyclisation since all proposed transition states could be formed in competition 
and it was hard to estimate the relative energies of them as well as kinetic effects. In 
addition, the precise nature of the reductive aldol cyclisation was not fully understood 
during methodology studies, adding to the confusion. It was becoming apparent that 
the cobalt- and nickel-catalysed processes did not undergo an enolate-type mechanism 
as was in operation under copper catalyses. 
Our efforts to cyclise amide 217 concentrated around cobalt and nickel-catalysed 
reductive aldol cyclisations as copper was not a suitable catalyst for formation of five-
membered lactam rings. Initially Co(acac)2 and Ni(acac)2 were used together with 
diethylzinc or triethylaluminum reagents. Unfortunately these standard sets of con-
ditions were not effective in the cyclisation of 217. Several combinations of catalyst, 
temperature and solvent were tried. The majority of these tests yielded mixtures of 
products. In an attempt to understand reaction mechanism several trials to isolate the 
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major product from complex mixtures were conducted without success. 
Further studies focused on the use of phosphine ligands together with nickel and 
cobalt salts. Addition of triphenyiphosphine did not have an effect if small quantities 
were used. However, it was able to completely inhibit the catalyst when substoichio-
metric quantities were added. A large bis-phosphine ligand DPPF did not change the 
course of the reaction and afforded a complex mixture of products. 
Upon analysis of the results obtained during the development of the reductive aldol 
cyclisations, we concluded that all possible reaction conditions from the methodology 
development studies had been exhausted. Any further search for a reaction cata-
lyst would have to be conducted on the difficult starting material and not on simple 
models. After a time consuming synthesis of significant quantities of amide 217 we 
continued the search for a suitable catalyst system. A screening of transition metal 
salts and several potential reducing agents was undertaken. Fortuitously, one of the 
reagents surveyed was (Ph3P)2 NiBr2. Knowing that the addition of triphenylphos-
phine to Ni(acac)2 did not yield any product we were not hopeful of this preformed 
Ni-triphenylphosphine complex. Surprisingly, the first trials of the cyclisation step 
yielded fairly clean TLC (as compared to previous ones) with two major products and 
small quantities of a third one. Upon purification, a 35% yield of product (in the form 
of a 'y-lactone-'y-lactam) was obtained together with 30% of the undesired diastere-
omer. These results were further improved by the use of (Me3P)2 NiC12 and starting 
reaction temperature of -15 °C. In this case, the desired product 131 was isolated in 
42% yield (Table 1.11). 
The observed low facial selectivity of the reductive aldol cyclisation indicated that 
the quaternary stereocentre was either ineffective at directing the approach of nickel 
catalyst or binding between nickel-methyl ester was comparable to nickel-benzyl ether. 
We speculated that the former is the case as the nickel catalyst is already occupied 
with two triphenylphosphine ligands. The only way to increase the effect of the qua-
ternary stereocentre would be to use a catalyst without ligands but that in turn caused 
many side reactions to occur. This dead circle prompted us to continue the synthe- 
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Entry Metal salt/ligand Reductant Result 
1 Ni(acac)2 Et2Zn intractable mixture 
2 CoC12 , Cy2 PPh Et2Zn intractable mixture 
3 Co(acac)2 Et2 Zn <10% conversion 
4 Ni(acac)2 Et3A1 intractable mixture 
5 Co(acac)2 Et2 A1 intractable mixture 
6 CoC12 , PPh3  Et2Zn 217 recovered 
7 CoCl, DPPF Et2 Zn intractable mixture 
8 (Ph3P)2 NiBr2 Et2 Zn 35% of 131, 30% of 132 
9 (Me3P)2 NiC12 Et2 Zn 42% of 131, 30% of 132 
Table 1.11: Conditions attempted in the cyclisation of 217 
sis of salinosporamide A without further optimisation of the reductive aldol cyclisation 
conditions. 
C14 
Figure 1.54: X-ray analysis of 132 
The formation of the additional 'y-lactone ring during reductive aldol cyclisation 
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was not anticipated. This process most likely occurred after zincalkoxide intermediates 
were formed. A highly probable mechanism involves an attack of the alkoxide anion 
onto the neighbouring ethyl ester with a release of zinc ethoxide. Similar processes were 
observed during methodology studies when a six-membered lactam of 229 and 230 was 
formed and only minor quantities were found in other cases. Compounds 131 and 132 
were the first examples of -y-lactone-'y-lactam ring system formation during reductive 
aldol cyclisations in our studies. One possible explanation is that steric bulk around 
the quaternary stereocentre causes a high strain in the 'y-lactam ring that brings the 
zincalkoxide and ethyl ester substituents in closer proximity to each other, facilitating 
the additional cyclisation. 
00 
0 	0 	Et2Zn (2 equiv) 	 1 
Et02C 	N 	
R2 Ni(acac)2 (5m % Et02C
N - R 	 - 
R 	 EtZnO 
229 R1 =PMPR2 =Ph 	 231 	 233>19:1dr,79% 
230 R1 =Bn,R2 =Me 232 234>19:1di,89% 
Scheme 1.55: Reductive aldol cyclisation leading to fused ring system 
Although the cyclisation precursor 217 was considered as a model study of cycli-
sation, an additional lactonisation step could allow the completion of the synthesis of 
salinosporamide A. Without lactonisation a difficult late stage reduction of the ethyl 
ester in the presence of a methyl ester would have to be done. However, 'y-lactone is 
relatively easy to reduce as this type of ester group is much more reactive then a lin-
ear methyl ester. Additionally, the 'y-lactone ring delivered a stable protection for the 
tertiary 3-hydroxyl substituent that otherwise would have to be protected in an ad-
ditional step. The configuration of the undesired diastereoisomer was confirmed by 
X-ray crystallography (Figure 1.54). 
Finishing formal synthesis 
Upon optimisation of the reductive aldol cyclisation of 217 the desired diastereomer 
of the cyclized product 131 was transformed in a few steps to the triol 20 that was an 
intermediate in the total synthesis of salinosporamide A by Corey. 45 
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Scheme 1.56: Deprotection of benzyl ether 
After successful separation of the diastereomers by column chromatography, com-
pound 131 was debenzylated by palladium-catalysed hydrogenation and the alcohol 
235 was obtained in good yield (Scheme 1.56). Fortunately it was possible to obtain 
crystals suitable for X-ray analysis and in this way the absolute stereochemistry of 235 













Figure 1.57: X-ray analysis of 235 
Dess-Martin oxidation 81,82  of the alcohol 235 provided 236 in good yield although 
the aldehyde product was unstable and so was quickly reacted with 2-cyclohexenyizinc 
chloride according to procedure of Corey.45 Upon completion, the homoallylic alcohol 
237 was isolated with very high diastereoselectivity (the minor diastereomer was not 
observed by 'H NMR) and 61% yield over two steps (Scheme 1.58). 
The alcohol 237 was a crystalline solid and so it was possible to confirm the con-
figuration of the two newly created stereocenters using X-ray crystallography. (Figure 
1.59) 
To complete the formal synthesis a 'y-lactone ring had to be selectively reduced in 
53 
Chapter 1. Formal Synthesis of Salinosporamide A 
ZnCI 




_4--1,, CH2OH CH2Cl2 	
N  
____ _________ 	
N' periodinane __________ 
'CHO THE, -78°C 
OH 
Me CO2Me 	 Me CO 2Me 	 Me CO2Me 
235 	 236 	 237 
Scheme 1.58: Dess-Martin oxidation and organozinc addition 
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Figure 1.59: X-ray analysis of 237 
the presence of a methyl ester. Fortunately the much higher reactivity of the lactone 
carbonyl allowed a smooth reduction with NaBH4 to give the triol 20 (Scheme 1.60). 
It was necessary to use a large excess of NaBH4 to achieve full conversion of the 
starting material. The product 20 was structurally identical to intermediates obtained 
by Corey45 and Pattenden48 in their total synthesis of salinosporamide A. Four further 
steps are required to convert 20 into salinosporamide A (1). 
0 	 0 
PMB- NaBH HO NH 
PMB 	 ci 	 P - __JN'  
' 	
MeOH 
OH  OH 	 o-4 OH Me CO2Me HO CO2Me 
237 	 20 	 1 
Scheme 1.60: Reduction of ylactonet 
Upon careful examination of the NMR data for triol 20 we observed some small 
54 
Chapter 1. Formal Synthesis of Salinosporamide A 
deviations from the values for the same compound reported by Corey and co-workers, 
these differences were most obvious in the '3C NMR spectra.45 We requested copies 
of NMR data from both the Corey and Pattenden groups and noticed that our results 
are in good agreement with the same compound obtained by Pattenden. It is possible 
that the chemical shifts of some '3C NMR signals are slightly dependent on concentra-
tion (intermolecular hydrogen bonding between hydroxyl and ester groups can change 
electron density on adjacent carbon atoms) the data acquired by Pattenden and our-
selves was from relatively dilute samples whereas Corey obtained his results using more 
highly concentrated samples. 
1.4.3 Future work 
One important feature to improve in our formal synthesis of salinosporainide A could 
be a reductive aldol cyclisation step. However, it is rather difficult to imagine what 
could be done to make this reaction more selective without some modification of the 
starting material. Any optirnisation of the catalyst system would at first require the 
development of a suitable model starting material that would be faster and cheaper 
to make followed by a careful screening of transition metals and analysis of products 
obtained. 
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Scheme 1.61: Homoallylation by Tamaru 
Another interesting and more probable project would be to take advantage of an 
unusual type of addition of cyclohexadiene to aldehydes. So far almoust all total syn-
theses of salinosporamide A455' have used Corey's procedure for the installation of the 
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cyclohexenyl side-chain using a cyclohexenyizinc reagent. The high diastereoselectiv-
ity of this process is impressive. However, the preparation of cyclohexenyizinc reagents 
involves several synthetic steps using highly toxic tin reagent, is atom-inefficient and is 
practically troublesome. Instead, another route could be proposed using new method-
ology developed by Tamaru.'°° A new nickel-catalysed homoallylation of aromatic and 
aliphatic aldehydes has been demonstrated using triethylborane or diethylzinc (in the 
case of sterically hindered aliphatic aldehydes and ketones). High levels of regio- and 
stereoselectivity have been reported (Scheme 1.61). 
In his original report, Tarnaru gave an example of a reaction between 1,3-cyclohexa-
diene and benzaldehyde that afforded allylation product 245 in good yield and moder-
ate diastereoselectivity (Scheme 1.62). If further improved, this type of reaction could 
be of great benefit for the synthesis of salinosporamide A as it uses more convenient 
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Scheme 1.62: Allylation example by Tamaru 
1.5 Conclusions 
We have successfully developed a formal synthesis of salinosporamide A. A reductive al-
dol cyclisation was used in the formation of the important 'y-lactam ring. Optimization 
of the reductive aldol conditions revealed a new catalyst (Me3P)2NiC12 for this trans-
formation and gave insight into the reaction mechanism. The desired diastereomer of 
the product was afforded in 42% yield together with 30% yield of the alternative prod-
uct. The observed low levels of diastereoselectivity gave more information about the 
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reaction mechanism. 
The reductive aldol cyclisation was followed by an unexpected formation of y-
lactone ring. This surprising result appeared to be beneficial, thanks to the protection 
of the tertiary alcohol that it provided the possibility of a selective reduction of the 
'y-lactone in the presence of the methyl ester. The highly efficient reductive aldol 
cyclisation-lactonisation reaction allowed the completion of formal the synthesis using 
several less steps then planned. Only four synthetic steps were required to transform 
the cyclisation product 131 into the intermediate obtained by Corey. A further four 
steps would allow the formation of salinosporamide A. 
We have developed a formal synthesis of salinosporamide A using 11 synthetic 
steps and 2.5% overall yield to intermediate 20. If recalculated, a total synthesis of 
this natural product would be achieved in 15 steps and 1.4% yield. A comparison with 
other syntheses of salinosporamide A is presented in table 1.12. 
Entry Author No of steps Overall yield Asymmetric/racemic 
1 Corey (Baylis-Hillman) 18 8.7% asymmetric 
2 Corey (Kulinkovich) 18 9.7% asymmetric 
3 Danishefsky 28 1.8% asymmetric 
4 Pattenden 14 11.5% racemic 
5 Langlois 18 4.0% asymmetric 
6 Romo 9 1.2% racemic 
7 Macherela 24 0.2% asymmetric 
8 Hatakeyama 21 4.4% asymmeteric 
9 Omura 36 2.0% asymmetric 
10 Bode 18 0.7% asymmeteric 
11 Lam 15 1.4% asymmetric 
Table 1.12: Comparison of reported syntheses of salinosporamide A (recalculated in 
case of formal synthesis) 
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Copper catalysed asymmetric 
reduction of alkenyiheteroarenes 
The development of modern pharmaceuticals requires increasingly more efficient and 
selective synthetic methods. Inspired by a growing number of procedures for enantios-
elective reductions and alkylations of alkenes (Scheme 2.1 eci 1) 101-108  conjugated to 
electron-withdrawing groups, we became interested in possible activation of a carbon-
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Scheme 2.1: General Idea 
The most common functional groups used to activate alkenes towards asymmetric 
conjugate additions possess a central atom with a considerably large partial positive 
charge induced by several 7-bonds to oxygen. This range includes carbonyls, sulfones, 
phosphonates, and nitro groups. It has also been shown that nitriles are suitable 
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is not necessary. 
Given that heteroarenes such as oxazoles, thiazoles, pyridines, and others are ubiq-
uitous in biologically active natural products, pharmaceuticals (Scheme 2.2), and agro-
chemicals, the ability to functionalise these privileged structures through a diverse set 
of asymmetric conjugate additions of 2-alkenyl derivatives (Scheme 2.1 eq 2) would 
open up broad-ranging applications. 
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Scheme 2.2: Examples of drugs containing electron-withdrawing heterocycle 
Our objective was to develop a new synthetic transformation for the highly enantios-
elective reduction of c8 unsaturated heteroarenes (Scheme 2.3). This would require 
the optimization of reaction conditions and an initial investigation into the substrate 
scope of this new process. We hoped that this procedure would broaden the field of 
synthetic tools available to the medicinal chemist and allow the quick preparation of a 
diverse family of compounds for which currently there is no efficient synthetic route. 
N 	 P3 
	
R4 R 	
M-H, hgand (cat.) 
2 reductant, 
proton source 	P 10~ 	RI 4 	 * P1 	 P1 
Scheme 2.3: Possible activation of alkene with oxazole heterocycle 
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2.1 Introduction 
Addition of a nucleophile to an alkene is one of the most popular classes of reactions 
in organic chemistry, examples of which can be found in almost all total synthesis of 
natural compounds. Ordinary alkenes are not susceptible to a nucleophilic attack (ap-
olar bond) and require activation from an electron-withdrawing substituent. Usually 
carbonyl groups like ketones or esters are used, reports of activation with aromatic sub-
stituents are also present in scientific literature.'09' 110  An overview of research relevant 
to this project is presented below. 
2.1.1 Nucleophilic addition reactions to alkenyiheteroarenes 
One of the earliest examples of a successful nucleophilic addition reaction to alkenyl-
heteroarenes was published by Levine and Wilt in 1953.111,112  They reported a reac-
tion between 2- and 4-vinylpyridine and a ketone in presence of 0.2 equiv. of sodium 
(Scheme 2.4). The products of mono alkylation were obtained in modest yields. 
0 
0 
+ 	RI.1_II. 	Na (0.2 equiv.) 
2 
reflux, 4-6 h 	
•_ 
H 
250 	 251 	 1i 252 
(2 equiv.) 










253 	 254 	 255 	 256 
20% 28% 1-2% 29% (Py = 2-pyridyl) 
22% (Py = 4-pyridyl) 
Scheme 2.4: Alkylation of 2-vinylpyridine 
The starting materials employed in this study contained several a-hydrogen and it 
was observed that varying levels of multiple alkylations can be obtained by changing 
the ratio of the starting materials used. When the starting ketone was in large excess 
only the mono-pyridylethylated products were observed, whereas multiple subsequent 
additions occurred when the ketone was the limiting reagent. Surprisingly acetone, 
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showed very limited reactivity giving only 1-2% of product. It was also observed that 
the c-methylene carbon in 251 was more reactive than the ct-methyl (giving product 
254). The last example 256 demonstrates that this reaction does not depend on a 
nitrogen atom in 2-position as there was only a small difference in the yields of products 
obtained with two different orientations of pyridine substituent. This methodology was 
later applied in the synthesis of biologically active compounds. 111,112 
Levine together with Magnus extended the previous methodology in 1956 pub-
lishing the results of the addition of amines, amides and nitriles to 2-, 4- and 5-
vmylpyrjml3 A mixture of starting materials in methanol were refluxed in the 
presence of concentrated acetic acid to promote the addition of nitrogen nucleophile to 
vinylpyridine, alternatively sodium was used in cases were acid catalysis did not afford 
good results (Scheme 2.5). 
N( N 
HNR2 
HOAc or Na, MeOH 
III 
reflux, 8-24 h 
2 257 	 58 
259 
0% (using 0.2 equiv. HOAc) 
74% (using 1 equiv. HOAc) 





75% (using 0.12 equiv. Na)  
260 
64% (No catalyst) 
63% (using 0.2 equiv. HOAc) 




13% (using 0.2 equiv. HOAc) 
Meh1 	N 'Ph 
Me 
263 	 264 
50% (using 0.12 equiv. Na) 	65% (using 0.12 equiv. Na) 
Scheme 2.5: Addition of amines to 4-vinylpyridine 
Although acetic acid was a good promoter for the reaction of 4-vinylpyridine, 
in the case of 2-methyl-5-vinylpyridine higher yields of addition were obtained with 
sodium. The paper also reports a very useful procedure for the formation of 2-
(aminoethyl)pyridine from 2-vinylpyridine by either direct amination with ammonium 
chloride or addition of acetic amide followed by hydrolysis of the amide bond (Scheme 
2.6). 
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Me NH2 NyMe 
C1,15 'N 	 0 
266 
Scheme 2.6: Direct amination and amide additoin/hydrolysis pathway 
Following the first route, the reaction of 2-vinylpyridine with an aqueous methano-
lic solution of ammonium chloride gave 2- (amino ethyl) pyridine in 85% yield, and the 
corresponding reaction of 4-vinylpyridine with an aqueous methanolic solution of am-
monium acetate gave 4-(aminoethyl)-pyridine in 77% yield. The second route also 
resulted in the formation of the desired product. 
Boy and Guernon showed that other vinyl-heterocycles could undergo similar reac-
tions (Scheme 2.7).114  They succeeded in the addition of various aliphatic amines to 
the ethyl-4-(trifluoromethyl)-2-vinylthiazole-5-carboxylate 267. Acyclic amines were 
observed to perform much better than cyclic amines suggesting strong influence of 
steric effects. 
CF3 	 CF3 





NH4CI in MeOH 
250 







269 	 270 
63% 79%  









271 	 272 
47% 24% 
Scheme 2.7: Addition of amines to 2-vinylthiazole 
Addition of carbon nucleophiles to 2-styrylbenzothiazole and 2-styryl-benzoxazole 
was reported by Dryanska and Ivanov in 1983 (Scheme 2.8).h15  A solution of the 
starting material 273, NaOH and nucleophile was stirred at room temperature for 24 
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h to deliver good to high yields of products. A broad scope of nucleophiles including 
ketones, esters, nitriles, 2-benzoxazole and 2-styrylthiazole was showed tolerated under 
the reaction conditions demonstrating that vinyl benzoxazoles and benzothiazoles are 
good electrophiles for nucleophilic addition reactions. 
	
cIIItIIX>—S..Ph ~ PhA 	
aq. NaOH (10 mol%) 	
II 	I 




273 	 274 	 275 A 
X> ph CC XPh 	 X Ph 	 X> h 
Ph 	 Ph~ 	 Ph 	 Ph 
0 	 0 	' t-Bu 	 N' 
276 	 277 	 278 	 279 
a 70% (X = S) 	 a 51% (X = S) 	 a 86% (X = S) 	 a 72% (X = S, Y = 0) 
b 70%(X = 0) b 71%(X = 0) b 82%(X = 0) b 50% (X = S, Y = S) 
C 81%(X = 0, Y= 0) 
d 46% (X =0, Y = S) 
Scheme 2.8: Alkylation of 2-styrylbenzoxazole 
An important research article was published by Houpis and co-workers involv-
ing nickel-catalysed nucleophilic conjugate addition of organometallic reagents to 4-
vinylpyridines with various substitution patterns (Scheme 2.9).h16 Grignard and organo 
zinc reagents were effective alkylating agents in this transformation. It was observed 
that reactions at 45 °C gave much higher yields (product 282 was formed with 95% 
yield at 45 °C as compared to only 40% at 25 °C) and significantly lower amounts of 
side products. 
Various nickel catalysts were trialled however, different ligands did not improve 
the reaction rates or selectivity. Only moderate levels of enantioselectivity (<15% cc) 
were obtained when a broad screening of chiral ligands was undertaken (bisphosphines, 
diamines, aminoalcohols, bissulphonamide, and diols) 
Finally it was also possible to successfully employ phenyl zincate reagents as nude-
ophiles when Ni(acac)2 was used as a catalyst. However, no improvement was observed 
using zinc based reagents in place of Grignard reagents with respect to enantioselec-
tivity (Scheme 2.10). 
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R1,_ 	 R2MgCI 
Ni catalyst (6 mol%) 
THE, 45-50 °C, 16 h 
280 	 281 
282 
93% (using Ni(DPPP)C12) 
95% (using Ni(acac)2) 
283 






79% (using Ni(DPPP)C12) 
285 
70% (using Ni(DPPP)C12) 
Scheme 2.9: Alkylation of 4-vinylpyridine with Grignard reagents 
In 1999, Molins reported an approach for stereoselective nucleophilic additions using 
chiral auxiliaries as selectivity inducing agents (Scheme 2.11).h17  Ni(sal)2 was used as 
an achiral catalyst for the addition of nucleophiles possessing a chiral auxiliary to 
various electrophiles. Later the same group published an improved procedure using 
a ruthenium based catalyst.118 Several products were made with good yields and 
moderate diastereomeric excess. Most importantly, product 293, derived from a 2-
vinylpyridine electrophile, gave 65% yield and 20% de. Although this result is much 
lower then other described by Molins, it is an important precedent. 
OCp 	 OCp 
MeO 	
Ni(acac)2 (7 mol%) 	
MeO 
THE, 45 C, 2-3 h 	 Ph'
Ph  
N 
286 	 287 	 288 
2 eq. Ph3ZnMgCI 	 93% >49% 
2 eq Ph3ZnLi 	 67% 	 >49% 
1.2 eq. PhZnMe2MgCI 	 65% 3% 
Scheme 2.10: Arylation of 4-vinylpyridine with zincate reagents 
As discussed in the review above, the nucleophilic additions to alkenylheteroarenes 
have been well studied. Diverse set of possible conditions using various bases, acids 
and transition metals to promote this reaction have been described. Although some 
examples of stereoselective additions have been reported, they suffer from relatively 
low efficiency and stereoselectivity. 
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65%; 20% de Ni(sali)2 
Me "C '0 Ph 
294 
97%; 30% de Ni(acac)2 
88%; 38% de Ni(sali)2 
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Me 	 Me 
296 
92%; 30% de RuCl2(PPh3)3 
69%; 27% de RuH2(PPh3)4) 
90%; 42% de PPh3 
Scheme 2. 11: Stereoselective additions using chiral auxiliaries 
2.1.2 CuH-catalysed 1,4-conjugate reduction reactions 
Conjugate reductions are a subset of nucleophilic addition reactions where the nu-
cleophile is a hydride. This type of transformation usually requires transition metal 
catalysts to achieve high levels of regioselectivity.119 
Historically the most significant example was the development of Stryker's reagent. 120 
It is best described as a hexamer [(Ph3P)CuH]6 in which triphenyiphospine plays a cru-
cial role in stabilising a copper hydride intermediate. Stryker's reagent is an effective 
reducing agent for a,/3-unsaturated carbonyl derivatives that can deliver high levels of 
selectivity12' (Scheme 2.12). 
Stryker's reagent can be efficiently prepared by pressurizing hydrogen gas over a 
solution of CuOt-Bu and triphenylphosphine in toluene. Although it is a stable solid 
when stored under an inert atmosphere (in fact can be exposed to the atmosphere 
without significant decomposition for short periods of time), in solution this copper 
hydride is very sensitive to oxygen. 
Stryker's reagent is used as a stoichiometric reducing agent and a big disadvantage 
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R6 	 R6'R7 R7 (0.32 equiv.) rt 
297 	 298 
0 	 0 	 0 
a Me., Me + Me 	..Me Ph Me 	Me O Ph 
>100 	 1 
299 	 300 	 301 	 302 
94% 88% 89% 95% 
Scheme 2.12: Stryker's reagent 
is the low atom efficiency of this reagent (326.8 g per 1 mol of hydride delivered) that 
limits its applicability in industrial processes. The first reports of trials to use this 
reagent catalytically came from the Stryker group itself. In their original paper they 
described an experiment in which CuOt-Bu and Ph3 P were stirred with cyclohexenone 
in toluene and subjected to 80 psi of hydrogen pressure. The product of reduction 
of cyclohexenone to cyclohexanone was observed albeit with a very slow rate (<1 
turnover/hour). Further increasing the pressure of hydrogen to >200 psi led to a side 
reaction giving cyclohexenol as the main product.121  
In later years, several groups reported the successful generation of stable and reac-
tive copper hydrides in situ by treatment of CuOt-Bu with silanes as the stoichiometric 
reductant. A selection of silanes can be used in this process: polymethylhydrosilane 
(PMHS), tetramethyldisiloxane (TMDS), dimethylphenylsilane and phenylsilane being 
the most popular. 
Although Stryker reported a high reactivity and good selectivity of [(Ph3 P)CuH}6 
in the reduction of o,8-unsaturated ketones, less activated alkenes require the use of 
more finely tuned copper hydride species. A broad scope of reactivity can be deliv-
ered by varying ligands.'22 Several enantioselective versions of this process have also 
been developed. The use of chiral non-racemic bisphosphines has proved to deliver re-
markable levels of enantioselectivity. A broad range of ligands can be used in such 
processes, most notably biaryl and ferrocenyl bisphosphines have shown high levels of 
enantioselectivity. It is also worth mentioning that these ligands usually improve the 
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reactivity of copper hydrides when compared with Stryker's reagent (Scheme 2.13). 
Me 








Fe 	h2 PCy2 
<o I 
(R)-MeO-Biphep (Ar = Ph) 	 (R)-Segphos (Ar = Ph) 	 (RA-.Josiphos 
(R-XyI-MeO-Biphep (Ar = 3,5-Me2C6H3 ) 	( R)-DTBM-Segphos (Ar = 3,54-Bu2 -Me0CO2 ) 
Scheme 2.13: Phosphine ligands for fine tuning of copper hydride reactivity 
More recent studies concentrate on further improving the reactivity of copper hy-
dride by application of a relatively new class of ligands. N-heterocyclic carbenes have 
recently enabled a lot of progress in many types of transition metal-catalysed processes. 
Their particular electronic properties as a-donors and 7-acceptors exert a strong ef-
fect on the nucleophilic properties of copper hydride, increasing the reactivity of these 
species. A linear arrangement between carbene ligand, copper and hydrogen atom 
makes it possible to effectively access sterically hindered alkenes. 
Ar 	 Ar 	 Ar 
F F I 
N@ N N 
> 	
NaOt-Bu 	
j ci 	 '—CuH 
CuCI, THE, rt. PhMe, r.t. 
N 
Ar 	 Ar 	 Ar 
303 	 304 	 305 
Scheme 2.14: N-heterocyclic ligands for activation of copper hydride 
Application of the right set of conditions is crucial to obtain high levels of reactivity 
in 1,4-conjugate reductions of substrates with various types of activating functional 
groups. 
Reduction of o,,@-unsaturated ketones 
The first report of a copper-catalysed asymmetric conjugate reduction of cyclic enones 
came from Buchwald and co-workers 123  (Scheme 2.15 eq B). Although a shorter ap-
proach to this class of compounds, involving direct asymmetric addition of a carbon 
nucleophile to cyclic enones (Scheme 2.15 eq A) was already known, 124-127  Buchwald's 
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new methodology delivered much higher enantioselectivity compared with other meth- 
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Scheme 2.15: Reduction of cyclic enones with copper hydride 
A solution of bisphosphine ligand, CuC1 and NaOt-Bu in toluene was treated with 
PMHS to form an active copper hydride species, and the resulting mixture was trans-
ferred to a solution of the starting material in toluene. A catalyst loading of 5 mol% 
was usually sufficient to obtain complete conversion within 24 Ii. The a-substituted 
cyclopentanone products were obtained in high yield and excellent levels of enantios-
electivity. The amount of PMHS added had to be precisely controlled (1.05 equiv. of 
PMHS in relation to starting material was used) as an excess of reducing agent led to 
an undesired 1,2-addition of hydride to form the alcohol. Significantly longer reaction 
times were needed when sterically hindered starting materials were used (Scheme 2.15 
product 313). 
It was shown that this type of copper hydride is able to discriminate between 
activated and apolar carbon-carbon double bonds, as in example 312 the terminal 
double bond was left intact. The presence of an ester functionality was also tolerated. 
The best results were obtained with cyclohexenones. When the ring size was further 











Chapter 2. Copper catalysed asymmetric reduction of alkenyiheteroarenes 
a competing 1,2-reduction together with desired product (314). 
Scheme 2.16: Mechanism of copper catalysed reduction 
A possible catalytic cycle for this process is depicted in scheme 2.16. A 1,4-
nucleophilic addition of copper hydride 315 to the starting enone 316 forms the copper 
enolate 317, subsequently a u-bond metathesis of this intermediate with a molecule of 
silane regenerates the copper hydride and produce silyl enol ether 318. Upon reaction 
work up the silyl enol ether is hydrolysed releasing the desired product. 




+ 	 + (S)-p-tol-Brnap (10 mol%) A 
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323 	 324 	 325 
51%; 91% se; s=52 	56%; 96% ee; s= 26 	45%; 72% ee; S = 32 
Scheme 2.17: Buchwald's results of kinetic resolution 
Shortly after his original work, Buchwald in collaboration with Jurkauska developed 
a dynamic kinetic resolution variant of the nucleophilic 1,4-conjugate reduction of 2,4-
dialkycyclopent-2-enones.128 The initial experiments without addition of a base proved 
to deliver high levels of enantioselectivity in kinetic resolution (Scheme 2.17). Although 
50% yield does not look good, this is a limiting factor in kinetic resolution processes 
where only half of starting material with matching chiral centers gets reacted while the 
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other half remains intact. 
To obtain better yields than those of kinetic resolution a base was added in an 
approach to achieve dynamic kinetic resolution. In this case the starting material is 
rapidly epimerized during the course of a reaction, copper hydride adds to one of the 
enantiomers of the starting material to form the previously proposed enol intermediate 
that undergoes or-bond metathesis with silane to give the silyl enol ether (Scheme 
2.18). As the ketone functionality in the product is masked as silyl enol ether during 
the course of reaction, no further epimerization can occur. 
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Scheme 2.18: Dynamic kinetic resolution mechanism and possible isomers of product 
Initial studies indicated that amide bases yielded low conversions and poor enan-
tioselectivities and so other bases were investigated. An excess of NaOt-Bu was able 
to effect the racemisation but this process was too slow when compared with the rate 
of conjugate reduction. Fortunately the addition of 5 equiv of t-BuOH accelerated 
the rate of racemisation dramatically and led to improved yields and high levels of 
enantiomeric and diastereomeric excess (Scheme 2.19). 
Enantioselective conjugate reduction of acyclic enones was reported in 2003 by Lip-
shutz and Servesko (Scheme 2.20)129 Such compounds possess more flexibility than 
cyclic enones and, for this reason, it is more difficult to achieve high levels of enantios- 
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94%; 91% ee(94:6 syn:anti) 95%; 93% ee(92:8 syn:anti) 90%; 91% ee(97:3 syn:anti) 
Scheme 2.19: Buchwald's results of dynamic kinetic resolution 
electivity. Broad screening of ligands proved that those used previously by Buchwald 
and co-workers were delivering low cc. However, a family of Josiphos ligands were 
found to work particularly well, giving the reduced products with superior selectiv-
ity (Scheme 2.20). Testing different solvents yielded analogous results and toluene was 
used in later experiments. 
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Me 
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96%(R isomer, 98% ee)(cnt-L2) 	 91% (5 isomer, 91% ee) (0) 
Scheme 2.20: Reduction of acyclic enones 
It is possible to control the stereoselective outcome of these reactions by changing 
the ligands. In example, ligand L2 usually gives the S enantiomer while ent-L2 pro-
ceeded to deliver the R enantiomers of starting materials (however in example 340 the 
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Me * Ph 
Scheme 2.21: Reduction of Qj3-unsaturated esters 
diminished enantioselectivity. Variation of the ligand (L2) enantiomers whilst using the 
same E/Z isomer of the starting material gave opposite configurations in the product 
without significant lost of selectivity in starting material 346. Similar to the previous 
work by Lipshutz, a very low ligand loading was required in these reactions (S:L 7700:1 
for compound 345). 
The ligand choice was crucial when a starting material containing a preexisting 
stereocentre was employed. Reduction of an optically pure starting material with the 
R,S isomer of L2, produced matching product 347 with 98% de and 91% conversion. 
However, the same starting material was reduced with much lower selectivity and 
conversion when the S,R isomer of L2 was employed (40% de and 70% conversion). 
The effect of an alcohol additive on reaction rate was also studied. The reduction 
of a,/-unsaturated lactone 348 was done in the presence of t-BuOD in benzene-d6 
(Scheme 2.22) and the reaction products were analyzed by proton NMR. It was observed 
that deuterium atoms were predominantly incorporated at the o position to the lactone 
349. A higher reaction rate in the presence of alcohol additive can be explained by a 
faster quenching of the copper enolate by the alcohol as compared to or-bond metathesis 
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Scheme 2.22: Studies of reaction rate using isotope-labelled alcohol 
with PMHS. 
Application of a copper hydride species in the asymmetric reduction of 'y-lactones 
was reported by Buchwald and co-workers in the total synthesis of Eupoinatilone-3 
(Scheme 2.23).'' In the key step, butenolide 350 was enantioselectively reduced to cis-
4,5-disubstituted lactone 351. The cis-stereoisomer was produced with no detectable 
levels of the trans-isomer. Once again ligand screening proved to be worthwile as 
different levels of reactivity and selectivity were observed. 
le 	CuCl2.2H20 (5 mol%), ligand (5 mol%), 
NaOt-Bu (1.2 equiv.), PMHS (6 equiv.)_  
t-BuOH, THE, CH2Cl2 
le 
350 	 351 
46% (87% ee) (Li, -30 C) 
100% (83% ee) (Li, r.t.) 
100% (93% ee) (L2, r.t.) 
0 
' 	 flIi 





Li 	 L2 	 L3 
Scheme 2.23: Comparison of ligand efficiency in the synthesis of Eupomatilone-3 
A wider range of 'y-aryl substituted lactones were tested (Scheme 2.24). The hg-
and applied in the total synthesis of Eupomatilone-3 (MeO-BIPHEP) did not deliver 
satisfactory results. It was discovered that SYNPHOS L3 was much more efficient 
both in terms of yield and diastereoselectivity although only moderate (as compared 
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Scheme 2.24: Reduction of 'y-aryl-lactones 
to the previous results) levels of enantioselectivity were produced. Poorer results were 
observed when starting materials containing 'y-alkyl substituents were used. In these 
cases, a maximum of 50% conversion of starting materials was reported suggesting that 
the racemisation of preexisting stereocenters in the lactone starting materials did not 
occur or was to slow to occur when compared with the rate of reduction. Both cis and 
trans isomers of the product were present in the reaction mixture with the cis product 
having very low levels of enantiomeric enrichment (< 25% cc). 
Reduction of o,/3-unsaturated sulfones 
CuCI, NaOt-Bu (5 mol%), 	
Ar Ligand (5 mol%), PhSiH3 (4 
Me 	 PhMe, it., 24 h 	 Me 
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95% (94% ee) (Li) 	93% (89% ee) (Li) 	93% (93% ee) (Li) 	89% (70% ee) (Li) 
95% (94% ee) (L2) 50% (78% ee) (L2) 45% (71% ee) (L2) <10% (L2) 
Scheme 2.25: Reduction of o,/-unsaturated sulfones 
The reduction of phenyl vinyl sulfones was investigated by Carretero and co-workers 
in 2007.132  Despite broad screening of three copper sources (Cu(OAc)2, CuF(PPh3)3  
and CuC1/t-BuONa) with phenylsilane and two chiral ligands (BINAP, Josiphos) in 
toluene for 24 h, only unsuccessful results were obtained. 
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Later studies were based on Rh-catalysed conjugate addition of boronic acids to 
aB-unsaturated sulfones. 133,134  Results of this research showed a significantly higher 
reactivity of 2-pyridylsulfones as compared to phenyl, tolyl or vinyl sulfones. Drawing 
precedent from these results, when compound 360, containing a 2-pyridyl substituent 
was tested, a highly rewarding reaction was observed (Scheme 2.25). Screening of 
possible ligands revealed the superior performance of BINAP, SEGPHOS and DTMB-
SEGPHOS ligands (with axial chirality) over Josiphos or Taniaphos with substrates 
containing -aryl substituents on a carbon-carbon double bond. 
-Py) 	CuCI, NaOt-Bu (5 mol%) 	
R1 
'(SO2(2-Py) 
A2 	 (R)-Binap (5 mol%), 	 A2 
PhSiH3 (4 equiv.) 




(S)- 92% (93% ee) (using (E)) 





(S)- 89% (91% ee) (using (E)) 









93% (90% ee) 
Scheme 2.26: Extension of previous results 
Extension of these results was done by testing the scope of the starting materials 
tolerated in this reaction. 3,/3-Dialkyl substituted starting materials were tested, along 
with cyclic substrates and E/Z isomers of double bonds (Scheme 2.26). Excellent 
results were obtained, with product yields above 90% and high enantiomeric excess. 
As predicted, the E/Z isomers produced opposite enantiomers of products. 
The utility of compounds prepared was demonstrated by converting the sulfonyl 
group in a straightforward process (Scheme 2.27). In a one or two-step reaction it 
was possible to convert the sulfonyl substituents to an ester (373), a phenyl (371) 
and a phenyl ketone (374) whilst preserving the configuration of the preformed stere-
ocentre. A Julia-Kocienski olefination of 370 provided alkene 372 with complete E 
stereoselectivity. 
This process was initially limited to 2-pyridyl sulfones, this issue was resolved by 
Charette and co-workers.'35 A different copper source (CuF2) and a hemilabile ligand 
(Me-Duphos monoxide Li) were employed (Scheme 2.28). 
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Scheme 2.27: Derivatization of sulfones 
S02Ph 	Li (5.5 mol%), 	 S02Ph 	
Me.... 
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NaOH (20 mol%) 
375 	 Benzene, r.t. 	 376 
Me-0 
Li 
S02Ph 	 S02Ph 
c Ph 	Me  cof Me 	0-- 
O2Ph 	
Me 
376 	 376 	 376 	 376 
85% (99% ee) 	85% (98% ee) 	 97% (99% ee) 	 61% (97% ee) 





MeOH, THE, r.t. 
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Na(Hg) 5%, THE, 
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377 	 378 
(99% ee) 56% (99% ee) 
Scheme 2.29: Derivatisation of sulfones 
Once more a possible transformation of sulfonyl groups was demonstrated with 
olefination and reduction (Scheme 2.29). 
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Reduction of nitroalkenes 
Despite their previous unsuccessful attempts to alkylate a,/3-unsaturated nitroalkenes 
using dialkyl zinc reagents, Carreira and Czekelius managed to develop a copper catal-
ysed asymmetric reduction procedure with tol-BINAP.'36 The commonly used system 
of CuCl, NaOt-Bu and tol-BINAP gave sluggish rates of reaction and only moderate 
yields. A significant improvement was achieved by the use of CuOt-Bu (instead of gen-
erating this reagent in situ). This copper source gave much higher reaction rates, good 
yields and enantiomeric excess (Scheme 2.30). 
NO2 	 NO2 
R1CR2 	
CuOt-Bu (0.1 mol%), ligand (0.1 mol%) 
PhS1H3 (1.2 equiv.), PMHS (0.1 equiv.), 
	
H20 (1.2 equiv.), PhMe, r.t., 18 In 	R 
380 	 381 Li (S)-toI-Binap 
L2 (SR)-Josiphos 
NO2 	 NO2 	 NO2 	 NO2 




382 	 383 	 384 	 385 
60% (78% ee) (Li) 	86% (92% ee) (1-2) 	(E)- 76% (S isomer; 66% ee) (Li) 	75% (84% ee) (1-2) 
77% (88% ee) (L2) 81%(S isomer; 86% ee) (1-2) 
(Z)- 82% (R isomer; 68% ee) (Li) 
77% (R isomer; 66% ee) (1-2) 
Scheme 2.30: Reduction of a,/3-unsaturated nitroalkenes 
Previous reports in the scientific literature suggest that the addition of inorganic 
salts such as LiC1 or KCN can lead to reduced reaction rates. It was concluded that the 
NaC1 generated in situ, as a by-product in the formation of CuOt-Bu, was inhibiting the 
activity of the copper phosphine catalyst. Interestingly, the best results were obtained 
when a combination of phenyl silane and PMHS were used. It was necessary to add 
1.2 equiv. of water to the reaction mixture to suppress over reduction. However, yields 
obtained are still approximately 15% lower compared to previous reports (Scheme 2.30. 
If required, enantioenriched products of copper catalysed asymmetric 1,4-conjugate 
reduction can be converted into corresponding amines with a known protocol without 
any loss of enantioenrichment (Scheme 2.31). 
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NO2 	 NH2 





Scheme 2.31: Possible derivatisation of nitroalkanes 
Reduction of a,/3-unsaturated phosphonates 
A very recent study by Xiang-Ping Hu and Zhuo Zheng demonstrated that phospho-
nates can also be a suitable activating group for enantioselective copper catalysed re-
duction of alkenes (Scheme 2.32).137 After an extensive screening of conditions it was 
found that Cu(OAc)2 and SEGPHOS, PMHS, t-BuOI-1 in a 4:1 mixture of Et20/THF 
provided the best results. The desired optically active 13-stereogenic alkylphosphonates 
were afforded in good to high yields and good levels of enantioselectivity (>90%). 
Me 0 	 Me 0 
	
,OEt Cu(OAc)2 (5 mol%), SEGPHOS (6 mol%) 	 POEt 
Ar 	 OEt 	PMHS (4 equiv.), t-BuOH (4 equiv), Ar 	 OEt 
Et20/THF (4/1), rt, 24 h 




Me 0 	 Me 0 	 Me 0 
lI_OEt II,OEt 
MeO 0 	 F3C 	 0 
105~ 
390 	 391 	 392 	 393 
86% (94% ee) 	 46% (93% ee) 	 96% (94% ee) 	 31% (93% ee) 
Scheme 2.32: Reduction of c3-unsaturated phosphonates 
It was shown that the addition of t-BuOH significantly increased the reaction rate 
whilst not affecting the enantioselectivity. A precise amount of t-BuOH and PMHS 
(4 equiv. of each) had to be used since a decrease in conversion was observed when 
suboptimal amounts were added. These results were in agreement with those obtained 
by Buchwald in his study of reduction of o-unsaturated esters. 138 
The effect of aryl substitution on the reaction efficiency was also studied. When 
starting materials having ortho-substituted aryl groups were used, a very low level of 
conversion was observed. The authors speculated that steric effects inhibit the copper 
hydride from coordinating to the alkene. Substrates having a para substitution were 
much more reactive and in those cases it was possible to study the electronic effect of 
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the substituent. Starting materials having electron-withdrawing groups on the phenyl 
ring were reduced more effectively and the desired products were isolated in much 
higher yields. However, electron-withdrawing or electron-donating substituents were 
not observed to have an effect on the stereoselectivity of this reaction. 
Reduction of o,/3-unsaturated nitriles 
A successful asymmetric conjugate reduction of 8-unsaturated nitriles was published 
by Yun and co-workers in 2006.139  This report is particularly interesting as the activa-
tion of the carbon-carbon double bond is done with the potentially troublesome nitrile 
group and as such, this class of compounds has not been extensively employed in the 
past. A nitrile substituent can coordinate to the metal catalyst in a linear fashion driv-
ing it away from possible reaction center. Yun and co-workers reported that Cu(OAc)2 
and Josiphos-type ligands can effectively overcome such problems in the reduction of 
/3-aryl,3-alkyl substituted starting materials (Scheme 2.33). 
Cu(OAc)2 (3 mol%) 
CN 	Li 13 M(11'/.l ) CN 
PMHS (4 equiv.) 
Ar'' 	 t-8uOH (4 equiv.) 









Me 	 Me 	 Me 
ME (::CMe 
396 	 397 	 398 	 399 
92% (97% ee) ((SR)-Li) 81% (99% ee) ((SR)-Li) 	92% (98% ee) 	96% (65% ee) ((SR)-L1) 
Scheme 2.33: Reduction of c,/3-unsaturated nitriles 
Later, it was reported that this system can perform equally well with /3,/3-diaryl 
substituted starting materials (Scheme 2.34).'° This process is highly competitive with 
Rh- and Ru-based hydrogenation catalysts that are known to underperform because 
of end-on coordination to metal. These catalysts usually require high pressure of 
hydrogen and an additional coordinating center next to the alkene moiety. 141-143  The 
catalyst developed by Yun is able to reduce acrylonitriles efficiently independent of 
the orientation of the pyridyl substituent (2, 3 or 4-pyridyl) with high yields and 
ME 
CN Li (2 mol%) 
Cu(OAc)2 (2 mol%) 
PMHS (4 equiv.), 
Ar' t-BuOH (4 equiv.) 
r.t., 1-18h 
400 
Ph..." , IN - N 
401 
92% (96% ee) 
401 
95% (91% ee) 
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enantioselectivity. Contrary, usage of Ph-MeO-BIPHEP, Mandyphos and Waiphos-
type ligands proved to deliver sluggish yields with relatively low ee. Interestingly, a 
large variation of yield and ee were observed when the temperature was different from 
the optimal. 
CN 





(S)- 86% (90% ee) 
(R)- 87% (92% ee) 
Me 
—4H 





(S)- 83% (86% ee) 
(R)- 86% (95% ee) 
Scheme 2.34: Reduction of biaryl substituted ciB-unsaturated nitriles 
Summary 
Asymmetric conjugate reduction of activated alkenes by copper hydride has received 
much attention in recent literature. Many groups have devoted a significant amount 
of time on the careful optimisation of reaction conditions. Reactivity problems were 
initially resolved by the use of stronger silanes but this in turn led to over reduction of 
products. Careful temperature control was crucial in obtaining high cc and reasonable 
reaction rates. The use of water and alcohols was introduced by Lipshutz to suppress 
side reactions and enhance the rate of the desired process. In the majority of cases, 
the key part of reaction development was to find a suitable ligand for particular class 
of starting materials, as all BINAP, SEGPHOS, Josiphos and others have performed 
well and yet none of them have proved to be the perfect solution in all cases. 
An often underestimated part of research in organic chemistry methodology is the 
synthesis of starting materials. Although approaches to trisubstituted double bonds 
exist in organic chemistry, an efficient synthesis of a broad variety of compounds is still 
difficult. The supporting information of the above articles provided valuable insight 
into possible synthetic routes to the compounds used in our study. 
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2.2 Results and Discussion 
2.2.1 Aims of project 
Although, as discussed in the introduction, conjugate additions to 2-vinyiheteroarenes 
(111 , R 	H in eq 2) are relatively common,113' 114,144-149  the corresponding reactions 
of mono- a-substituted substrates are much rarer. 115,116,150-155  Hypothetically, steric 
bulk around the a-carbon blocks attack of large nucleophiles, although there are no 
examples of successful alkylation of /,/-disubstituted alkenes. Furthermore, the only 
report of a catalytic enantioselective variant is limited to a poorly selective (15% cc) 
Grignard addition to 4-alkenylpyridines.116  Therefore, we initiated a program targeted 
at addressing these deficiencies 1. 
N 	 93 N 
R4 R 	
M-H, ligand (cat.) 
proton source 	R4 R2 
	
2 reductant, 
91 	 91 
P M M-H 












Scheme 2.35: General idea 
Several issues have to be addressed to fulfil this goal. The asymmetric copper-
catalysed conjugate reduction of activated alkenes is a well-established method for 
the synthesis of various useful chiral building blocks. '23' 128-131,138,156-163  Whether a 
nitrogen-containing heteroarene would provide sufficient activation to an adjacent alkene 
in an analogous reaction was uncertain. 
The predicted weak activation of the double bond was also potentially a restric-
tion on the scope of starting material. Specifically whether substituents with large 
steric bulk would be tolerated under our reaction conditions, in contrast to the known 
Work done in cooperation with Aakarsh Saxena, I is used to mark experiments conducted by 
Aakarsh 
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procedures. 
In addition, it seemed likely that coordination of the Lewis basic nitrogen of the het-
eroarene to the copper catalyst would occur in such a process. Whether this interaction 
would be beneficial, inconsequential, or detrimental was not easy to predict. 
However, the first and most pressing obstacle was the preparation of starting ma-
terials. We had to come up with an approach to prepare tn-substituted double bonds 
with high E/Z purity. Our preferred structure would have an electron-poor heterocycle 
at one end of the double bond and two aliphatic substituents at the other end. 
I 	R 	I 
R', R2 = Me, Et, Pr, etc. 
	
Het = ciç 	:, et c. 
Scheme 2.36: General starting material 
2.2.2 Preparation of starting materials 
Preparation of tn-substituted double bonds is a challenging endeavour in synthetic 
chemistry. Despite many transformations described in the literature, there was no 
existing single approach that could be applied for this project. Instead, we devised 
several independent strategies that promised to deliver a high level of flexibility in the 
formation of our starting materials compounds. 
Our initial target was 2-substituted oxazole (structure and potential retrosynthetic 
analysis on scheme 2.37). We anticipated that an aliphatic substitution on the alkene 
(R' and R2) would be preferential for enantioselective reduction as aromatic groups 
can have a negative effect on the polarity of a carbon-carbon double bond and so, 
make our starting materials less reactive. Five main approaches were considered for 
the synthesis of desired compounds. 
The preferred strategy would ideally start from commercially available starting 
materials and take no more then three synthetic steps to deliver the desired compounds. 
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R3 ° 	A2 
Direct alkenylation 
- R' M—R2 
A3 0 
Alkyne carbometalation 
Scheme 2.37: Retrosynthesis of starting material 
It would also be beneficial if the last step of a given strategy would allow some sort of 
diversity in the final product, reducing the total number of synthetic steps. However, 
none of depicted transformations have such properties. 
Oxazole formation and Horner-Wadsworth-Emmons olefination 
The first approach we attempted in this project involved the formation of an oxazole 
ring as a key step. Our target was to prepare several simple 2-alkenyl-oxazoles for a 
proof of concept study. By reacting a-azido ketones (403) and a,/3-unsaturated acid 
chlorides (404) in different combinations, we can potentially access a variety of desired 
2-alkenyl-oxazoles (Scheme 2.38). 
N 
0 	 0 A' 
R3O R1 I 	> R3N3 * CI R2 
402 	 403 	 404 
Scheme 2.38: Oxazole formation 
It quickly became obvious that there was no easy method of synthesising acid chlo-
rides with tn-substituted double bonds and this approach was modified to encompass 
a Horner-Wadsworth-Emmons reaction (Scheme 2.39). In this way, it was possible 
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to generate several substitution patterns on the double bond by changing the ketone 
reagent in the Horner-Wadsworth-Emmons olefination of compound 406. 
0 
N 	 II 
N P—OR 
R3 R' I 	> 	
OR 
R3 
405 	 406 
0 	 0 0 
11 
I 	> R3_IL__N3 * 
OR 
407 	 408 
Scheme 2.39: Oxazole formation and Horner-Wadsworth-Emmons olefination 
ct-Azido ketones (410) have been easily prepared through halogen exchange of c-
chioro ketones (409).164  The acid catalysed hydrolysis of the commercially available 
ethyl ester 411 gave acid 412 after a very short purification procedure.'65 Conver-
sion to the chloride derivative (413) was carried out with thionyl chloride, and the 
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O 0 	 0 0 
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Scheme 2.40: Synthesis of -azido-ketones and acid chlorides 
Oxazole ring formation was conducted with stoichiometric amounts of triphenyl 
phosphine in THF. This reaction gave yields of around 33-35% (Scheme 2.41) that 
were in line with the original publication of this procedure.166 Despite many trials it 
was not possible to reproduce yields (50-55%) published in a more recent article 167 
even when the same starting materials were employed. 
A possible mechanism of oxazole ring formation is depicted in scheme 2.42. Initially 
a complex between triphenylphosphine and the azide is formed. A release of a nitrogen 
molecule generates intermediate 422 that attacks an acid halogen derivative 423 to 
form 424. This compound undergoes an aza-Wittig rearrangement generating 425 
and triphenylphosphine oxide. An intramolecular cyclisation of 425 yields the final 
product 426. 
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Scheme 2.41: Oxazole formation 
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Scheme 2.42: Possible mechanism of oxazole ring formation 
Compound 416 cannot serve as a starting material for an enantioselective reduction. 
Indeed, it was an easily obtainable target that could be used in a proof of concept study 
to verify whether our idea of copper catalysed reductions was valid. 
Relatively low yields were not the only problem in during oxazole formation. Triph-
enyl phosphine oxide was produced as a by product in stoichiometric quantities making 
purification of the reaction mixture difficult in larger scale synthesis. 
Oxazole derivative 418 was deprotonated with LHMDS in THF and the resulting 
anion was reacted with different ketones (in this case with acetophenone) to give the 
desired olefin 427. Horner-Wadsworth-Emmons olefination proceeded with good yields 
unfortunately, only in a few cases was it possible to obtain a good E/Z selectivity 
(Scheme 2.43). This type of olefination is known to give high E/Z ratios with aldehydes, 
although ketones are usually much less selective. It was observed that good E/Z ratios 
were obtained for ketones with significantly different substituents (Me vs Ph) whereas 
dialiphatic ketones (Me vs Et or Et vs Bu) gave almost no selectivity. 
The mechanism depicted in scheme 2.44 illustrates that the selectivity in the Homer- 
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Scheme 2.43: Homer-Wadsworth- Emmons olefination 
Wadsworth-Emmons olefination comes from the thermodynamic equilibration of reac-
tion intermediates. Steric repulsion between the oxazole ring and one of the ketone 
substituents (R' and R2 ) is the main factor that determines the energies of these inter-
mediates and so their relative abundance in the reaction mixture. Large size differences 
between R1  and R2 are required to achieve good E/Z selectivity as demonstrated in 
the example with acetophenone (Scheme 2.43). 
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Scheme 2.44: Mechanism of Horner-Wadsworth-Emmons olefination with ketones 
Considering the practicality of this approach in obtaining a good diversity of start-
ing materials we decided to try and purify the mixtures of E/Z isomers. However, it 
was possible to separate these isomers by silica gel column chromatography with purity 
over 99% for a small number of examples. A high level of purity was required as it is 
known that the enantioselective reduction of such olefins commonly results in opposite 
enantiomers from the E and Z isomers of the olefin (Scheme 2.30). 
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Scheme 2.45: Starting materials made with this approach 
This synthetic approach to the desired starting materials only yielded three com-
pounds (Scheme 2.45) with high purity. However, it was enough to test whether our 
idea of enantioselective reduction of c,/9-unsaturated heteroarenes (in this case oxa-
zoles) was viable. A preliminary catalyst screening gave postive results and so we 
decided to concentrate on the synthesis of starting materials before any further exam-
inations. 
Zirconium catalysed carboaluminations and direct couplings 
Inspired by a growing number of C-H activation methodology developments in recent 
literature we envisioned an efficient and unprecedented approach to our target com-
pounds. A subproject was initiated to identify conditions that allow a direct coupling 
of vinyl iodides (439) to substituted oxazoles 438 (Scheme 2.46). 
CR3O> 1  
437 
N 
* 	 p1 
R3 0 
438 	 439 
Scheme 2.46: Retrosynthetic disconnection 
Vinyl iodides were obtained through carbo-alumination of substituted acetylenes 
with Cp2 ZrC12 and trimethyl aluminium followed by quenching of the aluminium in-
termediates with iodine (Scheme 2.48).168_170  This procedure requires stoichiometric 
amounts of zirconium reagent and long reaction times. However, after careful litera-
ture studies we managed to reduce the amount of zirconium reagent to 20% by addition 
of precise amounts of water 171  or MAO. 
This reaction is known to have superb selectivity producing E isomers with un- 
detectable levels of Z isomers. It is also possible, in cases of starting material with 
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Scheme 2.47: Temperature induced E-to-Z isomerisation 
hydroxyl groups, to reverse its selectivity by heating the reaction mixture to produce 
a metalacycle intermediate and upon quenching with iodine obtain only the Z isomers 
(Scheme 2.47). Optimised conditions for such E to Z isomerisation were recently pub-
lished by Negishi.'72 A big disadvantage of this transformation is its low reactivity with 
larger trialkylaluminium reagents restricting the possible products to those containing 
methyl as one of the substituents of the double bond. 
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Scheme 2.48: Preparation of vinyl-iodides 
As a free hydroxyl group could interfere during coupling to oxazole moiety, it was 

















Scheme 2.49: Protection of vinyl-iodides 
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At the time of this study there were only a few examples of direct coupling to 
the 2-position of oxazoles and this subject was considered "hot" as demonstrated by 
the large number of articles recently appearing in the scientific literature. 174-176  We 
were surprised to see that all of the published coupling procedures used aromatic and 
heteroaromatic halides as coupling partners for oxazoles and there were no examples 
of direct coupling between oxazole and vinyl halides. However, during the course of 
our studies a highly relevant article was published describing the direct alkenylation at 
the 2-position of oxazoles. 177  Based on catalyst systems developed for aryl halides we 
decided to investigate the possibility of coupling vinyl halides to oxazole. Our general 
idea was to take advantage of the relatively high acidity of the proton at the 2-position 
of the oxazole and couple the in-situ generated anion using a copper or palladium 
catalyst to the vinyl halide. 
Screening of known procedures for similar types of coupling involved many unsuc-
cessful trials with no conversion of starting materials. We tested several copper sources, 
and the addition of palladium, ligands and bases. It was not until a discovery that 1 
equiv. of Cul with 10% of Pd(OAc)2 and KOt-Bu as a base gave full conversion of the 
starting vinyl iodide that we realized the full potential of this transformation. Unfor-
tunately the desired product was obtained as a E/Z mixture of isomers, despite the 
isomeric purity of vinyl iodide. 
Me 
Me 	 Cul (1 eqiv), 	 N 	Ph 
Pd(OAc)2 (I0mol%) 
DMAP (2 eqiv), DMF, 150°C 	0:0 
15 min 40% 
453 	 446 	 454 
Scheme 2.50: Coupling of vinyl-iodides to benzoxazole 
Extensive studies to improve this procedure were then undertaken. It was not 
possible to reduce the amount of Cul used as this led to a decline in conversion. 
Palladium was necessary in the reaction mixture, in its absence no product was formed. 
A breakthrough came with the application of DMAP as a base/ligand with Cul and 
Pd(OAc)2 . These conditions did not give full conversion but the product was formed 
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as a single isomer (E/Z). Further studies indicated that quantitative conversion can be 
obtained using CuOAc although the reaction yields did not increase. As DMAP was the 
only example of an organic base we decided to screen several different nitrogen based 
ligand/bases, unfortunately these modified conditions did not offer any success. A 
short screening of solvents indicated that DMF with microwave heating is preferential. 
Interestingly it was observed that the addition of NaT or NaBr inhibits this process. 
The condition trialled during these studies are summarised below. 
Conditions: 
Catalyst: Cul, CuOAc, Pd(OAc)2, AgNO3, Rh 
Ligands: PPh3, 1,10-phenanthroline 
. Bases: KOt-Bu, NaOMe, BuLi, DMAP, Et3N 
Solvents: DMF, THF, Dioxane, DMSO 
Cul (0.1 equiv.) 
Ph____Br 
LI (0.2 equiv.) 




>.j__ '0 MeHN 
sealed vassel 
455 456 3h 457 	 Li 
33% 
Cul (0.1 equiv.) 
0 
*t-BuOLi 
Li (0.2 equiv.) 
(2.1 equiv.) 
dioxane, 100°C 
>__ ,J N\ 	Ph 
PMP sealed vassel PMP 
458 456 8h 459 
76% 
Scheme 2.51: Direct coupling to benzoxazole by Besselievre'77 
Unfortunately at the time of these studies an article appeared"' describing the 
successful coupling of vinyl bromides to benzoxazole (Scheme 2.51). In their examples, 
there was no problem of E/Z isomerisation. However, the conditions used by group 
of Piguel gave E/Z isomeric mixtures of product with our starting materials. This 
suggests that methyl substituent in our examples can be deprotonated after forming 
the product therefore isomerising the double bond upon quenching. 
The appearance of this article placed strong limitations on the possibility of pub-
lishing our own work. Therefore we decided to stop further investigations and apply 
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our suboptimal conditions (Scheme 2.50) to prepare starting materials for the main 
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Scheme 2.52: Starting materials made with this approach 
Carbometalation of alkynes 
The majority of starting materials obtained at this point contained a methyl group 
as one of the substituents at the double bond. We decided to take another approach 
to try to diversify our substrate pool through the carbometalation of alkynes (Scheme 
2.53). 
Het—__ 	 Het - P1 * M—R2 
464 
	
465 	 466 
Scheme 2.53: Retrosynthetic disconnection 
The first issue to address in this approach was the preparation of appropriate 
alkynes (465). The Sonogashira coupling of 2-chlorobenzoxazole (467) or 2-chloropyrazine 
(470) did not work. We then tried to obtain the trifiate or iodine derivatives. Unfor-
tunately, despite several published procedure, 178,179  it was not possible to isolate these 
materials cleanly as they proved to be highly unstable compounds. 
We also tried several procedures involving the direct coupling of benzoxazole to 
bromo-alkynes with no success. It was possible to obtain small quantities of product 
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Ph 
470 	 468 	 471 
(PPh3)2PdCl2, Cul 
Ph N 	Br 	 Et3N, rt, DMF, 60% oN- 
Ph 
472 	 468 	 473 
Scheme 2.54: Sonogashira coupling trials 
by deprotonating the phenylacetylene with butyl lithium first and then adding the 2-
chlorobenzoxazole. However, the low yields of this process were highly discouraging. 
We turned to known procedures for Sonogashira coupling 180,181  of 2-bromopyridine 
(472) to terminal acetylenes (for example 468) and obtained the product 473 in 60% 
yield (Scheme 2.54). 
oN- 7 Ph 
Ph  
473 	 474 
PhSi(Me)2H 
[Cp*Ru(MeCN)3]PF6 	 Me)2Ph 




Scheme 2.55: Carbometalation of 2-pyridinealkynes 
The addition of carbon nucleophiles to alkynes conjugated with a heterocycle proved 
to be more difficult than expected. Upon testing several catalyst systems (Rh, Ni, Cu) 
and alkylating agents (Et2 Zn, EtMgBr, Me3A1) we were not able to cleanly isolate the 
desired products. This research was later continued by Yi Wang in our group, who after 
extensive studies, discovered a set of suitable condition that allowed the addition of 
diethylzinc to some 2-pyridinealkynes with varying levels of E/Z selectivity (1:2 to 1:4) 
and moderate yields. However, the low reliability of this process and limited scope (only 
2-pyridinealkynes were tolerated) discouraged further investigation (Scheme 2.55). 
The low E/Z selectivity of the carbometallation step can possibly be explained 
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480 	 481 
Scheme 2.56: Possible explanation of low E/Z 
with reversible formation of an allene intermediate (479 Scheme 2.56) which looses 
E/Z information and the distribution of isomers produced comes from the relative 
energy differences of both forms (477 and 480) and not from the kinetics of addition. 
Presumably this unstable allene can also take part in a series of undesirable reactions, 
reducing the yield of the final product. 
Fortunately, it was possible to functionalise 2-pyridinealkynes through different 
reactions. Addition of dimethylphenylsilane proceeded smoothly with a ruthenium 
based catalyst.'82 Further studies were based on known protocols for rhodium catalysed 
hydroarylation of alkynes.'83"84 Conditions modified by Aakarsh Saxenaallowed the 
formation of differently substituted alkenes (Scheme 2.57). 
Wittig olefination and ester reduction 
Fortunately a simpler approach to the preparation of pyridine series of starting materi-
als was available. Wittig and Horner-Wadsworth-Emmons olefinations of pyridine and 
quinoline 2-carboxyaldehydes produced c,/-unsaturated esters (486 and 489) in good 
yields (Scheme 2.58). There were no problems in selectivity as aldehydes are known 
to give high E/Z ratios in this type of olefinations. In addition, if required it was also 
possible to separate the E and Z isomers by silica gel column chromatography as they 
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Scheme 2.57: Arylation of 2-alkenylpyridines by Aakarsh Saxena1  
showed significantly different retention factors. 
Me 1..COOEt 	toluene, reflux 	 Me 
N 	
'o
PPh3 	 60% COOEI 
484 485 486 
0 	 Me 
I I I 	EtO-P COOEt LHMDS 
II _ 
* 	
Et 	 -78 °C, THF, 65% 	 CO0Et 
Me 
487 	 488 	 489 
Scheme 2.58: Wittig olefination of aldehydes 
DIBAL reduction of these esters gave alcohols 490 and 491, it was also possible 
to form the tertiary alcohol 492 by the addition of a Grignard reagent (Scheme 2.59). 
In the case of the DIBAL reduction it was observed that temperature plays a crucial 
role in the control of this reaction and low temperatures are required to avoid the 
subsequent reduction of the carbon-carbon double bond. 
Protection of the obtained alcohol with TBSC1 or acetic anhydride gave the de-
sired starting materials (Scheme 2.60). Several other compounds were also prepared 
including a pivaloate and p-bromobenzoate ester t. 
Despite the relatively large number of steps required, this approach proved to be 
highly valuable because of the simplicity of the chemical reactions. Several starting ma- 
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Scheme 2.59: Reduction of ethyl esters 
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Scheme 2.60: Protection of hydroxyl group 
terials were prepared in this approach however, a major limitation was the commercial 
availability of the starting aldehydes. 
(Me 
1... 	OTBS 
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Me 
Me 
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Scheme 2.61: Starting materials made with this approach 
Aldol cross-condensation and aldehyde reduction 
To extend the previous approach, the Wittig olefination was replaced with an aldol 
condensation-elimination sequence to form aj3-unsaturated aldehydes (Scheme 2.62). 
This type of reaction is usually promoted by sodium and potassium hydroxides with 
catalytic amounts of phase-transfer- catalyst '85 but there are also other methods to 
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promote aldol condensation.'86 
As opposed to esters, oz,/3-unsaturated aldehydes can be easily reduced with milder 
and easier to handle reagents such as NaBH4 in ethanol. Despite the relatively low 
yielding condensation-elimination step, this procedure is highly valuable because it 
allows a broader diversity of substituents on the carbon-carbon double bond by varying 




* 	 O 	
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Scheme 2.62: Aldol condensation, aldehyde reduction and hydroxyl protection steps 
Protection of the primary alcohol 544 with TBSC1 or acetic anhydride provided the 
desired starting materials. Once again this approach was further extended by Aakarsh 
Saxena and several other compounds were prepared. 
Formation of vinyl triflates and iron catalysed coupling of Grignard reagents 
Additionally, another way to prepare the required starting materials was envisioned 
(Scheme 2.63). In this strategy, we tried to form a trifiate intermediate 505 through 
a series of acylation-trifiation steps of 2-methyl-heterocycles (507). This approach 
could possibly deliver a broad scope of desired compounds because of the availability 
of starting materials. It is also worth noticing that the trifiation step can produce 
intermediates with good E/Z ratios and easy purification. Finally an iron catalysed 
coupling of an organometallic reagent to an a,/3-unsaturated trifiate 505 could give 
many variations of the desired compound (504)187 in the last step of synthesis whilst 
preserving the E/Z configuration. 
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Scheme 2.63: Retrosynthetic analysis 
Acylation of 2-methylquinoline with butyllithium and dimethylacetamide provided 
ketone 511 in moderate yield on a large scale (50 g). Unfortunately when the same 
procedure was tried with 2-methylquinoxaline (512), no product was formed. In-
stead, NMR analysis of the crude reaction mixture together with mass spectroscopy 
data suggested the formation of the addition product between 2-methylquinoxaline 
and butyllithium, despite the significant energy required to break the arornaticity of 
quinoxaline. 
0 
1IIIIIIITIIL. 	)INe 	BuLi,THF, -78°C 	ii(i 	'R Me  
N 	Me I 	 50% 	 N 	M e Me 
509 	 510 	 511 
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512 	 510 	 513 
Scheme 2.64: Acylation of 2-methyiheteroarenes 
Trials with different bases and acceptors were made but we found acylation of 
the 2-methylpyrazine series of heterocycles in this way impossible. Surprisingly the 
same reaction involving 2-methylquinoline was unsuccessful when a larger acceptor 
(for example, dimethyipropionamide) was used. 
Addition of triethylamine and triflic anhydride to ketone 515 produced the desired 
,/-unsaturated trifiate ester, although with a low yield. After a short optimisation 
process, we decided to use another standard procedure for this type of reaction. 181 
Deprotonation of ketone 511 with KHMDS and addition of Tf2NPh gave the desired 
compound 515 as a single isomer in good yield. 
The iron catalysed coupling of Grignard reagents to c3-unsaturated trifiates pro-
ceeded smoothly, with retention of E/Z geometry (Scheme 2.66).187 Similarly, a Negishi 
coupling of organozinc reagent gave the desired compound 519 in moderate yield (no 
Chapter 2. Copper catalysed asymmetric reduction of a]kenylheteroarenes 
0 	 Ph 
I 	I 	I 	 I 	 KHMDS 
THF, , 66% m JO Tf NMe * TV If 	 N 	Me 
511 	 514 	 515 





MgBr Fe(acac)3, THF [1I1 	Y A °C, -30 	82% NMe 
515 516 517 
OTf ;_11 	
COOEt 
* BrZn 	COOEt (dppf)PdCl2, THF 
Me rt to 50°C, 50% N 	Me 
515 518 519 
Scheme 2.66: Fe/Mg and Pd/Zn coupling 
Despite a three step synthesis, by changing the organometallic reagent used in the 
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Scheme 2.67: Starting materials made with this approach 
2.2.3 Preliminary screening of catalyst systems 
Initial tests of catalyst systems for reduction of a,/3-unsaturated heteroarenes began 
shortly after the preparation of the first starting materials. At first we concentrated our 
efforts on finding a set of conditions that allowed the mild reduction of the disubstituted 
carbon-carbon double bond in 416 
We assumed that this type of transformation could potentially be catalysed by 
copper in the presence of a bisphosphine ligand and a silane reducing agent. Upon 
testing only a few sets of condition we managed to achieve 50% conversion in a reaction 
involving 416, Cu(OAc)2, BINAP, and PhSiH3 in toluene. 
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Scheme 2.68: Starting materials for preliminary screening 
With a promising result in hand it was time to try our reductions on "real" starting 
materials that would allow a test of the enantioselectivity of this processes. Unfortu-
nately when 427 (with methyl and phenyl substituents) was tried, almost no product 
was formed. An extensive screening was started to investigate many combinations of 
ligands, solvents, silanes and possible additives (summarised below). 
catalyst: Cu(OAc)2 
ligands: BINAP SEGPHOS 
. silanes: PhS11-13, (EtO)3SiH, PMHS 
additives: none, t-BuOH, NaOtBu 
. solvents: THF, toluene, dichloromethane 
This screening did not produce a working catalyst system although it was possible 
to see some patterns in the data obtained. Clearly, dichloromethane was the poorest 
solvent as it gave negligible product in all cases. It was also observed that the presence 
of additives did improve the conversion of starting materials. The best results obtained 
at this stage employed Cu(OAc)2, BINAP/SEGPHOS, PhSiH3, t-BuOH/NaOt-Bu in 
toluene however, it was still far from our goal. Further screening of different copper 
sources (Cu(OTf)2 , CuF2 ) and some rhodium catalysts proved to be unsuccessful and 
we decided to try a radically different approach. 
After some literature research we tried cobalt as a catalyst with BOX ligands and 
NaBH4 as the reducing agent in ethanol. Initial tests proved to be quite success-
ful providing only the desired product with full conversion of starting material and 
67% ee. Unfortunately further studies to improve the enantiomeric excess did not of-
fer any significant improvements. We realized that this type of catalyst system was 
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very unreliable, although 100% conversion was observed in every case, the same reac-







Scheme 2.69: Bisoxazoline ligands 
Once more we turned to copper catalysed reactions but this time with more dab-
orate ligands. Reduction of 428 (PhOx=Me,CH2CH2Ph) with PhSiH3 was smoothly 
catalysed by Cu(OAc)2 with Josiphos ligand and t-BuOH in toluene giving full con-




Fe PPh2 PCy2 	Fe PPh2 P(t-Bu)2 
Li (RS)-PPF-PCy2 	L2 (R,S)-PPF-Pt-Bu2 
Scheme 2.70: Josiphos ligands 
This surprising result prompted us to try more reactions with this particular ligand. 
It was observed that PMHS was not a strong enough reducing agent for this reaction 
and PhSiH3 was employed in later studies. Compound 427 possessing a phenyl sub-
stituent on the double bond was still not reactive, while starting materials without 
aromatic substitution were being reduced with 100% conversion in 2-18 h and usually 
with good enantiomeric excess. Having a good insight into the requirements of this re-
action we decided to undertake a careful ligand screening in order to further optimise 
the reaction conditions. 
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2.2.4 Ligand screening 
Based on preliminary results we began with a survey of chiral bisphosphine ligands 
L1-L6 using 2-alkenylbenzoxazole 460 as a model substrate (Scheme 2.71). Using 10 
mol % of Cu(OAc)2 , 10 mol % of ligand, and 4 equiv each of PhSiH3 and t-BuOH in 
toluene at room temperature. 
Compound 460 was chosen for the model studies as preliminary results indicated 
that benzoxazole heterocycles are good activating groups. This starting material was 
also preferred as it does not have aromatic substituents on the double bond which were 
problematic in preliminary screening. Relatively large catalyst and ligand loadings (10 
mol %), an excess of PhSiH3 and long reaction times (24 h) were used in this study 
to ensure that most reactions produced a sufficient amount of material for a precise 
analysis of the enantioselective excess obtained. 
QN 	Me 	
bisphosphine (10 mol%) QXJI  N  Me Cu(OAc)2 H20 (10 mol%) 
Ph 	PhSiH3 (4 equiv) 	 0 
t-BuOH (4 equiv) 
460 	 toluene, RT 	 522 
	
MeO PPh2 	0j1PPh 	
OJL 
PPh2 PPh2 	 PAr2 
PPh2 	
MeO cCr<0 
Li (R)-binap 	 L2 (R)-MeO-biphep 	 L3 (S)-segphos 	Ar = 3,5413u-4-MeO 
80% cony. 70% ee. 	88% cony. 86% ee. 99% cony. 91% ee. L4 (S)-DTBM-segphos 








L5 (R,S)-PPF-PCy2 	L6 (R,S)-PPF-Pt-Bu2 
100% cony. 76% ee. 95% cony. 87% ee. 
Scheme 2.71: Ligand screening 
Biaryl-based ligands L1-L4 proved competent in promoting the conjugate reduc-
tion. With (R)-BINAP (Li), both conversion and enantioselectivity were only moder-
ate. However, improved results were observed using (R)-MeO-BIPHEP (L2) and the 
SEGPHOS ligands L3 and L4, with 91% cc obtained using (S)-SEGPHOS (L3). The 
Josiphos ligands L5 and L6 were also effective, providing 522 in 89% and 87% cc, re- 
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spectively. Of all the ligands, the highest reaction rates were observed with L4 and 
L5 (reactions were complete in 2 h). However, the superior selectivity provided by 
L5 prompted us to select this ligand for further optimization and investigation of the 
reaction scope. 
2.2.5 Final Results 
Using 5 mol % each of Cu(OAc)2 and L5, PhSiH3 (1.5 equiv), and t-BuOH (2.0 equiv) 
at an initial temperature of 0 °C, a range of 3,/3-disubstituted 2-alkenyiheteroarenes 
underwent conjugate reduction with generally excellent levels of enantioselection (Ta-
ble 2.1). In addition to benzoxazole (entries 1-4), other effective nitrogen-containing 
hetero-arenes in this process included 5-phenyloxazole (entry 5), benzothiazole (en-
try 6), pyridine (entries 7-9), quinoline (entry 10), and pyrazine (entry 11). Tolerated 
functionality at the /3-positions of the alkene included simple aliphatic groups, a phenyl 
group (entry 4), a benzyl group (entry 9), various oxygenated alkyl groups (entries 2, 
3, 7-9, and 11), and a cyclopropane (entry 10). The process is tolerant of lower load-
ings of copper and ligand. For example, reduction of 493 on a 1.0 mmol scale using 
2 mol % each of Cu(OAc)2 and L5 provided 557 in 92% yield and 96% cc (entry 7, 
values in parentheses). 
The significantly lower ee reported in entry 4 can be explained in two fold. Aro-
matic substituents on carbon-carbon double bonds are known to be incompatible with 
Josiphos type ligands (examples of acyclic enones by Lipshutz'30 ). However, its difficult 
to directly translate results obtained for different class of compounds as benzoxazole is 
a significantly different activating group. Additionally, the electron-withdrawing prop-
erties of phenyl substituents limits the polarisation of carbon-carbon double bonds. 
The main aspect of activation of alkene comes from the electron withdrawing prop-
erties of benzoxazole that causes polarisation of double bond and a partial positive 
charge on /3 carbon that can be then attacked by a copper hydride species. An ad-
ditional electron-withdrawing group on the other end of alkene counters the electron 
withdrawing effect of the benzoxazole and so limits the difference of partial charges be- 
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tween c and 0 carbon (to benzoxazole), possibly resulting in the addition of hydride 
to c carbon. If this scenario is the case, then formation of the stereocentre at the 3 
carbon occurs by a comparably unselective protonation mechanism. 
No. 
L5 (5 mol %) 
N 	R1 	Cu(OAc)2 H20 (5 mol 	%) A1 
xA2 	
PhS1H3 (1.5 equiv) 
f-BuOH (2.0 equiv) 
toluene, 0°C to rt, 17 h 




522 90 / 93 7 
557 90(92) / 99(96) 
Me  
2 67 / 94 8 




3 553 88 / 95 9 
559 90 / 97 
Q. _ 	Ph 0-01 JMe 
4 o 95 / 87 10 
560 90 / 96 
N 	Me El 
CN 
N LLOTBS Ph 
93 / 90 11 
561 89 / 96 
a~- Ph 
6 S 	556 86/95  
Table 2.1: Scope of Cu-Catalyzed Asymmetric Conjugate Reduction 
Reductions of 4- and 3-alkenylpyridine 
Experiments to explore the origins of the reactivity of the starting meterials were then 
conducted. We hypothesised that two main effects are important for a reaction to occur. 
An electronic activation of the alkene by conjugation with an electron-withdrawing 
heterocycle and a possible coordination of the opper catalyst to the nitrogen present in 
all of the starting materials that we used. To verify the latter hypothesis a reduction of 
4-alkenylpyridine 523 was attempted. The substrate 523 does not allow coordination 
of copper next to the reaction center (alkene moiety) and therefore it should not react. 
Surprisingly, reduction of 523 provided 524 in 60% yield and 94% cc, albeit in a 
slower reaction that was incomplete even after 4 days. This result suggests that alkene 
reduction by copper hydride can occur without assistance of a directing effect from the 
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nitrogen atom. In contrast, 3-alkenylpyridine 525 was nonreactivet, demonstrating the 




R,S-PPF-Py2 (5 mol % 
Cu(OAc)2 H20 (5 mol % b 
PhSiH3 (1.5 equiv) 	I 
t-BuOH (20 equiv) 
Me 	
OTBS 
524 	94% ee, 60%, 4 d rI 	i)e 
OTBS toluene, 0 °C to rt H No reaction 
525 
Scheme 2.72: Reductions of 4- and 3a1kenylpyridinet 
X-ray and absolute configuration 
The stereochemistries of the products obtained herein were assigned tentatively by anal-
ogy with that of 491, which was secured through X-ray crystallography of a derivative 
528 (Scheme 2.73). 
~\ Q—//, N Me 	 H2, Pd/C (cat.) 
EIOH, rt 
461 
GOTs  Recrystallization 
from CH2Cl2/Et20 
0 	 Me 
528 
Q—,//, N Me 
O - L._ OH 
526 
TsCI, Et3N, DMAP 
CH2Cl2, rt 
\ / N Me 
527 
Scheme 2.73: Synthesis of derivative 528 for X-ray studies 
Reduction and subsequent acetyl transfer of 495 
An interesting observation has been made when reducing compounds containing an ac-
etate ester in the 'y position (495). In this case the reduction of the carbon-carbon 
double bond was followed by acetyl transfer from ester to the a position and intramolec-
ular hemiacetal formation. Product 529 was isolated as a single diastereoisomers in 
50% yield. Similar behaviour was observed with p-bromobenzoyl esters. However, p1-
valoate ester did not proceed through that pathway. Further studies are required to 
speculate on the utility of this process. 
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Figure 2.74: X-ray crystallography structure of 528 
Me 
Fe 	PPh2 PCy2 
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Scheme 2.75: Copper mediated reduction and acetyl transfer 
2.3 Future Work 
Possible future work could involve extensive screening of reaction conditions to find 
a way to improve the reaction scope in areas where this study has failed to deliver 
desired products. A probable improvement could come from the fine-tuning of ligand, 
as preliminary screening a showed huge correlation of reactivity with bisphosphine 
used. It would also be beneficial to change the reducing agent to the more stable 
TMDS or PMHDS as these are highly preferred in industry. Similar reactions could 
also proceed using boranes or even hydrogen as a reductant provided suitable catalysts 
can be found. These would offer huge advantages over the current conditions. 
The substrate, 4-alkenylpyridine 523, demonstrated that reduction by copper hy-
dride can occur without the assistance of a directing effect from the nitrogen atom and 
it is easy to envision that 4-alkenylnitrobenzene 532 or 4-alkenylcyanobenzene 530 
should give positive results. This research is currently under way in the Lam group 
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Cu(OAc)2 (5 mol %) 
(R,S)-PPF-PCy2 (5 mol %) 
PhSiH3 (1.5 equiv) 
t-BuOH (2.0 equiv) 
toluene, 0°C to it 
Cu(OAc)2 (5 mol %) 
(R,S)-PPF-PCy 2 (5 mol %) 
PhSiH3  (1.5 equiv) 
t-BuOH (2.0 equiv) 
toluene, 0°C to it 
N 	Me 
ILLJ....OTBS 
524 	94% ee, 60%, 4 d 
NCID R2  
531 
02N 	"AR" 	 Cu(OAc)2 (5 mol %) 	02N 
(R,S)-PPF-PCy 2 (5 mol %) 
PhSiH3 (1.5 equiv) 
532 	 f-BuOH (2.0 equiv) 
	
toluene, 0 °C to it 	 533 
Scheme 2.76: Extension of 4- alkenylpyridirie 
Further extension of the substrate scope can come from desymmetrization of C2 
symmetric molecules (Scheme 2.77). In this process enantiomeric excess can be ob-
tained if the catalyst (copper hydride) can differentiate between the two chemically 
identical parts of molecule. 
0 	 0 
L*CuH 	
R = Et, i-Pr, Ph 
M Me 	 e 
534 	 535 	EWG = NO2, CN, COOEt 
= H, Me, Et, Ph, OH 
R1 R2 	 R' R2 
L*Cu H 
EWG O EWG 
536 
	 537 
Scheme 2.77: Enantioselective desymmetrization 
In the long term it would be beneficial to investigate whether the addition of larger 
nucleophiles is possible. For example, PhSiH3 could be substituted with allylSi(OMe)3 . 
These type of alkylation are known to occur, although they usually require strongly 
activated starting materials. 190 
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2.4 Conclusions 
In summary, copper-catalysed asymmetric conjugate reductions of /,/l-disubstituted 
2-alkenyiheteroarenes are reported. In addition to serving as a further demonstration 
of the power of chiral copper hydride catalysis, this work has shown that nitrogen-
containing aromatic heterocycles can provide effective activation of an adjacent alkene 
for highly enantioselective catalytic conjugate addition reactions. Extension of the 
general concept to other classes of asymmetric reactions should provide a range of 




3.1 General Information 
All non-aqueous reactions were carried out under a nitrogen atmosphere in oven-dried 
apparatus. Toluene and THF were dried and purified by passage through activated 
alumina columns using a solvent purification system from "Glass Contour Solvent 
Systems". All commercially available reagents were used as received. Thin layer 
chromatography (TLC) was performed on Merck DF-Alufoilien 60F254 0.2 mm pre-
coated plates. Product spots were visualized by UV light at 254 nm, and subsequently 
developed using potassium permanganate or ceric ammonium molybdate solution as 
appropriate. Flash column chromatography was carried out using silica gel (Fisher Sci-
entific 60A particle size 35-70 micron) employing the method of Still and co-workers.' 
Melting points were recorded on a Gallenkamp melting point apparatus and are un-
corrected. Infra-red spectra were recorded on a Jasco FT/IR-460 Plus instrument as a 
thin film on sodium chloride plates or as a dilute solution in CHC13. 'H NMR spectra 
were recorded on a Bruker DMX500 (500 MHz) spectrometer, a Bruker DPX360 (360 
MHz) spectrometer, or a Bruker ARX250 (250 MHz) spectrometer. Chemical shifts 
(cl) are quoted in parts per million (ppm) downfield of tetramethylsilane, using resid-
ual protonated solvent as internal standard (CDC13 at 7.27 ppm). Abbreviations used 
'. Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, jS, 2923-2925. 
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in the description of resonances are: s (singlet), d (doublet), t (triplet), q, (quartet), 
app (apparent), br (broad). Coupling constants (J) are quoted to the nearest 0.1 Hz. 
Proton- decoupled'3C NMR spectra were recorded on a Bruker AVA500 (125.1 MHz) 
spectrometer, a Bruker DPX360 (90.6 MHz) spectrometer, or a Bruker ARX250 (62.9 
MHz) spectrometer. Chemical shifts (6) are quoted in parts per million (ppm) down-
field of tetramethylsilane, using deuterated solvent as internal standard (CD C13 at 77.0 
ppm, CD30D at 49.9 ppm). Assignments were made using the DEPT sequence with 
secondary pulses at 90° and 135°. High resolution mass spectra were recorded on a 
Finnigan MAT 900 XLT spectrometer or a Finnigan MAT 95XP spectrometer at the 
EPSRC National Mass Spectrometry Service Centre, University of Wales, Swansea, 
or on a Finnigan MAT 900 XLT spectrometer at the School of Chemistry, University 
of Edinburgh. Chiral HPLC analysis was performed on an Agilent 1100 instrument. 
Optical rotations were performed on an Optical Activity POLAAR 20 polarimeter. 
Microwave reactions were performed using a Biotage microwave synthesizer. Authen-
tic racemic samples of products for chiral HPLC assay determinations were obtained 
by hydrogenation of the alkene substrates in EtOH using a Pd/C catalyst, except in 
the case of rac-553 which was obtained by copper-catalyzed conjugate reduction of 
alkene 461 according to General Procedure C but using rac-BINAP as the ligand, and 
rac-559, which was obtained by hydrogenation of alkene 543 in EtOH using a Pt/C 
catalyst. 
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3.2 Formal Synthesis of Salinosporamide A 
S02Ci 	HCI 
H2N ..CO2H MeOH H
2N CO2Me 
HO1  Me 	
HO  Me 
198 199 
(L)-Threonine methyl ester (199) To a stirred solution of SOC12 (11.0 mL, 150 
mmol) in MeOH (115 mL) at 0 0C was added (L)-threonine (18.2 g, 150 mmol) in 
portions. After stirring for 30 inin at room temperature, the reaction was heated to 
refiux for 14 h and then concentrated in vacuo, to obtain a thick colourless oil. Methyl 
ester 199 was used in the next step without further purification. 'H NMRHH (360 
MHz, CD30D) 5 5.11 (3H, bs, NH2 + OH), 4.52 (1H, dq, J = 6.5, 4.2 Hz, CHCH3), 
4.19 (1H, d, J = 4.2 Hz, CHCHOH), 4.08 (3H, s, OCH3), 1.56 (3H, d, J = 6.5 Hz, 
CH3CH); 13C NMR (62.9 MHz, CD30D) 6 170.1 (C), 66.8 (CH), 60.3 (CH), 54.2 







200 	 201 
4-Methoxybenzimidate hydrochloride (201) To a stirred solution of p-methoxybenzonitrile 
200 (22.4 g, 168.6 nunol) in MeOH (85 mL, 2.0 mol) at 0 °C was added acetyl chlo-
ride (96.0 mL, 1.34 mol) slowly via syringe. The solution was stirred for 14 h at room 
temperature and then concentrated in vacuo which afforded 201 as a colourless solid. 
This solid was washed with Et20 (5 x 30 mL), dried and used without further purifica-
tion in the next step (30.5 g, 91%). m.p. 165-167 C; 'H NMRHH (360 MHz, CDC13) 
5 11.60 (1H, bs, NH), 8.39 (2H, d, J = 9.0 Hz, ArH), 7.02 (2H, d, J = 9.0 Hz, ArH), 
4.51 (3H, s, OCH3), 3.88 (3H, s, OCH3); '3C NMR (62.9 MHz, CDC13) ö 171.1 (C), 
165.5 (C), 132.1 (2 x CH), 116.7 (C), 114.6 (2 x CH), 60.8 (CH3), 55.6 (CH3). 
NH HCI 	HCI 
H2N.CO2Me 
MeOJ OMe + HO Me 
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(4S, 5 R)-Methyl 41  5-dihydro-2 (4-methoxyphenyl)-5-methyloxazole-4-carboxylate 
(202 )26  To a stirred solution of threonine methyl ester 199(25.5 g, 150 mmol) in 
CH2 C12 (175 mL) at room temperature was added Et3N (41.0 mL, 300 mmol) slowly 
via syringe, followed by the addition of 201 in one portion. The reaction was stirred 
for 1 h at room temperature, heated to refiux for 14 h, then it was quenched with 
saturated aqueous NH4C1 solution (150 mL) and extracted with CH202 (3 x 70 mL). 
The combined organic layers were dried (MgSO4 ), filtered and concentrated in vacuo. 
Purification of the residue by column chromatography (15% to 40% EtOAc/petrol) af-
forded oxazoline 202 (12.8 g, 40%) as a pale yellow solid. Rf (30% EtOAc in hexane) 
= 0.29; m.p. 87-88C, lit.26 86-87C {c] 	+76.5 (c 1.98, CHC13), lit. +69.4 (c 2.0,    
CHC13); 'H NMRHH (360 MHz, CDC13) 6 7.86 (211, d, J = 8.9 Hz, ArH), 6.83 (211, d, 
J = 8.9 Hz, ArH), 4.89 (111, dq, J = 7.4, 6.3 Hz, OCHCH3), 4.38 (1H, d, J = 7.4 Hz, 
NCH), 3.75 (3H, s, OCH3), 3.73 (311, s, OCH3), 1.45 (3H, d, J = 6.2 Hz, CHCH3); 
13  NMR (62.9 MHz, CDC13) 6 171.4 (C), 165.0 (C), 162.1 (C), 130.0 (2 x CH), 119.4 
(C), 113.4 (2 x CH), 78.4 (CH), 74.8 (CH), 55.0 (CH:3 ), 52.2 (CH3), 20.7 (CH3). 
Ci 	OBn 
LHMDS, 	 CO2Me CO2Me THF-HMPA _________ 	 JOBn 
MeO_O__< 	 -78 °C 	MeO_.Q__-J 
Me 	 0 Me 
202 	 203 
(4R , 5 R)-Methyl 4- [(benzyloxy) methyl] -4, 5-dihydro-2- (4-methoxyphenyl)-5-
methyloxazole-4-carboxylate (203) To a stirred solution of LHMDS (56.6 mL, 1 
M solution in THF, 56.5 mmol), in THF (200 mL) at -78 QC was added HMPA (30.0 
mL, 221 mmol), followed by the transfer of a solution of oxazoline 202 (12.8 g, 51.3 
mmol) in THF (100 mL) via cannula. This solution was stirred at -78 °C for 1 h to al-
low enolate formation. Benzyloxy chloromethyl ether (14.3 mL, 61.7 mmol) was then 
added and the reaction was stirred at -78 QC for 3 h, when it was quenched with sat-
urated aqueous NH4C1 solution (150 mL) and warmed up to room temperature for 30 
minutes. The aqueous layer was extracted with EtOAc (4 x 80 mL) and the combined 
organic layers were dried (MgSO4), filtered and concentrated in vacuo. Purification of 
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the residue by column chromatography (15% to 20% EtOAc/petrol) afforded alkylated 
oxazoline 203 (14.8 g, 75%) as a pale yellow oil. Rf (30% EtOAc in hexane) = 0.53; 
[o] 22  —6.0 (c 1.0, CHC13), lit.26 —6.3 (c 1.0, CHC13)-,'H  NMRHH (360 MHz, CDC13) 
5 7.97 (2H, d, J = 9.0 Hz, ArH), 7.29-7.24 (5H, in, ArH), 6.90 (2H, d, J = 9.0 Hz, 
ArH), 4.78 (1H, q, J = 6.6 Hz, OCHCH3), 4.61 (2H, s, OCH2Ar), 3.87 (1H, d, J = 
9.9 Hz, CHAHBO), 3.81 (1H, d, J = 9.9 Hz, CHAHBO), 3.80 (3H, s, OCH3), 3.73 
(3H, s, OCH3), 1.35 (3H, d, J = 6.6 Hz, CHCH3); 13C NMR (62.9 MHz, CDC13) ö 
170.8 (C), 165.0 (C), 162.2 (C), 137.8 (C), 130. 2 (2 x CH), 128.0 (2 x CH), 127.4 (2 
x CH), 127.3 (CH), 119.7 (C), 113.4 (2 x CH), 81.0 (C), 79.5 (CH), 73.5 (CH2 ), 73.0 










203 	 204 
(2 R , 3 R ) -Methyl 2-benzyloxymet hyl- 2- (4-met hoxybenzylamino ) -3- hydrox-
ybutanoate (204) To a stirred solution of oxazoline 203 (14.8 g, 40.0 mmol) in HOAc 
(50 mL) at room temperature was added NaCNBH3 (8.80 g, 132 mrnol) in small por-
tions over 2 h. The reaction mixture was stirred for 16 h at 50 °C, when it was diluted 
in water (100 mL), neutralised with solid Na2 CO3 and the aqueous layer was extracted 
with ethyl acetate (5 x 60 mL). The combined organic layers were dried (MgSO4), 
filtered and concentrated in vacno. Purification of the residue by column chromatog-
raphy (10% to 25% EtOAc/petrol) afforded aminoalcohol 204 (9.3 g, 65%) as a pale 
yellow oil. Rf (30% EtOAc in hexane) = 0.21; [o] 12 —5.8 (c 1.03, CHC13), lit.26 —9.1 (c 
1.0, CHC13); 'H NMRHH (360 MHz, CDC13) 6 7.54-7.44 (511, in, ArH), 7.43 (2H, d, 
J = 8.7 Hz, ArH), 7.02 (2H, d, J = 8.7 Hz, ArH), 4.71 (211, s, OCH2 Ph), 4.15 (1H, 
q, J = 6.4 Hz, HOCHCH3), 4.03 (1H, d, J = 9.8 Hz, NCHA HBAr), 3.98 (1H, d, J 
= 9.8 Hz, NCHAHBAr), 3.95 (3H, s, OCH3), 3.92 (3H, s, OCH3), 3.87 (1H, d, J = 
11.8 Hz, CHCHDOBn), 3.79 (1H, d, J = 11.8 Hz, CHCHDOBn), 2.28 (1H, bs, OH), 
1.35 (3H, d, J = 6.6 Hz, CHCH3); '3C NMR (62.9 MHz, CDC13) 6 172.8 (C), 158.8 
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(C), 137.5 (C), 131.7 (C), 129.5 (2 x CH), 128.4 (2 x CH), 127.8 (CH), 127.7 (2 x CH), 
113.8 (2 x CH), 73.5 (CH2 ), 69.8 (C), 69.5 (CH2 ), 69.4 (CH), 55.2 (CH3), 52.1 (CH3), 
47.3 (CH), 17.9 (CH3). 
_PMB 	 _PMB 
HN 	 (COd)2, DMSO, 	HN 
I OBn 	Et3N, CH2Cl2 I 	OBn 
Me 	 Me 
CO2Me 	 COMe 
OH 	 0 
204 205 
(R)-Methyl 2-benzyloxymethyl-2- (4-methoxybenzylamino)-3-oxobutanoate 
(205) To a stirred solution of oxalyl chloride (1.70 mL, 18.8 mmol) in CH2 C12 (40 
mL) at —78 °C, was added DMSO (2.10 mL, 37.6 mmol) dropwise over 3 mm. After 
stirring for 15 mm, a solution of alcohol 204 (3.34 g, 8.94 mmol) in CH202 (30 mL) 
was added via cannula over 5 mm. The reaction stirred at —78 °C for 1 h and Et3N 
(5.25 mL, 37.6 mmol) was then added over 1 mm. The reaction was stirred at —78 °C 
for 1 h, allowed to warm up to —40 °C over 2 h, and then quenched with saturated 
aqueous NH4C1 solution (40 inL). The aqueous layer was separated and extracted with 
CH202 (3 x 20 mL) and the combined organic layers were dried (MgSO4), filtered and 
concentrated in vacuo. Purification of the residue by column chromatography (10% to 
20% EtOAc/petrol) gave amino ketone 205 (2.39 g, 72%) as a pale yellow solid. Rf  
(30% EtOAc in hexane) = 0.55; m.p. = 60-62 °C; [c] 22 -12.7 (c 1.02, CHC13); JR 
(film) 3347 (NH), 2952, 2836, 1741 (C=O), 1718 (C=O), 1511, 1245, 1178, 1033, 700 
cm'; 'H NMRHH (250 MHz, CDC13) 7.39-7.28 (5H, m, ArH), 7.25 (2H, d, J = 8.7 
Hz, ArH), 6.85 (2H, d, J = 8.7 Hz, ArH), 4.59 (1H, d, J = 12.4 Hz, OCHA HBPh), 
4.53 (1H, d, J = 12.4 Hz, OCHAHBPh), 4.02 (1H, d, J = 10.1 Hz, NHCHH), 3.90 
(1H, d, J = 10.1 Hz, NHCHCHD), 3.80 (3H, s, OCH3), 3.74 (3H, s, OCH3), 3.59 
(1H, d, J 12.3 Hz, CHEHFOBII), 3.46 (1H, d, J = 12.3 Hz, CHEHFOBn), 2.53 (1H, 
br s, NH), 2.21 (3H, s, CH3C=O); 13C NMR (62.9 MHz, CDC13) 5 203.3 (C), 169.8 
(C), 158.7 (C), 137.6 (C), 131.7 (C), 129.3 (2 x CH), 128.4 (2 x CH), 127.8 (3 x CH), 
113.7 (2 x CH), 74.8 (C), 73.4 (CH2 ), 68.1 (CH2), 55.3 (CH3), 52.7 (CH3), 46.7 (CH2 ), 
25.7 (CH3); HRMS (ES) Exact mass calcd for C21H26 N05 [M+H]: 372.1805, found: 
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methoxybenzyl)carbamoyllacrylate (217) To a stirred solution of fumaric acid 
inonoethyl ester (858 mg, 5.65 mmol) in CH2C12 (10 mL) at 0 0C was added oxalyl 
chloride (0.56 mL, 6.40 mmol) followed by DMF (one drop). This solution was stirred 
at room temperature for 1 h, and then transferred via cannula to a solution of the 
amine 205 (1.34 g, 3.60 mmol) and diisopropylethyl amine (1.10 mL, 6.40 mmol) in 
CH2 C12 (10 mL). The reaction mixture was stirred at 0 OC for 10 min and then at 
room temperature for 18 h, when it was quenched with saturated aqueous NH4C1 so-
lution (20 mL). The aqueous layer was separated and extracted with CH202 (3 x 20 
mL), and the combined organic layers were dried (MgSO4), filtered and concentrated 
in vacuo. Purification of the residue by column chromatography (20% EtOAc/petrol) 
gave amide 217 (1.7 g, 95%) as a pale yellow oil. Rf (30% EtOAc in hexane) = 0.45; [] 
22 —18.2 (c 1.18, CHC13); IR (film) 2953, 2837, 1722 (C=O),1658 (C=O), 1513, 1408, 
1294, 1175, 1032, 974 cm'; 'H NMR (360 MHz, CDC13) 6 7.35-7.27 (5H, in, ArH), 
7.22 (1H, d, J = 15.3 Hz, =CH), 7.17-7.12 (2H, in, ArH), 6.95-6.89 (2H, dm, J = 8.8 
Hz, ArH), 6.80 (1H, d, J = 15.3 Hz, =CH), 4.95 (1H, d, J = 18.4 Hz, OCHAHBAr), 
4.81 (1H, d, J = 18.4 Hz, OCHAHBAr), 4.32 (1H, d, J = 11.9 Hz, NCHCHDAr), 4.28 
(1H, d, J = 11.9 Hz, NCHCHDAr), 4.19 (2H, q, J = 7.1 Hz, OCH2 CH3), 3.83 (3H, s, 
OCH3), 3.80 (311, s, OCH3), 3.78 (2H, s, CH2 0Bn), 2.45 (3H, s, CH3C=O), 1.26 (3H, 
t, J = 7.1 Hz, OCH2CH3); '3C NMR (62.9 MHz, CDC13) ö 197.6 (C), 168.0 (C), 167.5 
(C), 165.2 (C), 158.9 (C), 136.5 (C), 133.3 (CH), 133.1 (CH), 129.7 (C), 128.4 (2 
CH), 127.9 (CH), 127.5 (2 x CH), 127.1 (2 x CH) 114.2 (2 x CH), 77.5 (C), 73.7 (CH2 ), 
70.1 (CH2), 61.1 (CH2), 55.2 (CH3), 52.9 (CH3), 48.9 (CH2 ), 27.9 (CH3), 14.0 (CH3); 
HRMS (ES) Exact mass calcd for C27H32 N08 [M+H]: 498.2122, found: 498.2123. 
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(3aR,6 R ,6aS )-6-Benzyloxymethyl-5- (4-methoxybenzyl)-6a-methyl-2 ,4-dioxohexahyi 
c] pyrrole-6-carboxylic acid methyl ester (131) and (3aS ,6R ,6aR )-6-benzyloxymethyl 
5- (4- met hoxyb enzyl) - 6a- met hyl- 2,4-dioxohexahydrofuro [2,3-c] pyrrole-6-carboxylic 
acid methyl ester (132) A solution of amide 217 (875 mg, 1.75 mmol) and (Me3P)2 NiC12 (115 
mg, 0.175 mmol) in THF (75 mL) was stirred at room temperature for 30 min and 
then cooled to —15 °C (ice-salt bath). Et2 Zn (3.52 mL, 1 M solution in THF, 3.52 
mmol) was then added via syringe. The reaction was allowed to warm slowly to room 
temperature over 18 h, and then quenched carefully with saturated aqueous NH4C1 so-
lution (50 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layers 
were dried (MgSO4) and concentrated in vacuo. Purification of the residue by col-
umn chromatography (20% to 35 % EtOAc/petrol) gave the double cyclization product 
131 (354 mg, 42%) as a pale yellow oil, followed by the double cyclization product 132 
(253 mg, 30%) as a colourless solid. Recrystallization of 132 from EtOAc/petrol gave 
colourless crystals that were suitable for X-ray crystallography. 
Data for desired 131: Rf (30% EtOAc in CHC13) = 0.19; [c] 	—33.3 (c 1.02, 
CHC13); JR (film) 2955, 1789 (C=O), 1733 (C=O), 1699 (C=O), 1612, 1513, 1439, 
1404, 1248, 1178 cm'; 'H NMR (250 MHz, CDC13) 6 7.27-7.18 (3H + 2H, in, ArH), 
7.04-6.99 (2H, m, ArH), 6.69 (2H, d, J = 8.7 Hz, ArH), 4.97 (1H, d, J = 15.2 Hz, 
OCHAHBPh), 4.21 (1H, d, J = 15.2 Hz, OCHAHBPh), 3.83 (1H, d, J = 11.5 Hz, 
NCHCHDAr), 3.75 (1H, d, J = 10.4 Hz, CHEHFOBn), 3.73 (1H, d, J = 11.5 Hz, 
NCHCHDAr), 3.73 (3H, s, OCH3), 3.66 (3H, s, OCH3), 3.13 (1H, d, J = 10.4 Hz, 
CHEHFOBn), 2.97 (1H, dd, J = 9.3, 1.5 Hz, CHGHHCH), 2.88 (1H, dd, J = 18.3, 
1.5 Hz, CHGHHCH), 2.72 (1H, dd, J = 18.3, 9.3 Hz, CHGHHCH), 1.53 (3H, s, CH3); 
'3C NMR (62.9 MHz, CDC13) 8 173.5 (C), 172.9 (C), 166.9 (C), 159.0 (C), 136.7 (C) 
130.0 (2 x CH), 129.4 (C), 128.4 (2 x CH), 127.9 (CH), 127.3 (2 x CH), 113.6 (2 x CH), 
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88.4 (C), 75.8 (C), 72.8 (CH2 ), 67.7 (CH2 ), 55.2 (CH3), 52.8 (CH3), 47.5 (CH), 45.1 
(CH2), 30.7 (C H2),  19.4 (CH3); HRMS (ES) Exact mass calcd for C25H28N07 [M+H]: 
454.1860 , found: 454.1856. 
Data for undesired 132: Rf (30% EtOAc in CHC13) = 0.08; m.p. 	105 °C; [ce] 22 
-17.9 (c 1.01, CHC13); JR (film) 2952, 2870, 1789 (C==O), 1743 (C=O), 1703 (C=O), 
1613, 1512, 1434, 1246, 1128 cm-1; 'H NMR (250 MHz, CDC13) 6 7.38-7.21 (5H, in, 
ArH), 7.12 (2H, d, J = 8.7 Hz, ArH), 6.82 (2H, d, J = 8.7 Hz, ArH), 4.72 (1H, d, J 
= 15.2 Hz, OCHA HBPh), 4.40 (1H, d, J = 15.2 Hz, OCHAHBPh), 4.34 (1H, d, J = 
11.7 Hz, NCHCHDAr), 4.27 (1H, d, J = 11.7 Hz, NCHCHDAr), 3.94 (1H, d, J = 10.1 
Hz, CHE HFOBII), 3.82 (3H, s, OCH3), 3.74 (iH, d, J = 10.1 Hz, CHEHFOBn), 3.67 
(3H, s, OCH3), 3.07 (111, dd, J = 9.7, 1.8 Hz, CHG HHCH), 3.04 (1H, dd, J = 18.3, 
1.9 Hz, CHG HHCH), 2.88 (iH, dd, J = 18.3, 9.7 Hz, CHGHHCH), 1.51 (3H, s, 
'3C NMR (62.9 MHz, CDC13) 6 173.4 (C), 173.2 (C), 169.2 (C) 158.7 (C) 137.1 (C) 
129.2 (2 x CH), 129.0 (C), 128.3 (2 x CH), 127.7 (3 x CH), 113.6 (2 x CH), 86.6 (C), 
75.3 (C), 73.6 (CH2 ), 68.7 (CH2), 55.2 (CH3), 52.8 (CH3), 46.9 (CH), 45.1 (CH2), 30.9 
(CH2), 21.3 (CH3); HRMS (ES) Exact mass calcd for C25H28N07 [M+H]: 454.1860, 
found: 454.1858. 
	
0 	 0 4CN .PMB




O2Me 	 Me CO2Me 
131 	 235 
(3a11,6R ,6aS)-6-Hydroxymethyl-5- (4-methoxybenzyl)-6a-methyl-.2 ,4-dioxohexahydi 
c]pyrrole-6-carboxylic acid methyl ester (235) A mixture of benzyl ether 131 
(354 mg, 0.78 mmol) and 10% Pd/C (99 mg, 0.093 mmol) in EtOH (5 mL) at room 
temperature was evacuated and flushed with H2 (3 times) and then stirred vigorously 
under an atmosphere of H2 (1 atm, H2 balloon) at room temperature for 18 h. The 
reaction mixture was filtered through celite and concentrated in vacuo. Purification 
of the residue by column chromatography (50% EtOAc/petrol) gave alcohol 235 (240 
mg, 84%) as a white powder. Rf (100% EtOAc) = 0.52; m.p. 144-146 °C; [a]22  —30.1 
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(c 0.95, CHC13); JR (film) 3437 (OH), 2955, 2253, 1787 (C=O), 1757 (C=O), 1692 
(C=O), 1613, 1513, 1247, 1035, 951cm'; 1H NMR (250 MHz, CDC13) 6 7.37 (2H, 
d, J = 8.6 Hz, ArH), 6.87 (2H, d, J = 8.6 Hz, ArH), 5.22 (1H, d, J = 15.2 Hz, 
NCHA HBAr), 4.24 (1H, d, J = 15.2 Hz, NCHAHBAr), 3.95 (1H, dd, J = 13.0, 8.9 Hz, 
CHCHDOH), 3.83 (3H, s, OCH3), 3.80 (3H, s, OCH3), 3.43 (1H, dd, J = 13.0, 5.5 Hz, 
CHCHDOH), 3.04 (1H, dd, J = 9.1, 1.7 Hz, CHEHFCH), 2.96 (1H, dd, J = 18.1, 1.7 
Hz, CHE HFCH), 2.85 (1H, dd, J = 18.1, 9.1 Hz, CHEHFCH), 1.69 (3H, s, CH3); 13C 
NMR (62.9 MHz, CDC13) 6  173.7 (C), 172.7 (C), 167.1 (C), 159.5 (C), 129.6 (2 x CH + 
C), 114.6 (2 x CH), 88.3 (C), 77.3 (C), 60.9 (CH2 ), 55.3 (CH3), 52.8 (CH3), 47.6 (CH), 
44.9 (CH2 ), 30.5 (CH2 ), 19.8 (CH3); HRMS (ES) Exact mass calcd for C18 H25N207  
[M+NH4]: 381.1656, found: 381.1660. 
	







Me CO2Me 	 Me CO2Me 
235 	 236 
(3aR,6R ,6aS )-6-Formyl-5- (4-methoxybenzyl)-6a-methyl-2 ,4-dioxohexahydrofuro [2 ,:i 
c]pyrrole-6-carboxylic acid methyl ester (236) To a solution of alcohol 235 (30 
mg, 0.082 mmol) in CH202 (0.8 mL) at room temperature was added Dess-Martin pe-
riodinane (43 mg, 0.099 mmol). The reaction mixture was stirred for 1.5 h, quenched 
with water and extracted with EtOAc (3 x mL). The combined organic layers were 
dried (Na2SO4) and concentrated in vacuo as an oil. This aldehyde proved to be un-
stable and was generally used immediately in the next step without purification. On 
one occasion, purification of a small amount of crude product by column chromatog-
raphy (50% EtOAc/petrol) was performed for characterisation purposes. Rf (100% 
EtOAc) = 0.34; IR (film) 2956, 1788 (C=O), 1760 (C=O), 1728 (C=O), 1687 (C=O), 
1513, 1438, 1246, 1176, 949 cm 1 ; 'H NMRHH (250 MHz, CDC13) 6 9.47 (1H, s, CHO), 
7.05 (2, d, J = 8.7 Hz, ArH), 6.81 (2H, d, J = 8.7 Hz, ArH), 4.86 (1H, d, J = 14.4 
Hz, NCHA HBAr), 4.39 (1H, d, J = 14.4 Hz, NCHAHBAr), 3.90 (3H, s, OCH3), 3.78 
(3H, s, OCH3), 3.08 (1H, dd, J = 9.7, 1.8 Hz, CHCHDCH), 2.99 (1H, dd, J = 18.4, 
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1.8 Hz, CHCHDCH), 2.85 (1H, dd, J = 18.4, 9.7 Hz, CHCHDCH), 1.52 (3H, s, CH3); 
'3C NMR (62.9 MHz, CDC13) 6 195.5 (CH), 172.7 (C), 172.0 (C), 165.7 (C), 159.6 
(C), 131.1 (2 x CH), 126.8 (C), 114.2 (2 x CH), 87.3 (C), 79.0 (C), 55.2 (CH3), 53.4 
(CH3), 46.8 (CH), 45.6 (CH2), 30.6 (CH2 ), 20.5 (CH3); LRMS (EP) Mass calcd. for 
C18 H19N07Na [M+Na]: 384.3, found: 383.7. 
0 
N _ PMB 
SnBU3 CHO I) n-BuLl, -78°C 	ZnCI  
_ 	 N ii) ZnCl2, -78°C 
236 	Me CO2Me 
THF, -78°C 	0 o OH 
Me CO2 Me 
538 	 21 	 237 
(3aR,6R,6aS)-6-[(7S)-(8S)-Cyclohex-2-enylhydroxymethyl]-5-(4-methoxybenzyl)-
6a-methyl-2,4- dioxohexahydrofuro  [2,3-c] pyrrole-6-carboxylic acid methyl es-
ter (237) To a solution of cyclohexenyltributyltin (538 )36 (89.6 mg, 0.206 mmol) in 
THF (0.6 mL) at —78 °C was added n-BuLi (130 uL mL, 1.6 M solution in hexanes, 
0.206 mmol). After stirring at —78 °C for 1 h, ZnC12 (0.42 mL, 0.5 M solution in THF, 
0.21 mmol) was added and stirring was continued at this temperature for another 1 h. 
A solution of the crude aldehyde 236 from the above experiment (theoretically 0.082 
mmol) in THF (0.4 mL) was then added via cannula, and after stirring for 3 h at 
—78 °C, the reaction was quenched with H2 0 (5 mL) and extracted with EtOAc (3 x 5 
mL). The combined organic layers were dried (MgSO4) and concentrated in vacno, and 
purification of the residue by column chromatography (50% EtOAc/petrol) gave the 
hornoallylic alcohol 237 (22.4 mg, 61% over two steps) as a colourless solid. Rf (100% 
EtOAc) = 0.61; Rf (70% EtOAc in CIIC13) = 0.45; m.p. = 114-116 °C; [a] 22 +3-0 (c 
1.47, CHC13); JR (film) 3438 (OH), 2931, 2359, 1790 (C=O), 1755 (C=O) 1687 (C=O), 
1512, 1440, 1246, 1175, 807 cm'; 1H NMRHH (250 MHz, CDC13) 6 7.18 (2H, d, J = 
8.7 Hz, ArH), 6.84 (2H, d, J = 8.7 Hz, ArH), 5.91 (1II, dm, J = 10.2 Hz, CH=CH), 
5.68 (1H, dm, J = 10.2 Hz, CH=CH), 4.79 (1H, d, J = 14.9 Hz, NCHA HBAr), 4.54 
(1H, d, J = 14.9 Hz, NCHAHBAr), 4.12 (1H, t, J = 7.1 Hz, CHOH), 3.78 (6H, s, 2 x 
OCH3), 3.13 (1H, dd, J = 6.8, 3.3 Hz, CII2CHC=O), 2.92 (1H, br s, OH), 2.82-2.79 
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(2H, in, CH2CHC=O), 2.32 (1H, bs, CHOHCH), 2.02 (2H, bs, CH2), 1.81 (3H, s, 
CH3CO), 1.76-1-66 (2H, in, CH2), 1.57-1.46 (1H, in, CH2 ), 1.44-1.33 (1H, in, CH2 ); 
'3C NMR (62.9 MHz, CDC13) 6 174.8 (C), 173.0 (C), 167.8 (C), 158.3 (C), 131.8 (CH), 
129.3 (C), 127.6 (2 x CH), 125.2 (CH), 113.7 (2 x CH), 91.1 (C), 79.0 (C), 76.9 (CH), 
55.2 (CH3), 52.4 (CH3), 47.9 (CH), 47.8 (CH), 38.3 (CH), 30.9 (CH2), 27.0 (CH2), 
24.9 (CH2 ), 20.6 (CH2),  19.6 (CH3); HRMS (ES) Exact mass calcd for C24 H33N207  
[M+NH4]: 461.2282, found: 461.2283. 
MeOH 	HO 
OH 




(2 R , 3 S ,4R )-2- [(6 S)- (7S)-Cyclohex-2-enylhydroxymethyl}-3-hydroxy-4- (2-hydroxyet 
1- (4-methoxybenzyl)-3-methyl-5-oxopyrrolidine-2-carboxylic acid methyl es-
ter (20) To a solution of the lactone 237(19.3 mg, 0.043 mmol) in MeOH (0.6 mL) at 
room temperature was added NaBH4 (75 mg, 2.0 mmol) portionwise over 2 mm. The 
solution was stirred for 18 h, quenched with 120 (4 mL) and extracted with EtOAc 
(3 x 4 mL). The combined organic layers were dried (Na2SO4) and concentrated in 
vacuo. Purification of the residue by column chromatography (70% EtOAc/petrol) 
gave triol 20 (11.7 mg, 60%) as a white foam. Rf (70% EtOAc in CHC13) = 0.12; rn.p. 
= 82-83 QC, lit.  26 83-84 °C; [of] 	+3.5 (c 0.56, CHC13), lit.26 +5.2 (c 0.60, CHC13); JR 
(film) 3331(OH), 2925, 2853, 1752 (C=0), 1670 (C=0), 1512, 1441, 1245, 1175, 1034 
cm'; 'H NMRHH (250 MHz, CDC13) 6 7.29 (2H, d, J = 8.7 Hz, ArH), 6.85 (2H, d, 
J = 8.7 Hz, ArH), 5.93 (1H, dm, J = 10.2 Hz, CH==CH), 5.62 (1H, dm, J = 10.2 
Hz, CH=CH), 4.76 (1H, d, J 	15.2 Hz, NCHA HBAr), 4.39 (11, d, J = 15.2 Hz, 
NCHAHBAr), 4.15 (111, t, J = 6.3 Hz, CHOH), 3.87-3.81 (1H, in, HOCHCHD CH2), 
3.80-3.75 (1H, in, HOCHCHDCH2), 3.79 (3H, s, OCH3), 3.71 (3H, s, OCH3), 3.02 
(1H, dd, J = 8.1, 4.8 Hz, COCH), 2.20 (11, bs, CHOHCH), 2.01 (2H, bs, CH2 ), 1.93-
1.78 (2H, in, CH2), 1.76-1.65 (2H, in, CH2), 1.64 (3H, s, CH3CO), 1.54-1.41 (2H, in, 
CH2); '3C NMR (62.9 MHz, CDC13) 6 178.5 (C), 169.7 (C), 158.2 (C), 132.9 (CH), 
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130.2 (C), 128.0 (2 x CH), 124.8 (CH), 113.6 (2 x CH), 81.8 (C), 80.6 (C), 77.2 (CH), 
61.7 (CH2 ), 55.2 (CH3), 51.9 (CH), 51.3 (CH3), 47.8 (CH2 ), 38.6 (CH), 28.2 (CH2 ), 
26.8 (CH2 ), 25.0 (CH2 ), 21.2 (CH3), 20.6 (CH2 ); HRMS (ES) Exact mass calcd for 
C24 H33 NO7 Na [M+Na]: 470.2149, found: 470.2150. 
Comparison of 13C NMR in CDC13 for 20. 
HWL data ref- 
erenced at 77.0 
ppm 
Corey 	data 	referenced 
at 77.38 ppm (data ref- 
erenced at 77.0 ppm) 
A ppm Pattenden data ref- 
erenced 	at 	77.03 
ppm 
A ppm 
178.5 178.99 (178.61) -0.11 178.8 -0.3 
169.7 170.12 (169.74) -0.04 169.7 0 
158.2 158.27 (157.89) +0.31 158.2 0 
132.9 131.30 (130.92) +1.98 132.6 +0.3 
130.2 130.55 (130.17) +0.03 130.7 -0.5 
128.0 128.13 (127.75) +0.25 128.2 -0.2 
124.8 126.39 (126.01) -1.21 125.1 -0.3 
113.7 113.74 (113.36) +0.34 113.7 0 
81.8 81.93 (81.55) +0.25 81.8 0 
80.6 80.75 (80.37) +0.23 80.6 0 
77.2 76.87 (76.49) +0.71 77.2 0 
61.7 61.61 (61.23) +0.47 61.6 +0.1 
55.2 55.45 (55.07) +0.13 55.2 0 
51.9 51.97 (51.59) +0.31 51.9 0 
51.3 51.32 (50.94) +0.36 51.3 0 
47.8 48.07 (47.69) +0.11 47.9 -0.1 
38.6 39.17 (38.22) +0.38 38.7 - 0.1 
28.2 27.71 (27.82) +0.38 28.0 +0.2 
26.8 27.13 (26.75) +0.05 26.8 0 
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25.0 	 25.22 (24.84) +0.16 	25.0 	 0 
21.2 	 21.35 (20.97) +0.23 	21.1 	 +0.1 
20.6 	 21.22 (20.84) -0.62 	20.7 	 -0.1 
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3.3 Reduction of cj3 unsaturated heteroarenes 
Preparation of Alkenyl Iodides 
Alkenyl iodides 447,2  450, and 446 4  were prepared according to previously reported 
procedures. 
Me 	 Me 	 Me 
I L._ ph 
447 	 450 	 446 
Me 	 Me 
NaH, BnBr 
	
H 	DMF, RT 
449 	 452 
(E )-4-Iodo-3-methylbut-3-enyloxymethyl] benzene (452) To a stirred sus-
pension of NaH (60% dispersion in mineral oil, 280 mg, 7.00 mmol) in DMF (40 mL) at 
0 °C was added the alcohol 449 (1.06 g, 5.00 mmol) in DMF (10 mL) via cannula over 2 
min and the resulting mixture was stirred at room temperature for 15 mm. BnBr (713 
tL, 5.99 mmol) was then added over 1 min and the mixture was stirred at room tem-
perature for 5 h. The reaction was quenched carefully with saturated aqueous NH4C1 
solution (50 mL) and extracted with Et20 (3 x 50 mL). The combined organic layers 
were washed with brine (50 mL), dried (MgSO4) and concentrated in vacuo. Purifi-
cation of the residue by column chromatography (hexane-->5% EtOAc/hexane) gave 
the benzyl ether 452(1.43 g, 95%) as a pale yellow oil. JR (film) 3052, 2981, 2934, 
1706, 1638, 1584, 1563, 1465, 1431, 1390, 1366, 1254, 1206, 1120 cm'; 'H NMR (500 
MHz, CDC13) 5 7.33-7.20 (5H, in, ArH), 5.91 (1H, q, J = 1.0 Hz, CH==), 4.43 (2H, s, 
CH2Ph), 3.48 (2H, t, J = 6.6 Hz, CH20CH2 Ph), 2.44 (2H, t, J = 6.6 Hz, CH2 CH20), 
1.79 (3H, d, J = 1.0 Hz, CH3); '3C NMR (62.9 MHz, CDC13) 6 145.0 (C), 138.1 (C), 
128.4 (2 x CH), 127.6 (3 x CH), 76.4 (CH), 72.9 (CH2), 68.0 (CH2),  39.4 (CH2), 24.2 
(CH3). 
Me 	 Me 
- 	NaH, BnBr - 
OH 	DMF, AT 	 OBn 
449 	 452 
. Devine, S. K. J.; Van Vranken, D. L. Org. Lett. 2007, 9, 2047-2049. 
. Marshall, J. A.; Eidam, P. Org. Lett. 2004, 6, 445-448. 
'. Negishi, E.; Van Horn, D. E.; Yoshida, T. J. Am. Chem. Soc. 1985, 107, 6639-6647. 
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Preparation of 2-Alkenyiheteroarenes 
General Procedure A 
R1  
R1 .N 	 Me 	Gui (1.0 equiv) 
JL > + L3 
Pd(OAc)2 (10 	 Me 
R 
DMAP (2.0 equiv) 
R2 X DMF, 140°C 
A solution of the appropriate heterocycle (2.00 mmol), the appropriate vinyl iodide 
(1.00 mmol), Pd(OAc)2 (23 mg, 0.10 mmol), CuT (191 mg, 1.00 mmol), and DMAP 
(244 mg, 2.00 mmol) in DMF (2 mL) was heated at 140 °C for 15 min in a microwave 
synthesizer. The mixture was diluted with Et20 (10 mL) and washed with saturated 
aqueous NH4C1 solution (3 x 15 mL). The organic layer was dried (MgSO4) and con-
centrated in vacuo. Purification of the residue by column chromatography afforded 
the 2-alkenylheteroarene. 
General procedure B 
P1  
N Me 	CuOAC (1.0 equiv) 	
2_ 
P2 X 	
N Me III '> + I _.L3 Pd(OAC)2  (1 MON ---- 	P DMAP (2.0 equiv) 
DMF, 140°C 
A solution of the appropriate heterocycle (2.00 mmol), the appropriate vinyl iodide 
(1.00 mmol), Pd(OAc)2 (2.3 mg, 0.01 mmol), CuOAc (126 mg, 1.00 mmol), and DMAP 
(244 mg, 2.00 mmol) in DMF (2 mL) was heated at 140 °C for 15 min in a microwave 
synthesizer. The mixture was diluted with Et20 (10 mL) and washed with saturated 
aqueous NH4C1 solution (3 x 15 mL). The organic layer was dried (MgSO4) and con-
centrated in vaeuo. Purification of the residue by column chromatography afforded 
the 2-alkenylheteroarene. 
2-[(E)-2-Methyl-4-phenylbut-1-enyl]benzooxazole 
QN Me  (460). The title compound was prepared according to 
Ph 
460 	 General Procedure A from benzoxazole (243 mg, 2.00 
mmol) and vinyl iodide 447 (272 mg, 1.00 mmol) and purified by column chromatog-
raphy (hexane-->I% EtOAc/hexane) to give a colorless oil (141 mg, 53%). JR (film) 
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3061, 3027, 2926, 2858, 1942, 1885, 1653, 1603, 1547, 1454, 1247, 1134, 1003, 953, 744, 
699 cm'; 'H NMR (500 MHz, CDC13) 5 7.66-7.64 (1H, in, ArH), 7.39-7.38 (1H, in, 
ArH), 7.24-7.19 (4H, in, ArH), 7.14-7.13 (3H, in, ArH), 6.20 (1H, br s, CH=), 2.80-
2.77 (2H, in, CH2), 2.51-2.48 (2H, in, CH2 ), 2.33 (3H, d, J = 0.8 Hz, CH3); 13C NMR 
(62.9 MHz, CDC13) 5 162.8 (C), 153.2 (C), 149.7 (C), 142.0 (C), 141.1 (C), 128.5 (2 
x CH), 128.3 (2 x CH), 126.1 (CH), 124.5 (CH), 124.2 (CH), 119.6 (CH), 111.8 (CH), 
110.2 (CH), 42.9, 34.2 (CH2 ), 19.7 (CH2 ); HRMS (ES) Exact mass calcd for C18 H18 N0 
[M+H]: 264.1383, found: 264.1383. 
2- [(E )-4- ( tert-Butyldimethylsilyloxy)-2-methylbut- 
k\ Q—X~' N Me 1-eriyl]benzooxazole (462). The title compound was 
OTBS 
	
462 	prepared according to General Procedure B from ben- 
zoxazole (243 mg, 2.00 mmol) and vinyl iodide 450 (326 ing, 1.00 mmol) and purified 
by column chromatography (hexane-2% EtOAc/hexane) to give a colorless oil (133 
Ing, 42%). IR (film) 3054, 2954, 2928, 2901, 2857, 1936, 1773, 1651, 1548, 1454, 1361, 
1250, 1101, 1003, 837, 776, 744 cm'; 'H NMR (500 MHz, CDC13) 5 7.72-7.70 (111, in, 
ArH), 7.51-7.49 (111, in, ArH), 7.33-7.29 (2H, in, ArH), 6.31-6.30 (1H, in, CH=CCH3), 
3.85 (211, t, J = 6.6 Hz, CH2 0), 2.51 (2H, dt, J = 6.6, 0.9 Hz, CH2CH2 0), 2.39 (3H, 
d, J = 1.3 Hz, =CCH3), 0.90 (911, s, C(CH3 )3), 0.07 (6H, s, Si(CH3)2); '3C NMR 
(62.9 MHz, CDC13) 5 162.7 (C), 151.2 (C), 149.7 (C), 141.9 (C), 124.5 (CH), 124.1 
(CH), 119.6 (CH), 112.9 (CH), 110.2 (CH), 61.5 (CH2), 44.3 (CH2), 25.9 (3 x CH3), 
19.9 (CH3), 18.2 (C), —5.4 (2 x CH3); HRMS (ES) Exact mass calcd for C18H28NO2Si 
[M+H]: 318.1884, found: 318.1879. 
(I N Me 	
2-[(E)-4-Benzyloxy-2-methylbut-l-enyl]benzooxazole  
(461). The title compound was prepared according to Gen- 
OBn 
461 
eral Procedure B from benzoxazole (243 mg, 2.00 mmol) 
and vinyl iodide 452 (302 mg, 1.00 mmol) and purified by column chromatography 
(hexane—*3% EtOAc/hexane) to give a colorless oil (116 mg, 39%). JR (film) 3062, 
3029, 2858, 1652, 1546, 1453, 1361, 1247, 1101, 1076 cm'; 'H NMR (500 MHz, CDC13) 
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7.72-7.71 (1H, in, ArH), 7.51-7.49 (1H, in, ArH), 7.36-7.35 (411, in, ArH), 7.32-7.30 
(311, in, ArH), 6.36-6.35 (1H, in, CH=CCH3), 4.57 (2H, s, CH2 Ph), 3.71 (211, t, J = 
6.6 Hz, CH2CH2 0), 2.62 (2H, td, J = 6.6, 0.9 Hz, CH2 CH2 0), 2.40 (3H, d, J = 1.3 
Hz, CH3); '3C NMR (62.9 MHz, CDC13) 6 162.5 (C), 150.8 (C), 149.6 (C), 141.8 (C), 
138.0 (C), 128.3 (2 x CH), 127.5 (3 x CH), 124.4 (CH), 124.0 (CH), 119.5 (CH), 112.6 
(CH), 110.1 (CH), 72.9 (CH2 ), 67.9 (CH2), 40.9 (CH2 ), 19.6 (CH3); HRMS (ES) Exact 
mass calcd for C19 H20 NO2 [M+H]: 294.1489, found: 249.1482. 
Q, 
]benzooxazole (454). The title com- 
\/N Me 
I 	pound was prepared according to General Procedure A from ben- 
0 Ph 
454 	zoxazole (243 mg, 2.00 mmol) and vinyl iodide 446 (244 mg, 1.00 
mmol) and purified by column chromatography (hexane—+1% EtOAc/hexane) to give 
a colorless oil (93 mg, 39%). JR (CI-1C13) 3059, 2919, 1945, 1890, 1630, 1541, 1452, 
1249, 1150, 1140, 1003, 763, 744 cm'; 'H NMR (500 MHz, CDC13) 6 7.79-7.77 (1H, in, 
ArH), 7.62-7.60 (2H, in, ArH), 7.56-7.54 (111, in, ArH), 7.46-7.33 (5H, in, ArH), 6.82 
(111, br d, J = 1.2 Hz, CH=), 2.83 (3H, d, J = 1.2 Hz, CH3); '3C NMR (62.9 MHz, 
CDC13) ö 162.9 (C), 149.8 (C), 142.2 (C), 142.0 (C), 128.7 (CH), 128.5 (2 x CH), 126.2 
(2 x CH), 124.8 (CH), 124.3, (CH) 119.8 (CH), 112.7 (CH), 110.2 (CH), 18.7 (CH3); 
HRMS (ES) Exact mass calcd for C16 H14 N0 [M+H]: 236.1070, found: 236.1066. 
N 	Me 	2- [(E )-2-Methyl-4-phenylbut- 1-enyl] -5-phenyloxazole 
Ph 	
Ph (428). The title compound was prepared according to a 
428 
slight modification of General Procedure A from 5-phenyloxazole5 (581 mg, 4.00 mmol), 
vinyl iodide 447 (544 mg, 2.00 mmol), Pd(OAc)2 (65 mg, 0.29 mmol), CuT (381 mg, 
2.00 mmol), and DMAP (489 mg, 4.00 mmol) in DMF (5 mL) at 150 °C for 20 mm 
and purified by column chromatography (hexane—*3% EtOAc/hexane) to give a yellow 
gum (126 mg, 22%). JR (CHC13) 3061, 3027, 2927, 1694, 1494, 1450, 1226, 1025 cm-'; 
111 NMR (250 MHz, CDC13) 6 7.56-7.52 (211, in, ArH), 7.34-7.27 (311, in, ArH), 7.25-
7.19 (3H, in, ArH) 7.14-7.11 (3H, in, ArH), 6.12 (1H, s, CH=CCH3), 2.80-2.74 (2H, 
. Besselievre, F.; Mahuteau-Betzer, F.; Grierson, D. S.; Piguel, S. J. Org. Chem. 2008, 73, 
3278-3280. 
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in, CH2 ), 2.49-2.43 (2H, in, CH2), 2.24 (3H, s, CH3); 13C NMR (62.9 MHz, CDC13) ö 
161.1 (C), 149.6 (C), 148.4 (C), 141.2 (C), 128.8 (2 x CH), 128.4 (2 x CH), 128.2 (2 
CH), 128.1 (C), 128.0 (CH), 126.0 (CH), 123.9 (2 x CH), 122.8 (CH), 111.7 (CH), 42.6 
(CH2), 34.2 (CH2 ), 19.2 (CH3); HRMS (ES) Exact mass calcd for C20H20N0 [M+H]: 
290.1539, found: 290.1536. 
2- [(E )-2-Methyl-4-phenylbut- 1-enyl] benzothiazole 
Me 
(463). The title compound was prepared according to 
Ph 
463 
General Procedure A from benzothiazole (270 mg, 2.00 
mmol) and vinyl iodide 447 (272 mg, 1.00 mmol) and purified by column chromatog-
raphy (hexane-3% EtOAc/hexane) to give a pale yellow solid (242 mg, 43%). rn.p. 
56-58 °C; JR (CHC13) 3060, 3026, 2925, 1635, 1495, 1454, 1433, 1311, 1107, 758, 727, 
698 cm'; 'H NMR (500 MHz, CDC13)  6 8.02 (1H, din, J = 8.1 Hz, ArH), 7.87 (1H, 
din, J = 8.1 Hz, ArH), 7.49-7.46 (11-I, in, ArH), 7.38-7.31 (3H, m, ArH), 7.25-7.21 (3H, 
rn, ArH), 6.65 (1H, q, J = 1.2 Hz, CH=CCH3), 2.93-2.89 (211, in, C112 ), 2.63-2.60 
(2H, m, CH2 ), 2.33 (3H, d, J = 1.2 Hz, CH3); '3C NMR (201.1 MHz, CDC13) 6 165.3 
(C), 153.1 (C), 148.6 (C), 141.1 (C), 134.7 (C), 128.4 (2 x CH), 128.2 (2 x CH), 126.0 
(2 x CH), 124.6 (CH), 122.6 (CH), 121.1 (CH), 119.6 (CH), 43.1 (CH2 ), 34.2 (CH2 ), 
19.6 (CH3); HRMS (ES) Exact mass calcd for C18H18 NS [M+H]: 280.1154, found: 
280.1157. 
Initial approach through oxazol formation 
0 	 0 




414 	 415 	 416 
(E)-5-methyl-2-styryloxazole (416) To a solution of Ph3P (4.45 g, 17 mmol) in 
THF (50 mL) at rt was added azide (0.99 g, 10 mmol) and acid chloride (1.66 g, 10 
mmol). The resultant mixture was stirred for 12 h and then filtered. Purification of 
the residue by column chromatography (15% EtOAc/hexane -* 25% EtOAc/hexane) 
gave 416 (690 mg, 37%). 'H NMR (250 MHz, CDC13) 6 7.44 (3H, in, ArH), 7.29 (311, 
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in, ArH + =CH), 6.88 (1H, d, J = 16.4, =CH), 6.75 (1H, bs, OxH), 2.27 (3H, d, J = 
1.1, CH3); LRMS (ESI) [M+H]: 186.1. 
6 
0 II 
P-OEt XNLHMDS, THF 0°C Ph  0Et 	Me 	 60% E/Z 5:1 	Ph° Ph 
Ph 	 Me 
418 	 427 
(E)-5-phenyl-2-(2-phenylprop-1-enyl)oxazole (427) To a solution of phos-
phonoacetate 418 (1.18 g, 4 mmol) in THF (50 mL) was added LHMDS dropwise at 
0 °C under nitrogen. After 30 mm, acetophenone (0.56 mL, 4.8 inmol) was added. 
After 3 d reaction was quenched with NH4C1(aq), extracted with DCM dried over 
Na2SO4. Crude mixture was dissolved in small amount of EtOH and 400 mg of NaBH4 
was added to reduce excess of acetophenone after 30 min quenched with NH4C1(aq), 
extracted with DCM dried over Na2SO4. Purification of the residue by column chro-
matography (10% EtOAc/hexane - 20% EtOAc/hexane) gave 427 (624 mg, 60%). 
'H NMR (250 MHz, CDC13) S 7.73-7.26 (11H, in, ArH), 6.72 (1H, q, J = 1.1 Hz, 
=CH), 2.71 (3H, d, J = 1.3 Hz, CH3). '3C NMR (63 MHz, CDC13) 5 161.3 (C) , 150.1 
(C), 145.5 (C) , 142.5 (C), 128.9 (2 x CH), 128.5 (CH), 128.2 (CH), 128.0 (C), 126.0 
(CH), 124.1 (CH), 123.3 (CH), 112.7 (CH) , 18.3 (CH3); LRMS (ESI) [M+H]: 262.1. 
0 
II o o 	0 	 N P-OEt 
*Ph1 	





413 	 417 	 418 
diethyl (5-phenyloxazol- 2-yl) met hylphosphonat e (418) To a solution of Ph3P 
(47 g, 179 mmol) in THF (150 mL) at rt was added azide (17 g, 105 mmol) and acid 
chloride (22.6 g, 105 mmol). The resultant mixture was stirred for 12 h and then fil-
tered. Purification of the residue by column chromatography (10% EtOAc/hexane -k 
30% EtOAc/hexane) gave 418 (9.3 g, 30%). 'H NMR (360 MHz, CDC13) 8 7.66-7.17 
(6H, in, ArH), 4.17-4.05 (411, in, 2 x OCH2CH3), 3.40 (2H, d, J = 21.3 Hz, PCH2 ), 
b• Stephen, A.; Hashmi, K.; Weyrauch, J. P.; Frey, W.; Bats, J. W. Org. Lett. 2004, 6, 4391-4394. 
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1.25 (6H, bt, J = 7.1 Hz, 2 x OCH2CH3); '3C NMR (63 MHz, CDC13) 6 154.8 (C), 
151.0 (C), 132.9 (C), 127.8 (CH), 127.4 (CH), 123.1 (CH), 121.4 (CH), 61.8 (2 x CH2 ), 








NCHO L1HMDS, THF, 0 O 	 N LCO2E 
539 
(E/Z)-ethyl 2-(quinolin-2-ylmethylene)butanoate (495) To a solution of tn-
ethyl 2-phosphonobutyrate (1.26 g, 5 mmol) in THF (50 mL) at -78 °C was added L1H-
MDS (1 M in THF, 6.0 mL, 6.0 minol) over 5 mm, and the resulting solution was stirred 
at the same temperature for 15 min and then warmed to 0 °C. 2-Quinolinecarboxaldehyde 
(643 mg, 6.0 mmol) was then added over 1 niin and the mixture was stirred at 0 °C 
for 4 h before being quenched carefully with saturated aqueous NH4C1 (30 mL). The 
mixture was extracted with Et2 0 (3 x 20 mL), and the combined organic layers were 
dried (MgSO4) and concentrated in vacuo. Purification of the residue by column chro-
matography (10% EtOAc/hexane-*40% EtOAc/hexane) gave the alkene 495 (114 g, 
45%) as a pale yellow oil. 'H NMR (250 MHz, CDC13) 6 8.31 (2H, dd, J = 8.3, 5.0 
Hz, ArH), 8.00 (1H, m, ArH), 7.97 (s, 1H, =CH), 7.91 (1H ddd, J = 8.4, 6.9, 1.5 Hz, 
ArH), 7.73 (1H, dd, J = 11.2, 3.8 Hz, ArH), 7.64 (1H, d, J = 8.5 Hz, ArH), 4.53 (1H, 
q, J = 7.1 Hz, OCH2), 3.19 (2H, q, J = 7.4 Hz, =CCH2), 1.58 (3H, t, J = 7.1 Hz, 
OCH2CH3), 1.46 (3H, t, J = 7.4 Hz, =CCH2 CH3); LRMS (ESI) [MH-H]: 256.1. 
Preparation of Alkene 493 
Me 
Ph3PCO2Et()e 
N 	CHO 	toluene, 
DIBAL, toluene 





486 490 493 
Ethyl (E) - 2-met hyl-3-  (pyridin-2-yl) prop enoate (486). A solution of 2-pyridinecarboxal 
(1.90 mL, 20.0 mmol) and (carbethoxyethylidene)-triphenylphosphorane (94%, 8.70 g, 
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22.6 mmol) in toluene (200 mL) was heated under reflux for 18 h and then cooled to 
room temperature. The mixture was concentrated in vacno and the residue was pu-
rified by column chromatography (5% EtOAc/hexane—*10% EtOAc/hexane) to give 
the alkene 486 (1.91 g, 50%) as a pale yellow oil. IR (film) 3052, 2981, 2934, 1706, 
1638, 1584, 1563, 1465, 1431, 1390, 1366, 1254, 1206, 1120 cm 1 ; 1H NMR (360 MHz, 
CDC13) 6 8.68 (111, ddd, J = 4.8, 1.8, 1.0 Hz, ArH), 7.70 (1H, dt, J = 7.7, 1.8 Hz, 
ArH), 7.64 (1H, app q, J = 1.5 Hz, CH=CCH3), 7.37 (1H, app d, J = 7.9 Hz, ArH), 
7.19 (1H, ddd, J = 7.7, 4.8, 1.0 Hz, ArH), 4.28 (2H, q, J 	7.1 Hz, OCH2), 2.33 (3H, 
d, J = 1.5 Hz, =CCH3), 1.35 (3H, t, J = 7.1 Hz, OCH2CH3); '3C NMR (90.6 MHz, 
CDC13) 6 168.6 (C), 155.2 (C), 149.5 (CH), 136.6 (CH), 136.1 (CH), 132.4 (C), 125.7 
(CH), 122.4 (CH), 70.0 (CH2), 14.2 (CH3), 14.1 (CH3); HRMS (ES) Exact mass calcd 
for C,11-I14 NO2 [M+H]: 192.1019, found: 192.1022. 
(E)-Methyl-3-(pyridin-2-yl) prop- 2-en-1-ol (490). To a 
Me 
eOH 	
solution of the ester 486 (956 mg, 5.00 mmol) in CH202 (50 
490 
mL) at —78 °C was added DIBAL (1.2 M in toluene, 8.75 mL, 
10.5 mmol) over 2 mm, and the resulting mixture was stirred at —78 °C for 2 h and 
then at 0 °C for 1 h. The reaction was quenched carefully with saturated aqueous 
Rochelle's salt solution (50 mL) and the resulting mixture was stirred vigorously for 1 
It The aqueous layer was separated and extracted with CH202 (3 x 50 mL), and the 
combined organic layers were dried (Na2SO4) and concentrated in vacuo. Purification 
of the residue by column chromatography (30% EtOAc/hexane) gave the alcohol 490 
(553 mg, 74%) as a yellow oil. JR (film) 3273, 2910, 2852, 1662, 1589, 1564, 1471, 1433, 
1375, 1076 cm'; 'H NMR (360 MHz, CDC13) ö 8.57-8.55 (1H, in, ArH), 7.66-7.61 (1H, 
in, ArH), 7.24 (1H, app d, J = 7.9 Hz, ArH), 7.11-7.08 (1H, m, ArH), 6.65 (1H, br d, 
J = 1.1 Hz, CH=CCH3), 4.19 (2H, s, CH2 0), 3.72 (1H, br s, OH), 2.01 (3H, s, 
'3C NMR (62.9 MHz, CDC13) 6 156.8 (C), 148.8 (CH), 143.0 (C), 136.1 (CH), 124.0 
(CH), 123.1 (CH), 121.0 (CH), 67.8 (CH2 ), 15.4 (CH3); HRMS (ES) Exact mass calcd 
for C9H,2N0 [M+H]h 150.0913, found: 150.0911. 
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The stereochemistry of alcohol 490 was determined using an NOE experiment, 
which displayed the following diagnostic enhancement: 
Me 
1 LX _OH  490 






2- [(E)-3- ( tert-Butyldimethylsilyloxy) -2-methyipropenyl] pyrid 
(493). To a solution of the alcohol 490 (298 mg, 2.00 mmol) 
and imidazole (340 mg, 5.00 mmol) in DMF (10 mL) at room temperature was added 
a solution of TBSC1 (392 mg, 2.60 mmol) in DMF (10 mL) via cannula over 3 mm 
and the mixture was stirred at room temperature for 5 h. The reaction was quenched 
with saturated aqueous NH4C1 solution (20 mL) and extracted with Et2 0 (3 x 30 mL). 
The combined organic layers were washed with brine (2 x 30 mL), dried (MgSO4), 
and concentrated in vacno. Purification of the residue by column chromatography (5% 
EtOAc/hexane) gave the silyl ether ig (501 mg, 95%) as a pale yellow oil. IR (film) 
2954, 2928, 2855, 1664, 1586, 1561, 1471, 1430, 1252, 1111, 1089 cur'; 'H NMR (360 
MHz, CDC13) 6 8.59 (1H, app d, J = 4.7 Hz, ArH), 7.60 (1H, dt, J = 7.7, 1.8 Hz, ArH), 
7.22 (1H, app d, J = 7.9 Hz, ArH), 7.08-7.04 (1H, in, ArH), 6.61 (3H, s, CH=CCH3), 
4.20 (2H, s, CH2 0), 2.03 (3H, s, CH3), 0.95 (9H, s, C(CH3)3), 0.12 (6H, s, Si(CH3)2); 
13C NMR (62.9 MHz, CDC13) 6 157.2 (C), 149.1 (CH), 142.1 (C), 135.8 (CH), 124.0 
(CH), 122.8 (CH), 120.7 (CH), 68.1 (CH2 ), 25.9 (3 x CH3), 18.4 (C), 15.2 (CH3), —5.3 
(2 x CH3); HRMS (ES) Exact mass calcd for C15H26 NOS1 [MH-H]: 264.1778, found: 
264.1779. 
(E)-2-Methyl-3-pyridin-2-ylpropenyl benzoate (540) 
Me 	
BzCI, Et3N, DMAP 	
Me 
(11 .OBZ  
N 	
OH 	CH2Cl2, 	
5 490 	 40 
To a solution of the alcohol 490 (84 mg, 0.56 mmol), Et3N (390 JLL, 2.80 mmol), and 
DMAP (17 mg, 0.14 mmol) in CH202 (5 mL) at room temperature was added BzC1 
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(140 jL, 1.21 mmol), and the resulting mixture was stirred at room temperature for 4 
h. The reaction was quenched with saturated aqueous Na2 CO3 solution (20 mL) and 
extracted with CH2 C12 (3 x 20 mL). The combined organic layers were dried (Na2SO4) 
and concentrated in vacuo. Purification of the residue by column chromatography 
(20% EtOAc/hexane) gave the benzoate ester 540 (83 mg, 58%) as a colorless oil. JR 
(film) 2922, 1718 (C=O), 1585, 1450, 1313, 1269, 1111, 1068, 1026, 712 cur'; 'H NMR 
(250 MHz, CDC13) 6 8.54 (1H, d, J = 4.2 Hz, ArH), 8.05-8.08 (2H, in, ArH), 7.60-7.46 
(211, in, ArH), 7.40-7.34 (2H, in, ArH), 7.20-7.16 (1H, in, ArH), 7.06-7.02 (1H, in, 
ArH), 6.59 (111, app br d, J 	1.2 Hz, CH==CCH3), 4.84 (2H, s, CH2 0), 2.11 (3H, 
br d, J = 0.9 Hz, CH3); 13C NMR (62.9 MHz, CDC13) 8 166.2 (C), 156.1 (C), 149.2 
(CH), 137.2 (C), 136.0 (CH), 133.0 (CH), 130.0 (C), 129.6 (2 x CH), 128.3 (2 x CH), 
126.7 (CH), 124.2 (CH), 121.3 (CH), 69.9 (CH2), 15.7 (CH3); HRMS (ES) Exact mass 
calcd for C16 H16 NO2 [M+H]: 254.1176, found: 254.1172. 
MeMgBr, THE 	(iie 







(E)-2 ,3-dimethyl-4- (pyridin-2-yl) but- 3-en-2-ol (492) Purification of the residue 
by column chromatography (10% EtOAc/hexane - 30% EtOAc/hexane) gave 418 (9.3 
g, 30%). A solution of methylmagnesium bromide (2 mL, 6 mmol, 3 M in THF) was 
added to ester 486 in 20 mL of THF at 0 °CReaction mixture was allowed to warm up 
to rt and was quanched after 1 h with NH4C1 (aq). Crude product was extracted with 
EtOAc and dried over MgSO4. Purification of the residue by column chromatography 
(10% EtOAc/hexane -* 40% EtOAc/hexane) gave 492 (286 mg, 81%). 'H NMR (250 
MHz, CDC13) 6 8.67 (1H, d, J = 4.1 Hz, ArH), 7.71 (1H, td, J = 7.7, 1.9 Hz, ArH), 
7.31 (111, d, J = 7.9 Hz, ArH), 7.17 (1H, ddd, J = 7.5, 4.9, 1.0 Hz, H), 6.87 (1H, bs, 
=CH), 2.87 (111, s, OH), 2.15 (3H, d, J = 1.3 Hz, =CCH3), 1.54 (611, s, 2 x CH3); 13C 
NMR (63 MHz, CDC13) 6 158.5 (C), 150.3 (C), 149.9 (CH), 136.9 (CH), 125.3 (CH), 
122.9 (CH), 121.8 (CH), 74.8 (C), 29.8 (2 x CH3), 15.7 (CH3); LRMS (ESI) [M+H]: 
178.1. 
132 
Chapter 3. Experimental Data 










N 	CHO KOH, Bu4NPF6 CHO 	EtOH, rt DMAP, CH2Cl2, rt N 
toluene, rt 5 42 541 543 




a slight modification of a literature procedure for a similar 
542 
compound, to a vigorously stirred suspension of Bu4 NPF6 
(387 mg, 1.00 mmol) and KOH (84 mg, 1.50 mmol) in toluene (15 mL) was added 
2-pyridinecarboxaldehyde (0.95 mL, 10.0 mnmol) dropwise over 1 mm, followed by hy-
drocinnamaldehyde (1.76 mL, 12.0 mmol) dropwise over 2 mm. The reaction was 
stirred vigorously at room temperature for 5 h, and then partitioned between H20 
(50 mL) and CH2 C12 (50 mL). The aqueous layer was separated and extracted with 
CH202 (2 x 50 mL) and the combined organic layers were dried (Na2SO4) and con-
centrated in vacno. Purification of the residue by column chromatography (20% 
EtOAc/hexane—*60% EtOAc/hexane) gave the enal 542 (819 mg, 37%) as a red-
brown solid. m.p. 46-48 °C; JR (CHC13) 3059, 2924, 2823, 2717, 2360, 1684 (C=O), 
1631 (C==C), 1579, 1308, 1136, 739; 'H NMR (250 MHz, CDC13) (59.53 (1H, s, CHO), 
8.61-8.59 (1H, in, ArH), 7.57 (1H, dt, J = 7.8, 1.9 Hz, ArH), 7.29 (111, d, J = 7.8 
Hz, ArH), 7.21-6.98 (7H, in, ArH and CH=CCH2Ph), 4.24 (2H, s, CH2Ph); '3C NMR 
(62.9 MHz, CDC13) 6 195.3 (CH), 153.7 (C), 149.8 (CH), 147.6 (CH), 143.7 (C), 139.0 
(C), 136.4 (CH), 128.6 (2 x CH), 128.1 (2 x CH), 126.2 (CH), 125.8 (CH), 123.7 (CH), 
29.8 (CH2); HRMS (ES) Exact mass calcd for C15 H14N0 [M+H]: 224.1070, found: 
224.1065. 
Ph 	 (Z )-2-Benzyl-3-pyridin-2-ylprop-2-en- 1-1 (541). To a 
N 	
OH 	solution of aldehyde 542(447 mg, 2.00 mmol) in EtOH (10 
541 
mL) at room temperature was added NaBH4 (227 mg, 6.00 
mmol) portionwise over 5 mm. The resulting mixture was stirred at room temperature 
for 1 h and quenched carefully with saturated aqueous NH4C1 solution (20 mL). Most 
. 	 Ziotin, S. G. Eur. J. Org. Chem. 2005, 2822-2827. Kryshtal, G. V.; Zhdankina, G. M.;  
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of the EtOH was removed in vacno, and the aqueous residue was extracted with EtOAc 
(3 x 30 mL). The combined organic layers were dried (MgSO4) and concentrated in 
vacno. Purification of the residue by column chromatography (50% EtOAc/hexalle) 
gave the alcohol 541 (451 mg, 99%) as a cream solid. m.p. 67-69 °C; JR (film) 3273 
(OH), 3025, 2906, 1659 (C=C), 1585, 1472, 1151, 1052, 733, 620 cm'; 'H NMR (360 
MHz, CDC13) 6 8.46-8.40 (1H, in, ArH), 7.49 (1H, dt, J = 7.7, 1.8 Hz, ArH), 7.16-7.03 
(6H, in, ArH), 7.00 (1H, ddd, J = 7.5, 4.9, 0.9 Hz, ArH), 6.75 (1H, s, CH=CCI-I2 Ph), 
4.04 (2H, d, J = 1.2 Hz, CH20H), 3.88 (2H, s, CH2Ph); '3C NMR (62.9 MHz, CDC13) 
6 156.3 (C), 148.8 (CH), 145.0 (C), 139.2 (C), 136.3 (CH), 128.4 (2 x CH), 128.3 (2 x 
CH), 125.9 (CH), 124.3 (CH), 123.7 (CH), 121.3 (CH), 65.2 (CH2 ), 34.2 (CH2 ); HRMS 
(ES) Exact mass calcd for C15H16 NO [M+H]: 226.1226, found: 226.1223. 
The stereochemistry of alcohol 541 was determined using an NOE experiment, 
which displayed the following diagnostic enhancement: 
Ph 
"N -' ~OH  541 
H H  
Ph 	 (Z )-2-Benzyl-3-pyridin-2-ylpropenyl pivaloate (543). 
N 	
OPiv To a solution of the alcohol 541(338 mg, 1.50 mmol), Et3N 
543 
(638 L, 4.50 mmol), and DMAP (18 mg, 0.15 mmol) in 
CH2 C12 (10 mL) at room temperature was added trimethylacetyl chloride (370 jL, 
3.00 mmol) over 1 mill, and the resulting mixture was stirred at room temperature for 
5 h. The reaction was quenched with saturated aqueous Na2CO3 solution (20 mL) and 
extracted with CH202 (3 x 20 mL). The combined organic layers were dried (Na2SO4) 
and concentrated in vacno. Purification of the residue by column chromatography (5% 
EtOAc/hexane) gave the pivaloate ester 543 (458 mg, 99%) as a colorless oil. JR 
(film) 2973, 1729 (C=O), 1658 (C=C), 1585, 1479, 1280, 1149, 1031, 740, 700 cm'; 
'H NMR (360 MHz, CDC13) 6 8.50-8.48 (1H, in, ArH), 7.49 (1H, dt, J = 7.7, 1.9 Hz, 
ArH), 7.18-7.04 (6H, m, ArH), 6.99 (1H, d, J = 7.6, 4.8, 1.1 Hz, ArH), 6.59 (1H, s, 
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CH==CCH2 Ph), 4.48 (2H, d, J = 1.3 Hz, CH20), 4.05 (2H, s, CH2 Ph), 1.10 (9H, s, 
C(CH3)3); '3C NMR (90.6 MHz, CDC13) 6 177.8 (C), 155.6 (C), 149.1 (CH), 139.7 
(C), 138.9 (C), 136.0 (CH), 128.6 (2 x CH), 128.3 (2 x CH), 127.4 (CH), 126.0 (CH), 
124.1 (CH), 121.6 (CH), 67.4 (CH2 ), 38.7 (C), 34.4 (CH2), 27.1 (3 x CH3); HRMS (ES) 
Exact mass calcd for C20 H24 NO2 [M+H]: 310.1802, found: 310.1802. 
Ph 	 Ph 
CXN)-I:II1 Ac20, DMAP, Et3N DCM, rt, 50% 	-... )N- 
OH 	 OAc 
544 	 503 
(E)-2-benzyl-3-(quinolin-2-yl)allyl acetate (503) To a solution of alcohol 544 
(826 mg, 3 mmol), DMAP (91 mg, 0.75 mmol), Et3N (1.6 mL, 12 mmol) in 20 mL 
of DCM at rt, was added acetic anhydride (643 mg, 6.3 mmol). After 2 h reaction 
mixture was quenched with NH4C1 (aq). Crude product was extracted with EtOAc 
and dried over MgSO4. Purification of the residue by column chromatography (10% 
EtOAc/hexane - 30% EtOAc/hexane) gave 503 (476 mg, 50%). 'H NMR (250 MHz, 
CDC13) ö 7.92 (1H, d, J = 8.5 Hz, ArH), 7.87 (1H, d, J = 8.1 Hz, ArH), 7.59 (1H, 
d, J = 8.0 Hz, ArH), 7.50 (1H, ddd, J = 8.5, 6.9, 1.4 Hz, ArH), 7.32 (1H, t, J = 
7.5 Hz, ArH), 7.24-6.91 (6H, in, ArH), 6.70 (1H, s, ==CH), 4.48 (2H, s, CH2 ), 4.07 
(2H, s, CH2 ), 1.89 (3H, s, CH3); '3C NMR (63 MHz, CDC13) 6 171.0 (C), 156.1 (C), 
148.3 (C), 141.5 (C), 139.5 (C), 136.5 (CH), 129.9 (CH), 129.9 (CH), 129.3 (CH), 128.8 
(CH), 128.2 (CH), 127.8 (CH), 127.2 (C), 126.7 (CH), 126.6 (CH), 122.9 (CH), 67.8 
(CH2), 35.2 (CH2 ), 21.3 (CH3); LRMS (ESI) [M+H]: 317.1. 





Fe(acac)3 (10 mor %) 
N 	Me 	THE, 78°CtoO°C N 	 Me THE, -30°C NMe 
511 515 517 
Trifluoromethanesulfonic acid (Z)-1-methyl-2-quinolin-2-yl vinyl ester 
(515). To a solution of the ketone 5118 (370 mg, 2.00 mmol) in THF (15 mL) at 
. (a) Wolfe, J. F.; Murray, T. P. J. Org. Chem. 1971, 86, 354-357. (b) Langer, P.; Doring, M.; 
Seyferth, D.; Görls, H. Chem. Eur. J. 2001, 7, 573-584. 
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-78 °C was added KHMDS (0.5 M in toluene, 4.4 mL, 2.2 mmol) over 2 mm. After 15 
mm, a solution of PhNTf2 (857 mg, 2.40 mmol) in THF (5 mL) was added via can-
nula over 2 min and the mixture was stirred at -78 °C for 30 mill before being warmed 
slowly to 0 °C over 2 h. The reaction was quenched with saturated aqueous NH4C1 so-
lution (30 mL) and the mixture was diluted with Et20 (30 mL). The aqueous layer 
was separated an extracted with Et20 (2 x 30 mL) and the combined organic layers 
were dried (MgSO4) and concentrated in vacuo. Purification of the residue by recrys-
tallization from hot hexane gave the vinyl triflate 515 (423 mg, 67%) as an amorphous 
yellow solid. JR (CHC13) 3061, 2926, 1685, 1597, 1503, 1419, 1240, 1208, 1143, 1113, 
1029 cm-1; 1H NMR (360 MHz, CDC13) 6 8.18-8.16 (2H, in, ArH), 7.81-7.79 (1H, in, 
ArH), 7.73 (ill, ddd, J = 8.4, 6.9, 1.4 Hz, ArH), 7.57-7.53 (2H, in, ArH), 6.53 (1H, 
q, J = 1.0 Hz, CH=CCH3), 2.34 (3H, s, CH3); '3C NMR (90.6 MHz, CDC13) 6 151.2 
(C), 148.0 (C), 136.7 (CH), 130.0 (CH), 129.3 (CH), 127.4 (CH), 127.1 (CH), 127.1 
(C), 121.4 (CH), 120.8 (CH), 118.3 (C, q, JF = 320.0 Hz), 21.0 (CH3); Exact mass 
calcd for C13H11F3NO3S [M+H]: 318.0406, found: 310.0403. 
2- [(Z )-2- Cyclopropyipropenyl] quinoline (517). To a 
Me 	solution of the vinyl trifiate 515 (317 mg, 1.00 mmol) and 101- J 
517 
Fe(acac)3 (35 mg, 0.10 mrnol) in THF (20 mL) at -30 °C was 
added a solution of cyclopropylmagnesiuin bromide (0.5 M in THF, 4.0 mL, 2.0 mmol) 
rapidly in one portion and the mixture was stirred at -30 °C for 1 h. The reaction was 
quenched carefully with saturated aqueous NH4C1 solution (20 mL) and the mixture 
was diluted with Et2 0 (30 mL). The aqueous layer was separated and extracted with 
Et2 0 (2 x 30 mL) and the combined organic layers were dried (MgSO4) and concen-
trated in vacuo. Purification of the residue by column chromatography (hexane-5% 
EtOAc/hexane) gave the trisubstituted alkene 517 172 mg, 82%) as a pale brown oil. 
JR (film) 3056, 3006, 2915, 1635, 1597, 1553, 1500, 1422, 1304, 1065 cm 1; 1H NMR 
(360 MHz, CDC13) 6 8.07-8.02 (2H, in, ArH), 7.75 (1H, dd, J = 8.1, 1.3 Hz, ArH), 
7.66 (1H, ddd, J = 8.4, 6.9, 1.5 Hz, ArH), 7.49-7.44 (2H, in, ArH), 6.59 (1H, br s, 
CH=CCH3), 2.89-2.81 (1H, in, =CCH), 1.70 (3H, d, J = 1.4 Hz, CH3), 0.80-0.75 (4H, 
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in, CH2CH2 ); 13C NMR (90.6 MHz, CDC13) 5 157.6 (C), 147.9 (C), 146.0 (C), 135.5 
(CH), 129.2 (CH), 129.1 (CH), 127.3 (CH), 126.3 (C), 126.1 (CH), 125.6 (CH), 122.7 
(CH), 19.5 (CH3), 13.8 (CH), 5.9 (2 x CH2 ); Exact mass calcd for C15H16 N [M+H]: 
210.1277, found: 210.1281. 
The stereochemistry of alkene 517 was determined using an NOE experiment, which 
displayed the following diagnostic enhancement: 
CH3 517 
H  
Me 	(Z)-2-(2,4-dimethylpent-1-enyl)quinoline (521) To a 
Me solution of the vinyl trifiate 515 (1.26 g, 4.0 mmol) and Fe(acac)3 
521 	
Me 
(141 mg, 0.40 mmol) in THF (80 mL) at -30 °C was added a 
solution of isobutylmagnesium chloride (2.0 M in THF, 4.0 mL, 8.0 mmol) rapidly in 
one portion and the mixture was stirred at -30 °C for 1 h. The reaction was quenched 
carefully with saturated aqueous NH4C1 solution (60 mL) and the mixture was diluted 
with Et2 0 (120 mL). The aqueous layer was separated and extracted with Et2 0 (2 x 30 
mL) and the combined organic layers were dried (MgSO4) and concentrated in vacuo. 
Purification of the residue by column chromatography (hexane-5% EtOAc/hexane) 
gave the trisnbstituted alkene 521 567 mg, 63%) as a pale brown oil. 'II NMR (250 
MHz, CDC13) 5 7.96 (2H, dd, J = 8.3, 2.0 Hz, ArH), 7.67 (1H, dd, J = 8.0, 1.3 Hz, 
ArH), 7.59 (1H, ddd, J = 8.5, 6.9, 1.5 Hz, ArH), 7.39 (1H, ddd, J = 8.1, 6.9, 1.2 Hz, 
ArH), 7.23 (1H, d, J = 8.5 Hz, ArH), 6.48 (1H, s, ==CH), 2.51 (2H, dd, J = 7.3, 0.7 
Hz, ==CCH2 ), 1.98-1.79 (1H, in, CH(CH3)2) 1.91 (3H, d, J = 1.4 Hz, =CCH3), 0.81 
(6H, d, J = 6.7 Hz, 2 x CH3); LRMS (ESI) [M+H]: 226.2. 
COOEt 
cIIIIITIIii....j... 	BrZn..,.COOEt (dppf)PdC2, THE OT N 	 Me 	 to 50 00, 50% '~a N 	Me 
515 	 518 	 519 
(Z)-ethyl 5-methyl-6-(quinolin-2-yl) hex- 5-enoate (519) To a solution of enol 
trifiate 515 (634 mg, 2.0 mmol) and PdC12(dppf) (7 mg, 0.06 mmol) in THF (6 
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mL) was added a 0.5 M THF solution of 3-(ethoxycarbmetyl)-propylzinc bromide 
518 (8.2 mL, 4.1 mmol). After being stirred for 2 h at 50 CC, a saturated aque-
ous NaHCO3 solution was carefully added. Crude product was extracted with EtOAc 
and dried over MgSO4. Purification of the residue by column chromatography (5% 
EtOAc/hexane-15% EtOAc/hexane) gave the trisubstitnted alkene 519 283 mg, 50%) 
as a pale brown oil. 'H NMR (360 MHz, CDC13) S 7.98 (2H, dd, J 	12.6, 8.5 Hz, 
ArH), 7.68 (1H, dd, J = 8.1, 1.3 Hz, ArH), 7.59 (1H, ddd, J = 8.4, 6.9, 1.5 Hz, ArH), 
7.40 (111, ddd, J = 8.1, 6.9, 1.2 Hz, ArH), 7.24-7.17 (1H, in, ArH), 6.44 (1H, s, =CH), 
3.97 (2H, q, J = 7.1 Hz, COCH2), 2.66-2.56 (2H, in, =CCH2 ), 2.28 (2H, t, J = 7.5 
Hz, Et02CCH2 ), 1.91 (3H, d, J = 1.5 Hz, =CCH3), 1.89-1.79 (211, in, CH2CH2 CH2 ), 
1.10 (3H, t, J = 7.2 Hz, OCH2CH3); LRMS (ESI) [M+H]: 284.2. 
Preparation of Alkene 547 
OH 
Pd2(dba)3 (2.5 mol(N' 
1 	PCy3(10moI%) 
N2CI 	Cul (10 mo 1%) 
Et3N, MeCN, 100°C 




az TBSCI, imidole 	 Et 
CN 	 EtMgBr, THF, 100°C 	 DMF, 
545 
OH 	 546 	 547 
3-Pyrazin-2-ylprop-2-yn-1-ol (545). A solution of 2-
chloropyrazine (440 pL, 5.00 mmol), Pd2 (dba)3 (115 mg, 0.125 
mmol), PCy3 (140 mg, 0.50 mmol), Cul (95 mg, 0.50 minol), 
and Et3N (2.1 mL, 15 mmol) in MeCN (15 mL) was stirred at room temperature for 
15 mm. Propargyl alcohol (437 1L, 7.50 mmol) was then added and the mixture was 
heated at 100 °C for 24 h. After cooling to room temperature, the mixture was fil-
tered through a short plug of celite, eluting with EtOAc (200 mL). The filtrate was 
washed with saturated aqueous NaHCO3 solution (200 mL), and aqueous layer was 
separated and extracted with EtOAc (200 mL). The combined organic layers were 
dried (Na2SO4) and concentrated in vacno. Purification of the residue by column chro-
matography (40% EtOAc/hexane—* EtOAc) gave the alkyne 545 (147 mg, 22%) as a 
red amorphous solid. JR (CHC13) 3387 (OH), 2924, 1642, 1464, 1397, 1277, 1143, 1037, 
964, 851 cm'; 111  NMR (360 MHz, CDC13) 8 8.65 (1H, d, J = 1.5 Hz, ArH), 8.52 (1H, 
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dd, J = 2.6, 1.5 Hz, ArH), 8.48 (1H, d, J = 2.6 Hz, ArH), 4.54 (2H, s, CH20), 2.76 
(1H, br s, OH); 13C NMR (90.6 MHz, CDC13) 6 147.5 (CH), 144.2 (CH), 143.1 (CH), 
139.6 (C), 92.4 (C), 81.5 (C), 50.8 (CH2); Exact mass calcd for C7H7N2O [M+H]: 
135.0553, found: 135.0554. 
N 	 2- [(E )- 1-Pyrazin-2-ylmethylidene] butan- 1-ol (546). To 
Et 
LN OH 	a solution of CIII (19 mg, 0.10 mmol) in THF (4 mL) at room 
546 
temperature was added EtMgBr (1 M in THF, 2.5 mL, 2.5 
mmol), and the resulting dark brown solution was stirred for 10 mm. The solution 
was then added via cannula to a suspension of the propargylic alcohol 545 (134 mg, 
1.00 mmol) in THF (5 mL) in a microwave vial, using further THF (1 mL) as a rinse. 
The mixture was then heated to 100 °C for 10 min in a microwave synthesizer. Af-
ter cooling to room temperature, the reaction was quenched carefully with 2 M HC1 
(20 mL), and saturated aqueous Na2 CO3 solution (30 mL) was then added carefully. 
The mixture was extracted with EtOAc (3 x 25 mL) and the combined organic layers 
were dried (Na2SO4) and concentrated in vacno. Purification of the residue by column 
chromatography (60% EtOAc/hexane—EtOAc) gave the alkene 546 (95 mg, 71%) as 
a yellow oil. JR (film) 3848, 2968, 1651, 1517, 1463, 1404, 1128, 1086, 1018, 873 cm'; 
'H NMR (250 MHz, CDC13) 6 8.50 (111, dd, J = 2.5, 1.5 Hz, ArH), 8.44 (1H, br s, 
ArH), 8.29 (1H, d, J = 2.5 Hz, ArH), 6.55 (1H, s, CH=CCH2 ), 4.25 (2H, d, J = 1.2 
Hz, CH20), 3.58 (1H, br s, OH), 2.54 (2H, q, J = 7.5 Hz, CH2CH3), 1.08 (3H, t, J = 
7.5 Hz, CH2CH3); '3C NMR (62.9 MHz, CDC13) 6 152.6 (C), 152.4 (C), 144.9 (CH), 
143.8 (CH), 141.0 (CH), 118.3 (CH), 65.6 (CH2), 22.3 (CH2 ), 12.8 (CH3); Exact mass 
calcd for C9H13N2 0 [M+H]: 165.1022, found: 165.1023. 
The stereochemistry of alkene 546 was determined using an NOE experiment, which 
displayed the following diagnostic enhancement: 
cy_- OH 
H H H 546 
0 
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2- [(E)-2- ( tert-Butyldimethylsilyloxymethyl) but- 1-enyl] pyrazine (547). To 
a solution of the alcohol 546 (82 mg, 0.50 mmol) and imidazole (85 mg, 1.25 mmol) 
in DMF (2 mL) at room temperature was added TBSC1 (98 mg, 0.65 mmol) in one 
portion, and the mixture was stirred at room temperature for 2 h. The reaction was 
quenched with saturated aqueous NH4C1 solution (20 mL) and the mixture was ex-
tract with Et2 0 (2 x 25 mL). The combined organic layers were washed with brine (20 
mL), dried (MgSO4), and concentrated in vacuo. Purification of the residue by column 
chromatography (2.5% EtOAc/hexane-5% EtOAc/hexane) gave the silyl ether 547 
(100 mg, 72%) as a yellow oil. IR (film) 3424, 2955, 2929, 2856, 1654 (C=C), 1463, 
1258, 1115, 837, 768 cm'; 'H NMR (250 MHz, CDC13) 6 8.53 (1H, s, ArH), 8.46 (1H, 
s, ArH), 8.31 (1H, s, ArH), 6.56 (lI-I, s, CH=CCI-12), 4.26 (2H, d, J = 1.6 Hz, CH20), 
2.56 (2H, q, J = 7.5 Hz, CH2CH3), 1.11 (3H, t, J = 7.5 Hz, CH2CH3), 0.96 (9H, s, 
C(CH3)3), 0.12 (6H, s, Si(CH3)2); '3C NMR (62.9 MHz, CDC13) ö 152.8 (C), 152.0 
(C), 145.3 (CH), 143.8 (CH), 141.0 (CH), 117.9 (CH), 66.0 (CH2), 25.9 (3 x CH3), 
22.2 (Cl-I2 ), 18.4 (C), 13.0 (CH3), —5.4 (2 x CH3); Exact mass calcd for C15 H27N2 OSi 
[M+H]: 279.1887, found: 279.1887. 
PhSI(Me)2H 
[Cp*Ru(MeCN)s]PF6 




(Z)-2- (2- (dimethyl (phenyl) silyl) hex- 1-enyl) pyridine (476) The alkyne 475 
(318 mg, 2 mmol), was dissolved in DCM (0.5 M solution) and treated with di-
ethylphenylsilane (327 mg, 2.4 mmol). The flask was cooled to 0 °C, and catalyst 
(10 mg, 0.02 mmol) was added at this temperature. The flask was immediately al-
lowed to warm to ambient temperature and stirred for 30 mm. The crude reaction 
mixture was concentrated under reduced pressure. Purification of the residue by col-
umn chromatography (hexane -* 15% EtOAc/hexane) gave 476 (449 mg, 75%). 'H 
NMR (250 MHz, CDC13) f 8.15 (1H, dd, J = 4.8, 0.9 Hz, ArH), 7.48-7.31 (3H, in, 
ArH), 7.21-7.09 (3H, in, ArH), 6.97 (1H, d, J = 7.8 Hz, ArH), 7.03 (1H, s, ==CH), 
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6.84 (1H, ddd, J = 7.3, 4.8, 0.9 Hz, ArH), 2.39-2.17 (2H, in, =CCH2 ), 1.47-1.14 (4H, 
in, CH2CH2CH2CH3), 0.79 (3H, t, J = 7.2 Hz, CH3), 0.31 (6H, s, Si(CH3)2 ); 13C 
NMR (63 MHz, CDC13) 6 155.9 (C), 148.0 (C), 147.7 (CH), 141.7 (C), 140.5 (CH), 
135.6 (CH), 133.2 (CH), 127.7 (CH), 127.1 (CH), 122.9 (CH), 121.1 (CH), 39.3 (CH2), 
32.7 (CH2 ), 22.5 (CH2 ), 13.9 (CH3), 0.0 (CH3); LRMS (ESI) [M+H]: 196.2. 






M 	 NI DIBAL, toluene 	 TBSCI, imidazole 	 le 
CHO LiHMDS, THF, 0°C 	 DM F, it CO2Et CH2Cl2, -78°CtoO°C - 	- 
539 	 548 	 549 
NMe 	
Ethyl (E)-2-methyl-3-(pyridin-4-yl)propenoate (539). 
- 	CO2E 	To a solution of triethyl 2-phosphonopropionate (5.1 mL, 24 
539 
mmol) in THF (200 mL) at —78 °C was added L1HMDS (1 M 
in THF, 28.0 mL, 28.0 mmol) over 5 mm, and the resulting solution was stirred at 
the same temperature for 15 mill and then warmed to 0 °C. 4-Pyridinecarboxaldehyde 
(1.90 rnL, 20.0 mmol) was then added over 1 min and the mixture was stirred at 0 
°C for 4 h before being quenched carefully with saturated aqueous NH4C1 (100 mL). 
The mixture was extracted with Et2 0 (3 x 150 mL), and the combined organic layers 
were dried (MgSO4) and concentrated in vac'uo. Purification of the residue by column 
chromatography (10% EtOAc/hexane—*40% EtOAc/hexane) gave the alkene 539 (1.60 
g, 41%) as a pale yellow oil. JR (film) 3430, 1710 (C=O), 1641 (C=C), 1366, 1330, 
1261, 1198, 1114, 1030, 809 cm'; 'H NMR (360 MHz, CDC13) 6 8.67 (2H, br s, ArH), 
7.57 (1H, s, CH=CCH3), 7.26 (2H, br s, ArH), 4.29 (2H, q, J = 7.1 Hz, OCH2 ), 
2.10 (3H, d, J = 1.5 Hz, =CCH3), 1.36 (3H, t, J = 7.1 Hz, 0CH2CH3); '3C NMR 
(90.6 MHz, CDC13) 6 167.8 (C), 149.9 (2 x CH), 143.5 (C), 135.5 (3 x CH), 132.6 
(C) , 61.2 (CH2 ), 14.2 (CH3), 14.1 (CH3); Exact mass calcd for C,1H14 NO2 [M+H]H 
192.1019, found: 192.1020. 
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(E)-Methyl-3-(pyridin-4-yl) prop- 2-en-1-ol (548). To a solution of the ester 
539 (382 ing, 2.00 mmol) in CH2 C12 (20 mL) at —78 °C was added DIBAL (25 wt. 
% in toluene, 3.1 mL, 4.6 mmol) over 2 ruin, and the resulting mixture was stirred at 
—78 °C for 1.5 h, then at —20 °C for 1 h, and finally at —10 °C for 2 h. The reaction 
was quenched carefully with saturated aqueous Rochelle's salt solution (50 rnL) and 
the resulting mixture was stirred vigorously for 1 h. The aqueous layer was separated 
and extracted with CH2 C12 (3 x 50 mL), and the combined organic layers were dried 
(Na2SO4) and concentrated in vacuo to leave the alcohol 548 as a white solid which 
was used immediately in the next step without further purification. 
	
N 	 Me 	4- [(E )-3- ( tert-Butyldimethylsilyloxy) -2-methyipropenyl] - 
I OTBS 	pyridine (549). To a solution of the above alcohol 548 (the- 
549 
oretically 2.00 mmol) in DMF (10 mL) at room temperature 
was added imidazole (340 mg, 5.00 mmol) followed by TBSC1 (452 mg, 3.00 mmol) in 
one portion. The mixture was stirred at room temperature for 1 h and then partitioned 
between Et20 (80 mL) and saturated aqueous NH4C1 solution (100 mL). The organic 
layer was separated and washed with further saturated aqueous NH4C1 solution (2 x 
100 mL), dried (MgSO4) and concentrated in vacuo. Purification of the residue by 
column chromatography (hexane-15% EtOAc/hexane) gave the silyl ether 549 (402 
mg, 76% over two steps) as a colorless oil. JR (film) 3431, 2954, 2856, 1596 (C=C), 
1471, 1255, 1169, 1111, 838, 777 cm'; 'H NMR (250 MHz, CDC13) 5 8.53 (211, d, J 
= 5.2 Hz, ArH), 7.16 (2H, m, ArH), 6.48 (1H, br s, CH=CCH3), 4.18 (2H, d, J = 
0.8 Hz, CH2 0), 1.84 (311, d, J = 0.7 Hz, =CCH3), 0.95 (9H, s, C(CH3)3), 0.12 (6H, 
s, Si(CH3)2); '3C NMR (62.9 MHz, CDC13) 5 149.5 (2 x CH), 145.6 (C), 142.0 (C), 
123.6 (2 x CH), 120.9 (CH), 67.7 (CH2 ), 25.9 (3 x CH3), 18.4 (C), 15.1 (CH3), —5.4 (2 
x CH3); Exact mass calcd for C15H26 NOS1 [M+H]: 264.1778, found: 264.1778. 
Preparation of Alkene 525 
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CHO KOH, Bu4NPF6 EtOH, rt DMF, It 
toluene, rt 550 551 525 
Me 	(E )-2-Methyl-3-pyridin-3-ylpropenal (550). Following 
Jr) 	
CHO 	a literature procedure for a similar compound, to a vigorously 
550 
stirred suspension of Bu4 NPF6 (194 mg, 0.50 mmol) and KOH 
(42 mg, 0.75 mmol) in toluene (8 mL) was added 3-pyridinecarboxaldehyde (469 AL, 
5.00 mmol) dropwise over 1 mm, followed by propionaldehyde (437 tL, 6.00 mmol) 
dropwise over 2 mm. The reaction was stirred vigorously at room temperature for 5 
h, diluted with toluene (10 mL), and washed with H20 (2 x 5 mL). The organic layer 
was dried (MgSO4) and concentrated in vacuo. Purification of the residue by column 
chromatography (20% EtOAc/hexane-40% EtOAc/hexane) gave the enal 550 (551 
mg, 75%) as a white solid. rn.p. 36-38 °C; JR (CHC13) 3433, 2110, 1675 (C=O), 1640 
(C=C), 1430, 1361, 1260, 1200, 1013, 709 cm'; 'H NMR (250 MHz, CDC13) S 9.60 (1H, 
s, CHO), 8.75 (1H, br s, ArH), 8.58 (111, app dd, J = 4.8, 1.4 Hz, ArH), 7.87 (1H, app 
dt, J = 8.0, 1.8 Hz, ArH), 7.41-7.36 (1H, in, ArH), 7.27 (1H, br s, CH=CCH3), 2.03 
(3H, d, J = 1.4 Hz, CH3); '3C NMR (62.9 MHz, CDC13) 5 194.0 (CH), 150.1 (CH), 
149.4 (CH), 144.8 (CH), 139.3 (C), 135.8 (CH), 130.3 (C), 122.8 (CH), 10.2 (CH3); 
LRMS (ES) 148 ([M+H], 100). 
Me 	
(E)-Methyl-3-(pyridin-3-yl) prop- 2-en-1-ol (551). To 
NOH 	a solution of aldehyde 550 (545 mg, 3.70 mmol) and CeC13•7H20 
551 
(1.65 g, 4.44 mmol) in EtOH (30 mL) at room temperature was added NaBH4 (148 mg, 
3.89 mmol) portionwise over 5 mm. The resulting mixture was stirred at room tem-
perature for 18 h and quenched carefully with saturated aqueous NH4C1 solution (25 
mL). Most of the EtOH was removed in vacuo, and the aqueous residue was extracted 
with EtOAc (3 x 50 mL). The combined organic layers were dried (Na2SO4) and con-
centrated in vacuo. Purification of the residue by column chromatography (EtOAc) 
gave the alcohol 551 (410 mg, 74%) as a yellow oil. JR (film) 3398 (OH), 2857, 1645 
(C=C), 1479, 1416, 1197, 1074, 1027, 843, 713 cm'; 1H NMR (250 MHz, CDC13) S 
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8.34 (1H, br s, ArH), 8.25 (111, app d, J = 4.4 Hz, ArH), 7.49-7.44 (1H, in, ArH), 
7.13 (app dd, J = 7.8, 4.9 Hz, ArH), 6.42 (1H, s, CH=rCCH3), 5.56 (1H, s, OH), 4.10 
(2H, s, CH2 0), 1.73 (3H, br s, CH3); 13C NMR (62.9 MHz, CDC13) 6 149.1 (CH), 
146.2 (CH), 141.2 (C), 135.9 (CH), 133.6 (C), 123.0 (CH), 119.4 (CH), 67.0 (CH2 ), 
14.9 (CH3); LRMS (ES) 150 ([M+H], 100). 
(Me 
	 3- [(E)-3- ( tert-Butyldimethylsilyloxy) -2-methyipropenyl] pyrid 
N 	 'OTBS (525). To a solution of the alcohol 551 (149 mg, 1.00 mmol) 
525 
and imidazole (170 mg, 2.50 rnmol) in DMF (2 mL) at room 
temperature was added TBSC1 (196 mg, 1.30 mmol) in one portion, and the mixture 
was stirred at room temperature for 1 h. The reaction was quenched with saturated 
aqueous NH4C1 solution (20 niL) and the mixture was extracted with Et20 (2 x 25 
mL). The combined organic layers were washed with brine (20 mL). The brine layer 
was separated and extracted with Et2 0 (2 x 25 mL), and the combined organic layers 
were dried (MgSO4), and concentrated in vacuo. Purification of the residue by column 
chromatography (5% EtOAc/hexane-20% EtOAc/hexane) gave the silyl ether 525 
(247 mg, 94%) as a yellow oil. JR (film) 3432, 2954, 2856, 1642 (C=C), 1472, 1415, 
1254, 1110, 837, 776 cm'; 'H NMR (250 MHz, CDC13) 5 8.53 (1H, br s, ArH), 8.42 
(1H, br s, ArH), 7.58 (111, br d, J = 7.8 Hz, ArH), 7.27-7.24 (1H, in, ArH), 6.48 (1H, 
s, CH=CCH3), 4.17 (2H, s, CH20), 0.93 (9H, s, C(CH3)3), 0.10 (6H, s, Si(CH3)2 ); 
'3C NMR (62.9 MHz, CDC13) 6 149.9 (CH), 147.0 (CH), 139.9 (C), 135.7 (CH), 133.5 
(C), 122.9 (CH), 119.7 (CH), 67.8 (CH2), 25.8 (3 x CH3), 18.3 (C), 14.8 (CH3), —5.4 
(2 x CH3); LRMS (ES) 264 ([M+H], 100). 
Enantioselective Copper-Catalyzed Reductions: General Procedure C 
Me 
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A solution of the appropriate alkene (0.20 mmol), Cu(OAc)2.H20 (2.0 mg, 0.01 
mmol), Josiphos ligand (6.1 mg, 0.01 mmol), and t-BuOH (38 L, 0.40 mmol) in 
toluene (1 mL) was stirred at 0 °C for 15 mill. PhSiH3 (37 ML, 0.30 mmol) was then 
added dropwise. The mixture was stirred at 0 °C for 2 h, then at room temperature 
for 15 h. The reaction was quenched carefully with silica gel (ca. 250 mg), and the 
resulting suspension was stirred for 15 mill before being filtered through a short pad of 
silica gel using EtOAc (20 mL) as eluent. The filtrate was concentrated in vacuo and 
the residue was purified by column chromatography to give the reduced product. 
ao Me 	
2- [(S )-2-Methyl-4-phenybutyl] benzooxazole (522). 
The title compound was prepared according to General 
Procedure C from alkene 460 (53 mg, 0.20 nunol) and 
purified by column chromatography (hexane-3% EtOAc/hexane) to give a colorless 
oil (48 mg, 90%). [] —26.9 (c 0.52, CHC13); JR (film) 3060, 3026, 2927, 2860, 1940, 
1614, 1570, 1454, 1242, 746, 698 cm 1 ; 1H NMR (500 MHz, CDC13) 6 7.68-7.66 (1H, 
in, ArH), 7.48-7.46 (1H, in, ArH), 7.30-7.24 (4H, in, ArH), 7.18-7.16 (3H, in, ArH), 
2.97 (1H, dd, J 14.8, 6.0 Hz, N=CCH2), 2.80 (1H, dd, J = 14.8, 8.1 Hz, N=CCH2 ), 
2.73 (1H, ddd, J = 13.8, 10.5, 5.7 Hz, CH2Ph), 2.64 (1H, ddd, J = 13.8, 10.5, 6.1 
Hz, CH2 Ph), 2.25-2.16 (1H, m, CHCH3), 1.80-1.73 (1H, in, CH2 CH2 Ph), 1.65-1.57 
(1H, in, CH2CH2Ph), 1.07 (3H, d, J = 6.7 Hz, CH3); '3C NMR (62.9 MHz, CDC13) 
6 166.4 (C), 150.8 (C), 142.2 (C), 141.4 (C), 128.3 (2 x CH), 125.8 (CH), 124.4 (CH), 
124.0 (CH), 119.6 (CH), 110.3 (CH), 38.4 (CH2 ), 35.9 (CH2), 33.3 (CH2), 31.8 (CH), 
19.6 (CH3); HRMS (ES) Exact mass calcd for C18H20 N0 [M+H]h 266.1539, found: 
266.1532. Enantiomeric excess was determined by HPLC with a Chiralpak OD-H col-
umn (98:2 hexane:isopropanol, 0.8 mL/min, 225 nm, 25 °C); tr (major) = 9.8 mm; tr 
(minor) = 14.4 mm, 93% ee. 
2- [(S)-4- ( tert-Butyldimethylsilyloxy) -2-methylbutyl] benzooxazole (552). 
The title compound was prepared according to General Procedure C from alkene 462 
(63 mg, 0.20 mmol) and purified by column chromatography (hexane--->3% EtOAc/hexane) 
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to give a pale yellow oil (43 mg, 67%). [c] +2.0 (c 1.00, CHC13); JR (film) 2960, 2929, 
2856, 1614, 1572, 1456, 1244, 1099, 837, 775, 744 cm'; 'H NMR (500 MHz, CDC13 ) 
5 7.70-7.66 (1H, m, ArH), 7.51-7.47 (1H, m, ArH), 7.32-7.28 (2H, m, ArH), 3.76-3.67 
(2H, in, CH2 0), 2.98 (1H, dd, J = 14.7, 6.1 Hz, N=CCH2 ), 2.80 (111, dd, J = 14.7, 8.1 
Hz, N=CCH2 ), 2.38-2.28 (1H, m, CHCH3), 1.72-1.65 (1H, in, CH2CH2 0), 1.55-1.49 
(1H, in, CH2CH2 0), 1.04 (3H, d, J = 6.7 Hz, CHCH3), 0.89 (9H, s, SiC(CH3)3), 0.05 
(3H, s, SiGH3), 0.04 (3H, s, SiCH3); '3C NMR (62.9 MHz, CDC13) ö 166.4 (C), 150.8 
(C), 141.4 (C), 124.4 (CH), 124.0 (CH), 119.5 (CH), 110.3 (CH), 60.9 (CH2), 39.4 
(CH2), 36.0 (CH2 ), 29.1 (CH), 25.9 (3 x CH3), 19.7 (CH3), 18.3 (C), —5.4 (2 x 
HRMS (ES) Exact mass calcd for C18 H30NO2Si [M+H]: 320.2040, found: 320.2045. 
Enantiorneric excess was determined by HPLC with a Chiralpak OD-H column (99:1 
hexane:isopropanol, 0.8 mL/rnin, 225 rim, 25 °C); tr (major) = 5.3 mm; tr (minor) = 
5.7 mm; 94% ee. 
2- [(S )-4-Benzyloxy-2-methylbutyl] benzooxazole (553). 
ao 
Me 
OBn 	The title compound was prepared according to General 
Procedure C from alkene 461 (59 mg, 0.20 mmol) and purified by column chromatog-
raphy (hexane-3% EtOAc/hexane) to give a pale yellow oil (52 mg, 88%). [a] 24  +3.8 
(c 1.04, CHC13); JR (film) 3060, 3030, 2958, 2927, 2858, 1614, 1570, 1454, 1365, 1242, 
1101, 937, 839, 746, 694 cm'; 'H NMR (500 MHz, CDC13) 6 7.69-7.68 (1H, m, ArH), 
7.50-7.48 (1H, in, ArH), 7.35-7.28 (7H, m, ArH), 4.50 (2H, s, CH2Ph), 3.61-3.54 (2H, 
in, CH2CH20), 2.99 (1H, dd, J = 14.7, 5.9 Hz, N=CCH2), 2.81 (JH, dd, J = 14.8, 8.1 
Hz, N=CCH2 ), 2.43-2.33 (1H, m, CHCH3), 1.84-1.78 (in, m, CH2CH2 0), 1.66-1.59 
(1H, m, CH2CH2 0), 1.04 (3H, d, J = 6.7 Hz, CH3); '3C NMR (62.9 MHz, CDC13) 
(2 quaternary carbon signals unresolved) 141.4 (C), 138.4 (C), 128.3 (2 x CH), 127.6 (2 
x CH), 127.5 (CH), 124.4 (CH), 124.0 (CH), 119.5 (CH), 110.3 (CH), 72.9 (CH2), 68.1 
(CH2 ), 36.3 (CH2), 35.9 (CH2 ), 29.3 (CH), 19.7 (CH3); HRMS (ES) Exact mass calcd 
for C19H22 NO2 [M-+-H]: 296.1645, found: 296.1653. Enantiomeric excess was deter-
mined by HPLC with a Chiralpak OD-H column (98:2 hexane:isopropanol, 0.8 mL/min, 
225 urn, 25 °C); tr (major) = 12.0 mm; tr (minor) = 19.6 mm; 95% ee. 
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ao"Ph 2- [(R)-2-Phenylpropyl]benzooxazole (554). The title compound was prepared according to a modification 
554 
of General Procedure C from alkene 454 (36.5 mg, 0.155 mmol), Cu(OAc)2.2H20 (1.4 
mg, 0.008 mmol), josiphos ligand L5 (4.9 mg, 0.008 mmol), t-BuOH (29 ,uL, 0.31 
mmol), and PhSiH3 (29 ,uL, 0.23 mmol) in toluene (0.5 mL) and purified by column 
chromatography (hexane-3% EtOAc/hexane) to give a pale pink oil (35 ing, 95%). 
[c] 24 -45.2 (c. 0.57, CHC13); JR (film) 3060, 3028, 2964, 2927, 1614, 1570, 1495, 1454, 
1242, 1146, 762, 746, 700 cm'; 'H NMR (500 MHz, CDC13) 6 7.70-7.66 (1H, in, ArH), 
7.50-7.47 (1H, in, ArH), 7.34-7.29 (6H, m, ArH), 7.24-7.21 (1H, in, ArH), 3.55-3.48 
(in, in, CHCH3), 3.26 (1H, dd, J = 14.9, 6.2 Hz, N=CCH2 ), 3.16 (1H, dd, J = 14.9, 
9.0 Hz, N=CCH2), 1.39 (3H, d, J 7.0 Hz, CH3); '3C NMR (62.9 MHz, CDC13) c 
165.8 (C), 150.8 (C), 145.4 (C), 141.3 (C), 128.6 (2 x CH), 126.7 (2 x CH), 126.6 (CH), 
124.5 (CH), 124.1 (CH), 119.6 (CH), 110.3 (CH), 38.2 (CH), 37.3 (CH2), 21.5 (CH3); 
HRMS (ES) Exact mass calcd for C161-116 N0 [M+H]: 238.1226, found: 238.1226. 
Enantiomeric excess was determined by HPLC with a Chiralpak OD-H column (99:1 
hexane:isopropanol, 0.8 mL/rnin, 210 nm, 25 °C); tr (major) = 10.1 nun; tr (minor) = 
11.8 mm; 87% ee. 
Me 	 2- [( S)-2-Methyl-4-phenylbutyl] -5-phenyloxazole (555). 
Ph 	0 	555 	
Ph 	The title compound was prepared according to General 
Procedure C from alkene 428 (58 mg, 0.20 mmol) and purified by column chromatog-
raphy (hexane—*3% EtOAc/hexane) to give a colorless oil (54 mg, 93%) that solidified 
on standing. m.p. 50-52 °C; [c] —21.0 (c 0.66, CHC13); JR (CHC13) 3060, 3026, 
2925, 2848, 1554, 1493, 1454, 1122, 1026, 941, 825, 760, 649 cur'; 'H NMR (500 
MHz, CDC13) 6 7.63-7.61 (2H, in, ArH), 7.44-7.40 (2H, in, ArH), 7.34-7.27 (3H, in, 
ArH), 7.25 (JH, br s, ArH), 7.20-7.17 (3H, in, ArH), 2.89 (1H, dd, J = 14.8, 6.1 Hz, 
N=CCH2), 2.77-2.71 (2H, in, N=CCH2 and CH2Ph), 2.66 (iH, ddd, J = 13.7, 10.2, 
6.2 Hz, CH2Ph), 2.19-2.09 (1H, in, CHCH3), 1.80-1.73 (1H, in, CH2CH2 Ph), 1.64-1.57 
(1H, in, CH2CH2 Ph), 1.08 (3H, d, J = 6.7 Hz, CH3); '3C NMR (62.9 MHz, CDC13) 
6 163.7 (C), 150.9 (C), 142.3 (C), 128.8 (2 x CH), 128.3 (4 x CH and C), 128.1 (CH), 
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125.7 (CH), 124.0 (2 x CH), 121.8 (CH), 38.3 (CH2 ), 35.4 (CH2 ), 33.3 (CH2), 31.9 
(CH), 19.6 (CH3); HRMS (ES) Exact mass calcd for C20H22 N0 [M+H]: 292.1696, 
found: 292.1699. Enantiomeric excess was determined by HPLC with a Chiralpak AD-
H column (98:2 hexane:isopropanol, 0.8 mL/min, 225 nm, 25 °C); tr (minor) = 16.6 
mm, tr (major) = 17.6 mm; 90% ee. 
as
Me 	
2- [(S )-2-Methyl-4-phenybutyl] benzothiazole (556). 
Ph 	The title compound was prepared according to General 
Procedure C from alkene 463 (56 mg, 0.20 mmol) and purified by column chromatog-
raphy (hexane—*3% EtOAc/hexane) to give a colorless amorphous solid (48 mg, 86%). 
[o]
14 
D —32.7 (c 0.61, CHC13); JR (CHC13)  3060, 3026, 2956, 2925, 1518, 1454, 1435, 1311, 
1124, 912, 760, 729, 698 cm-'; 'H NMR (500 MHz, CDC13) 6 7.99 (1H, d, J = 8.1 Hz, 
ArH), 8.00 (1H, din, J = 8.0 Hz, ArH), 7.48-7.45 (1H, in, ArH), 7.38-7.35 (1H, m, 
ArH), 7.30-7.27 (2H, in, ArH), 7.20-7.18 (3H, in, ArH), 3.18 (1H, dd, J = 14.4, 6.2 
Hz, N==CCH2 ), 2.99 (1H, dd, J = 14.4, 8.1 Hz, N=CCH2 ), 2.77 (1H, ddd, J = 13.7, 
10.6, 5.5 Hz, CH2 Ph), 2.66 (111, ddd, J 	13.7, 10.5, 6.0 Hz, CH2 Ph), 2.21-2.12 (1H, 
in, CHCI-13), 1.85-1.78 (1H, in, CH2CH2 Ph), 1.66-1.59 (1H, in, CH2CH2 Ph), 1.10 (3H, 
d, J = 6.6 Hz, CH3); '3C NMR (62.9 MHz, CDC13) 6 170.9 (C), 153.2 (C), 142.2 (C), 
135.2 (C), 128.3 (4 x CH), 125.8 (CH), 125.7 (CH), 124.6 (CH), 122.5 (CH), 121.4 
(CH), 41.5 (CH2 ), 38.4 (CH2 ), 34.0 (CH), 33.3 (CH2),  19.5 (CH3); HRMS (ES) Exact 
mass calcd for C18 H20NS [M+H]: 282.1311, found: 282.1310. Enantiomeric excess 
was determined by HPLC with a Chiralpak OD-H column (98:2 hexane:isopropanol, 
0.8 mL/min, 225 nm, 25 °C); tr (major) = 12.9 mm; tr (minor) = 19.7 mm; 95% ee. 
2- [(R)-3- (tert-Butyldimethylsilyloxy)-2-methylpropyl] pyz 
557 
	 (557). The title compound was prepared according to 
General Procedure C from alkene 493 (53 mg, 0.20 mmol) and purified by column chro-
24 matography (hexane-->2% EtOAc/hexane) to give a colorless oil (48 mg, 90%). [c] 
—8.0 (c 0.75, CHC13); JR (film) 2954, 2894, 2856, 1560, 1569, 1472, 1433, 1257, 1089, 
1006 cm4 ; 'H NMR (500 MHz, CDC13) 6 8.53 (111, app d, J = 2.8 Hz, ArH), 7.58 (1H, 
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app d, J = 7.4 Hz, ArH), 7.14 (1H, d, J = 7.1 Hz, ArH), 7.10 (1H, app t, J = 5.6 Hz, 
ArH), 3.51-3.45 (2H, in, CH2 0), 2.94 (1H, dd, J = 13.1, 5.9 Hz, N=CCH2 ), 2.54 (1H, 
dd, J = 13.1, 8.5 Hz, N=CCH2), 2.16-2.09 (111, in, CHCH3), 0.90 (12H, br s, CHCH3  
and SIC(CH3)3), 0.03 (6H, s, Si(CH3)2); '3C NMR (62.9 MHz, CDC13) à 161.3 (C), 
149.1 (CH), 136.0 (CH), 123.5 (CH), 120.8 (CH), 67.6 (CH2), 42.0 (CH2), 36.7 (CH), 
25.9 (3 x CH3), 18.3 (C), 16.5 (CH3), —5.4 (2 x CH3); HRMS (ES) Exact mass calcd for 
C15 H28NOS1 [M+H]: 266.1935, found: 266.1933. Enantiomeric excess was determined 
by HPLC with a Chiralpak OD-H column (99.5:0.5 hexane:isopropanol, 0.8 mL/min, 
210 nm, 25 °C); tr (major) = 12.2 mm, tr (minor) ca 15 mm (not detected); >99% ee. 
A similar experiment conducted using alkene 493 (264 mg, 1.00 mmol), Cu(OAc)2.H20 
(3.9 mg, 0.02 mmol), josiphos ligand L5 (12.3 mg, 0.02 mmol), t-BuOH (190 pL, 2.00 
mmol), and PhSiII3 (185 pL, 1.50 mmol) in toluene (5 mL) gave pyridine 557 (244 mg, 
92%) in 96% ee after a total reaction time of 17 h. Enantiomeric excess was determined 
by HPLC with a Chiralpak OD-II column (99.5:0.5 hexane:isopropanol, 0.8 mL/min, 
210 nm, 25 °C); tr (major) = 12.7 min,tr (minor) = 15.1 mill; 96% ee. 
ni 	Me 	
(R)-2-Methyl-3-pyridin-2-ylpropyl benzoate (558). 
N 	
558 
OBz 	 The title compound was prepared according to a modifi- 
cation of General Procedure C from alkene 540 (25 mg, 0.10 mmol), Cu(OAc)2.2II20 
(1.0 mg, 0.005 mmol), josiphos ligand L5 (3.2 mg, 0.005 mmol), t-BuOH (19 pL, 0.20 
mmol), and PhSiH3 (25 pL, 0.20 mmol) in toluene (0.5 mL) for 72 h and purified by 
column chromatography (5% EtOAc/hexane-20% EtOAc/hexane) to give a yellow 
oil (21 mg, 81%). [o] 24  —8.8 (c 0.45, CHC13); JR (film) 2924, 2852, 1718 (C=O), 1589, 
1452, 1273, 1111, 1026, 756, 712 cm'; 'H NMR (360 MHz, CDC13) 6 8.57 (1H, br s, 
ArH), 8.05-8.01 (2H, in, ArH), 7.61-7.54 (2II, in, ArH), 7.46-7.42 (2H, in, ArH), 7.18-
7.11 (2II, in, ArH), 4.27 (1H, dd, J = 10.9, 5.8 Hz, CH20), 4.22 (1H, dd, J = 10.9, 
6.0 Hz, CH2 0), 3.00 (1H, dd, J = 13.5, 6.6 Hz, N=CCH2), 2.76 (1H, dd, J = 13.5, 
7.8 Hz, N=CCH2), 2.63-2.50 (1H, in, CHCH3), 1.07 (3H, d, J = 6.8 Hz, CH3); 13C 
NMR (90.6 MHz, CDC13) 6 166.6 (C), 160.2 (C), 149.3 (CH), 136.2 (CH), 132.8 (CH), 
130.3 (C), 129.5 (2 x CH), 128.3 (2 x CH), 123.6 (CH), 121.2 (CH), 69.2 (CH2), 42.4 
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(CH2 ), 33.5 (C H), 16.9 (CH3); HRMS (ES) Exact mass calcd for C,6 H,8NO2 [M+H]: 
256.1332, found: 256.1334. Enantiomeric excess was determined by HPLC with a Chi-
ralpak AD-H column (98:2 hexane:isopropanol, 0.8 mL/min, 225 nm, 25 °C); tr (minor) 
= 20.6 mm, tr (major) = 22.9 mm; 98% ee. 
Ph 	 (R )-2-Benzyl-3-pyridin-2-ylpropyl pivaloate (559). 
N 	
OPiv 	The title compound was prepared according to General 
559C  
Procedure C from alkene 543 (62 mg, 0.20 minol) but using half the volume of toluene 
(0.5 mL) as solvent. Purification by column chromatography (10% EtOAc/hexane-20% 
EtOAc/hexane) gave a dark brown oil (56 mg, 90%). [c] —2.0 (c 1.00, CHC13); IR 
(film) 3420, 2931, 2360, 1726 (C=O), 1653, 1570, 1476, 1283, 1158, 700 cm'; 'H NMR 
(360 MHz, CDC13) 6 8.56-8.55 (111, in, ArH), 7.59 (1H, dt, 7.6, 1.6 Hz, ArH), 7.29-
7.27 (21-I, in, ArH), 7.20-7.10 (511, in, ArH), 3.91 (211, app d, J = 4.6 Hz, CH20), 
2.86 (211, app d, J = 7.1 Hz, CH2Ar), 2.74-2.72 (211, m, CH2Ar), 2.68-2.60 (111, in, 
CHCH2 Ph), 1.24 (911, s, C(CH3 )3); '3C NMR (90.6 MHz, CDC13) 5 178.4 (C), 160.0 
(C), 149.4 (CH), 139.6 (C), 136.3 (CH), 129.1 (2 x CH), 128.4 (2 x CH), 126.1 (CH), 
123.7 (CH), 121.3 (CH), 65.2 (CH2 ), 40.1 (CH), 40.0 (CH2), 38.9 (C), 37.5 (CH2), 27.3 
(3 x CH3); HRMS (ES) Exact mass calcd for C20 H26 NO2 [M+H]h 312.1958, found: 
312.1954. Enantiomeric excess was determined by HPLC with a Chiralpak AD-H col-
umn (98.2 hexane:isopropanol, 0.8 mL/min, 225 nm, 25 °C); tr (minor) = 17.9 min,tr 
(major) = 19.0 mill; 97% ee. 
2- [(S)-2-Cyclopropylpropyl] quinoline (560). The 
IJ Me 	
title compound was prepared according to General Pro- n-N 560 
cedure C from alkene 517 (42 mg, 0.20 mmol) and purified by column chromatography 
(hexane-->3% EtOAc/hexane) to give a brown oil (38 mg, 90%). [] +22.0 (c 1.00, 
CHC13); JR (film) 3073, 2955, 2925, 2870, 1619, 1599, 1563, 1504, 1455, 1426, 1116, 
1016 cm'; 111  NMR (360 MHz, CDC13) S 8.07-8.03 (2H, in, ArH), 7.78 (1H, dd, J 
= 8.1, 1.3 Hz, ArH), 7.68 (111, ddd, J = 8.5, 6.9, 1.3 Hz, ArH), 7.48 (1H, ddd, J 
= 8.1, 6.9, 1.3 Hz, ArH), 7.29 (1H, d, J = 8.5 Hz, ArH), 3.13 (1H, dd, J = 13.0, 
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6.6 Hz, N=CCH2), 2.94 (1H, dd, J = 13.0, 8.0 Hz, N=CCH2 ), 1.42-1.30 (1H, in, 
CHCH3), 1.02 (3H, d, J = 6.7 Hz, CH3), 0.72-0.62 (1H, in, CH(CH2 CH2)), 0.72-0.28 
(211, in, CH(CH2CH2)), 0.11-0.04 (1H, in, CH(CH2CH2 )), —0.02 to —0.09 (1H, in, 
CH(CH2CH2)); '3C NMR (90.6 MHz, CDC13), 6 162.1 (C), 147.8 (C), 135.7 (CH), 
129.2 (CH), 128.8 (CH), 127.4 (CH), 126.6 (C), 125.6 (CH), 122.3 (CH), 46.8 (CH2 ), 
39.8 (CH), 19.7 (CH3), 18.0 (CH), 4.5 (CH2), 3.3 (CH2 ); HRMS (ES) Exact mass calcd 
for C15 H18N [M+H]: 212.1434, found: 212.1436. Enantiomeric excess was determined 
by HPLC with a Chiralpak AD-H column (98.2 hexane:isopropanol, 0.8 mL/min, 254 
nm, 25 °C); tr (minor) 	7.2 mm, tr (major) = 7.9 mill; 96% ee. 
N 	 2- [(R )-2- ( tert-Butyldimethylsilyloxymethyl) butyl] - 
IL CN OTBS 	pyrazine (561). The title compound was prepared ac561 - 
cording to General Procedure C from alkene 547 (56 mg, 0.20 mmol) and purified 
by column chromatography (5% EtOAc/hexane) to give a yellow oil (50 mg, 89%). 
[c]' —18.0 (c 0.78, CHC13); IR (film) 3436, 2928, 2857, 2098, 1643, 1402, 1258, 1084, 
835, 749 cm-'; 'H NMR (360 MHz, CDC13) 6 8.58 (3H, br s, ArH), 3.54-3.46 (2H, 
in, CH20), 2.92 (1H, dd, J = 13.7, 7.5 Hz, ArCH2 ), 2.76 (111, dd, J = 13.7, 6.7 
Hz, ArCH2 ), 2.05-1.91 (111, in, CHCH2 0), 1.51-1.29 (2H, in, CH2CH3), 0.92 (3H, t, 
J = 7.4 Hz, CH2 CH3), 0.90 (911, s, C(CH3)3), 0.02 (311, S1CH3), 0.01 (3H, SiCH3); 
'3C NMR (125.1 MHz, CD30D, 348 K) 6 160.1 (C), 147.1 (CH), 146.4 (CH), 143.8 
(CH), 66.5 (CH2 ), 45.0 (CH), 38.9 (CH2), 27.3 (3 x CH3), 25.7 (CH2 ), 20.0 (C), 12.5 
(CH3), —4.5 (2 x CH)3; Exact mass calcd for C15H29 N20Si [M+H]: 281.2044, found: 
281.2042. Enantiomeric excess was determined by HPLC with a Chiralpak OD-H col-
umn (99.5:0.5) hexane:isopropanol, 0.8 mL/min, 254 nm, 25 °C); tr (minor) = 10.3 
min,tr (major) = 11.0 mm; 96% ee. 
_!_ 	
Ph 	
4-benzyl- 2-met hyl-3- (pyri din- 2-yl) tet rahydrofuran- 2- 
ol (529) The title compound was prepared according to Gen- 
HO Me 
	 eral Procedure C and purified by column chromatography (hexane-10°/ 
529 
EtOAc/hexane) to give a pale yellow oil (26 mg, 50%) 'H NMR (800 MHz, CDC13) 6 
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8.56-8.54 (1H, in, ArH), 7.60 (1H, td, J = 7.7, 1.7 Hz, ArH), 7.22-7.17 (3H, in, ArH), 
7.16-7.12 (1H, in, ArH), 7.08-7.02 (3H, in, ArH), 4.25 (1H, t, J = 8.5 Hz, CHCH20), 
3.76 (111, dd, J = 8.5, 7.2 Hz, CHCH2 0), 3.21-3.15 (1H, in, PhCH2 CH), 2.94 (1H, 
d, J = 10.2), 2.78 (1H, dd, J = 13.8, 6.0 Hz, PhCH2), 2.73 (1H, dd, J = 14.0, 9.2 
Hz, PhCH2), 1.45 (3H, s, CH3 ); 13C NMR (201 MHz, CDC13) 5 161.20 (C), 151.33 
(CH), 142.17 (C), 139.70 (CH), 131.23 (CH), 131.00 (CH), 128.85 (CH) , 127.89 (CH) 
124.82 (CH) , 107.73 (C), 73.85 (CH2), 62.52 (CH), 49.64 (CH), 41.99 (CH2 ), 28.80 
(CH3); LRMS (ESI) [M-H2 0]: 252.1, [M+Najh 292.1. 
4- [(R)-3- ( tert-Butyldimethylsilyloxy) -2-methyipropyl] pyridine (4). The 
title compound was prepared according to General Procedure C from alkene 3 (53 mg, 
0.20 minol) for a reaction time of 4 days and purified by column chromatography 
(hexane—*15% EtOAc/hexane) to give a yellow oil (32 mg, 60%). [c] +2.6 (c 0.75, 
CHC13); JR (film) 3417, 2955, 2857, 1603, 1471, 1255, 1097, 1027, 837, 776 cm; 1H 
NMR (360 MHz, CDC13) 5 8.49 (2H, d, J = 5.7 Hz, ArH), 7.10 (2H, d, J = 5.7 Hz, 
ArH), 3.46 (1H, dd, J = 9.9, 5.4 Hz, CH20), 3.40 (1H, dd, J = 9.9, 6.2 Hz, C1420), 
2.83 (1H, dd, J = 13.3, 5.9 Hz, ArCH2), 2.33 (1H, dd, J = 13.3, 8.4 Hz, ArCH2 ), 
1.99-1.86 (1H, in, CHCH3), 0.92 (9H, s, Si(CH3 )3), 0.86 (3H, d, J = 6.7 Hz, CHCH3), 
0.05 (6H, s, 2 x S1CH3); '3C NMR (90.6 MHz, CDC13) 5 150.3 (C), 149.5 (2 x CH), 
124.7 (2 x CH), 67.1 (CH2), 38.9 (CH2), 37.2 (CH), 25.9 (3 x CH3), 18.3 (C), 16.3 
(CH3), -5.4 (2 x CH3); Exact mass calcd for C15H28NOS1 [M+H]: 266.1935, found: 
266.1931. Enantiorneric excess was determined by HPLC with a Chiralpak OD-H col-
umn (99.3:0.5:0.2 hexane:isopropanol:diethylamine, 0.8 rnL/min, 254 rim, 25 °C); tr 
(minor) = 29.1 Min,tr  (major) = 30.0 mill; 94% ee. 
Determination of Absolute Configurations 
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Q_//I N Me 
OL.._L. OH 
526 
TsCI, Et3N, DMAP 
CH2Cl2, rt 
Recrystallization 
from CH2Cl2/Et20 \ / N 	Me 
527 
Me 	 H2, Pd/C (Cat.) 
O1..OBn EtOH, rt 
461 
A suspension of the benzoxazole 553 (131 mg, 0.44 mmol) and 10% Pd/C (26 mg) 
in EtOH (1 mL) was stirred at room temperature under an atmosphere of H2 (1 atm) 
for 30 mm. The mixture was then filtered through a short plug of celite, eluting with 
EtOAc (20 mL), and the filtrate was concentrated in vacuo to leave the alcohol 526 
which used directly in the next step without purification. To a solution of the alcohol 
526, Et3N (139 iiL, 1.00 mmol), and DMAP (6 mg, 0.05 mrnol) in CH202 (3 inL) was 
added a solution of TsCl (143 mg) in CH202 (2 mL) via cannula and the resulting 
mixture was stirred at room temperature for 18 h. The reaction was quenched with sat-
urated aqueous NH4C1 solution (10 mL) and rextracted with CH202 (3 x 15 rnL). The 
combined organic layers were dried (MgSO4) and concentrated in vacuo. Purification 
of the residue by column chromatography (5% EtOAc/hexane-20% EtOAc/hexane) 
gave the sulfonate ester 527 (80 mg, 51%) as a light brown solid. 'H NMR (360 MHz, 
CDC13) 6 7.78 (2H, dm, J = 8.3 Hz, ArH), 7.69-7.63 (1H, in, ArH), 7.52-7.47 (111, in, 
ArH), 7.34-7.30 (4H, in, ArH), 4.19-4.08 (2H, CH20), 2.88 (iF, dd, J = 14.9, 6.3 Hz, 
N=CCH2), 2.78 (1H, dd, J = 14.9, 7.6 Hz, N=CCH2 ), 2.43 (3H, s, ArCH3), 2.35-2.26 
(1H, in, CHCH3), 1.89-1.80 (1H, in, CH2 CH20), 1.68-1.58 (1H, in, CH2CH2 0), 0.99 
(3H, d, J = 6.7 Hz, CHCH3). 
This material was not stable, and was found to cyclize to the corresponding tosy-
late salt during recrystallization, which was conducted by gently layering Et20 on top 
of a solution of 527 in CH2 Cl2 . The resulting crystals 528 were suitable for X-ray crys-
tallography, which allowed determination of the absolute configuration of benzoxazole 
553: 
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Scheme 3.1: X-ray crystalography structure 
The stereochemical outcome of the conjugate reduction to produce 553 is consis-
tent with other reports of copper-catalyzed enantioselective conjugate reductions using 
josiphos ligands.9 The absolute configurations of the remaining conjugate reduction 
products were assigned tentatively by analogy. 
. (a) Lipshutz, B. H.; Servesko, J. M. Angew. Chem., mt. Ed. 2003, 42, 4789-4792. (b) 
Lipshutz, B. H.;Servesko, J. M.; Taft, B. R. J. Am. Chem. Soc. 2004, 126, 8352-8353. (c) Lipshutz, 
B. H.;Tanaka, N.; Taft, B. R.; Lee, C.-T. Org. Lett. 2006, 8, 1963-1966. (d) Czekelius, C.; Carreira, 
E. M. Angew. Chem. mt. Ed. 2003, .2, 4793-4795. (e) Czekelius, C.; Carreira, E. M.; Org. Lett. 
2004, 6, 4575-4577. (f) Lee, D.; Kim, D.; Yun, J. Angew. Chem. mt. Ed. 2006, 45, 2785-2787. (g) 
Yoo, K.; Kim, H.; Yun, J. J. Org. Chem. 2009, 7, 4232-4235. 
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Application of a sequential nickel-catalyzed reductive aldol cyclization-lactonization reaction in a short 
formal synthesis of salinsporamide A, a potent 20S proteasome inhibitor and anti-cancer compound, is 
described. 
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1. Introduction 
Advances in transition-metal-catalyzed cyclization reactions 
provide the means to access increasingly diverse carbocyclic and 
heterocyclic compounds from relatively simple starting materials, 
with often impressive levels of diastereo- and enantiose-
lectivity.1' 23 Reductive cyclizations, where reaction is promoted by 
stoichiometric reductants such as molecular hydrogen, silanes, 
formic acid, stannanes, borohydrides or main-group organometal-
lic reagents, represent an important class of these trans-
formations.23 Many of these reactions have been developed to 
a level of utility that enable their application in natural product 
synthesis.4 
Our research in this area has led to the development of a series 
of metal-catalyzed reductive aldol cyclization reactions that form 
-hydroxylactones and 13-hydroxylactams in highly diaster-
eoselective fashion.5 A notable result is the cyclization of I using 
Ni(acac)2 as the precatalyst and Et2Zn as the stoichiometric re-
ductant, which provided 13-hydroxy-y-lactam 2 as a single dia-
stereomer (Eq. 1)5d6  This outcome was of interest because 
examination of the structure of 2 revealed similarities with the core 
of salinosporamide A (3) (Fig. 1), a secondary metabolite isolated by 
Fenical and co-workers from marine actinomycete bacteria of Sal-
inospora strain CNB-392.7 This compound has attracted significant 
attention because of its impressive biological activity.7 Not only is 3 
a highly potent inhibitor of the 20S proteasome, an abundant 
complex within cells that plays an important role in the degrada-
tion and removal of misfolded proteins,8 it also exhibits promising 
potential as an anti-cancer therapeutic agent. Indeed, 3 is currently 
in clinical trials for this purpose.9 
* corresponding author. Tel.: +44 131 650 4831 fax: +44 131 650 6453. 
E-mail address: h.lam©ed.ac.uk (1-lw. Lam). 
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Figure 1. 
Structurally, salinosporamide A (3) shares its fused y-lactam-
3-lactone bicyclic core with omuralide (4), a product derived 
from the terrestrial microbial metabolite lactacystin (5)1011  Al-
though omuralide (4) is also an effective 20S proteasome in-
hibitor, differences between 3 and 4 at C2, C3 and C5 render 3 
approximately 35 times more potent than 4•7  Salinosporamide A 
(3) has also elicited significant interest from a synthetic per-
spective, with a number of total and partial syntheses having 
been reported. 02 
Given the huge interest in salinosporamide A (3), and the 
resemblance of 13-hydroxy-y-lactam 2 to the core of 3, we be-
came interested in the possibility of applying our nickel-cata-
lyzed reductive aldol methodologySd  in a synthetic route towards 
this natural product. Strategically, construction of the y-lactam of 
3 by formation of the C2—C3 bond has already been accom-
plished by Corey and co-workers (Scheme I )12a.b  In their original 
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total synthesis of salinosporamide A (3), acrylamide 6 was 
cyclized in a Baylis-Hillman reaction 13 (method A) to provide y-
lactam 7 as a 9:1 mixture of diastereomers after I week. 12a The 
same group subsequently developed improved conditions for this 
cyclization, involving the Kulinkovich reagent 14 formed from 
Ti(Oi-Pr)4 and cyclopentylmagnesium chloride (method B).12b A 
sequence of several steps including a tin hydride-mediated rad-
ical cyclization was then required to transform the exomethylene 
group of 7 into the chloroethyl functionality of salinosporamide 
A (3)•12a 
0 0 
.)' N PMB 	 PMB 





II COMe 	Method B 99:1 dr, 83/o 
0 	 HO CO2Me 
6 7 
Method A: quinuclidine, DME, 0 C, 7 d. 
Method B: (i) Ti(O/-Pr)4, c-05H9MgCI, t-BuOMe, -40 C, 30 mm, 
then I> -40 C, 2 h, then 0 C, 2 h. 
(ii) Et3N, CH2Cl2, rt, 30 mm. 
Scheme 1. Construction of y-lactam 7 by Corey and co-workers.l2th 
Since the ethyl ester-containing side-chain in 2 can be converted 
into the chloroethyl group of salinosporamide A (3) without further 
carbon-carbon bond formation, we envisaged that a suitably more 
functionalized variant of Eq. 1 might prove advantageous in a syn-
thetic route towards 3. Accordingly, aM-unsaturated amide 8 be-
came a target for our investigations (Scheme 2). 
O 	 0 
EtO2CAN PMB 	 PMB 













salinosporamide A (3) 
Scheme 2. Reductive aldol cyclization strategy towards 3. 
Compared with 1, substrate 8 possesses a more densely func-
tionalized, more sterically congested structure containing several 
Lewis basic groups that could potentially bind the catalyst and 
organometallic reductant and divert the course of the proposed 
cyclization towards deleterious side reactions. Furthermore, we 
would be reliant upon the single stereocenter present in 8 to 
control the absolute configurations of the two new stereocenters 
formed in the cyclization to provide 9 preferentially, and pre-
diction of the sense of diastereoselectivity (if any) was by no 
means straightforward. Therefore, substrate 8 would provide 
a challenging test for our methodology. In this article, we describe 
the successful utilization of 8 in a formal synthesis of salinospor-
amide A (3). 
2. Results and discussion 
Cyclization precursor 8 was prepared in straightforward fash-
ion as illustrated in Scheme 3. Swern oxidation15 of the pre-
viously described amino alcohol 1012, provided aminoketone 11, 
which was then acylated with the acid chloride 12 derived from 
mono-ethyl fumarat&6 to afford aM-unsaturated amide 8 in high 
yield. 
N H PM B 





10 	 Et02C r OH 
(COd6 DMSO, Et3N 	 (COd)2, DMF 
CH2Cl2, -78 C to -40 C CH202, 0 C to rt 
72% 
NHPMB 	 0 
Me(çOBfl + 	E102C °oCl 
C:02Me 	 12 
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0 C tort 
>99% (based on 11) 





Scheme 3. Preparation of substrate 8 for reductive aldol cyclization. 
With 8 in hand, the crucial reductive aldol cyclization was 
attempted (Table 1). Unfortunately, exposure of 8 to Ni(acac)2 and 
Et2Zn (as in Eq. 1 )5d provided only an intractable mixture of products 
(entry 1). The situation was not improved upon replacing Et2Zn with 
Et3Al5c (entry 2), or by replacing Ni(acac)2 with Co(acac)2 .2H205c 
(entries 3 and 4). The effect of phosphine ligands on the reaction was 
then examined. Although the combination of CoCl2 and DPPF offered 
no improvement (entry 5), it was found that commercially available 
nickel-phosphine complexes were effective precatalysts. Using 
(Ph3P)2NiBr2 (entry 6), none of the initially desired product 9 was 
isolated. Instead, fused y-lactone-y-lactam 15 containing the 
Table I 
Reductive aldol cyclization of S 
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5 C0C12/DPPF Et2Zn Intractable mixture 
6 (Ph3P)2NiBr2 Et2Zn 35% of 15, 30% of 16 
(Me3P)2NiCl2 Et2Zn 42% of 15, 30% of 16 
Isolated yield. 




N 	 periodinane 
CH2Cl2, rt Me CO2Me 
18 
I—ZnCI 
I THF -78 °C 
19 	

















salinosporamide A (3) 
7898 
	
1. Villanueva Margalef et at / Tetrahedron 64 (2008) 7896-7901 
desired stereochemistry was isolated in 35% yield, along with 
a comparable amount of the alternative diastereomer 16, the ste-
reochemistry of which was established by X-ray crystallography. 17 
Marginally superior results were obtained using (Me3P)2NiCl2 at an 
initial temperature of -15 °C (entry 7). Attempts to increase the 
diastereoselectivity of the reaction in favor of 15 by further modifi-
cation of the conditions have so far been unsuccessful. 
The lactones 15 and 16 are produced presumably as a result of 
the zinc alkoxides 13 and 14, formed upon reductive aldol reaction, 
cyclizing onto the pendant ethyl esters. Although lactonization was 
unexpected in light of the reaction shown in Eq. 1, it turned out to 
be a useful bonus, since it conveniently protected the tertiary 
alcohol towards subsequent transformation s.18  
The desired diastereomer 15 was subjected to palladium-cata-
lyzed debenzylation to provide alcohol 17 (84% yield) (Scheme 4). 
X-ray crystallography of this compound allowed confirmation of its 
stereochemistry, and hence that of its immediate precursor 15.17 
Oxidation of 17 to aldehyde 18 in readiness for installation of the 
cyclohexenyl group was accomplished using the Dess-Martin 
periodinane.19 Aldehyde 18 proved to be somewhat unstable, and 
was immediately reacted with 2-cyclohexenylzinc chloride (19) as 
described by Corey and co-workers 12a  to give homoallylic alcohol 
20 in highly selective fashion (one observable diastereomer by 1H 
NMR analysis). X-ray crystallography of 20 showed that the desired 
stereochemistry had been obtained in the allylation.17 Finally, re-
ductive ring-opening of the lactone in 20 was accomplished using 
NaBH4 to give triol 21, the conversion of which into salinospor-
amide A (1) has already been described by the groups of Corey 12a  
and Pattenden.12d 
Q n 	 OH 
Me CO2Me 	84% 	 Me CO2Me  
15 	 17 
Scheme 4. Completion of the formal synthesis of 3. 
Conclusion 
Largely following the strategy of Corey and co_workers,12a 
a concise formal synthesis of salinosporamide A (3) has been ach-
ieved. The distinguishing feature of the work described herein is 
the use of a sequential nickel-catalyzed reductive aldol cyclization-
lactonization reaction of 8 to construct the y-lactam of 3. Although 
the diastereoselectivity of this transformation remains to be im-
proved, this approach represents an attractive method to install the 
C2 side-chain with simultaneous protection of the CS oxygen, and 
further demonstrates the utility of nickel catalysis in complex 
molecule synthesis.1b4cf  Further applications of our reductive 
aldol cyclization methodology will be reported in due course. 
Experimental section 
4.1. General 
All non-aqueous reactions were carried out under a nitrogen 
atmosphere in oven-dried apparatus. CH2Cl2 and THF were dried 
and purified by passage through activated alumina columns using 
a solvent purification system from www.glasscontoursolventsys-
tems.com. Petrol' refers to that fraction of light petroleum ether 
boiling in the range 40-60 °C. Commercially available CoCl2 was 
dried by heating under vacuum until it turned from purple to blue. 
All other commercially available reagents were used as received. 
Thin layer chromatography (TLC) was performed on Merck DF-
Alufoilien 60F254 0.2 mm precoated plates. Product spots were vi-
sualized by liv light at 254 nm, and subsequently developed using 
potassium permanganate or ceric ammonium molybdate solution 
as appropriate. Flash column chromatography was carried out us-
ing silica gel (Fisher Scientific 60 A particle size 35-70 jim). Melting 
points were recorded on a Gallenkamp melting point apparatus and 
are uncorrected. Infra-red spectra were recorded on a jasco FT/IR-
460 Plus instrument as a thin film on sodium chloride plates or as 
a dilute solution in CHCI3. 1H NMR spectra were recorded on 
a Bruker DPX360 (360 MHz) spectrometer or a Bruker ARX250 
(250 MHz) spectrometer. Chemical shifts (ô) are quoted in parts per 
million (ppm) downfield of tetramethylsilane, using residual pro-
tonated solvent as internal standard (CDCI3 at 7.27 ppm). Abbre-
viations used in the description of resonances are: s (singlet), 
d (doublet), t (triplet), q (quartet), app (apparent) and br (broad). 
Coupling constants (J) are quoted to the nearest 0.1 Hz. Proton-
decoupled 13C NMR spectra were recorded on a Bruker ARX250 
(62.9 MHz) spectrometer. Chemical shifts (ó) are quoted in parts per 
million (ppm) downfield of tetramethylsilane, using deuterated 
solvent as internal standard (CDCI3 at 77.0 ppm). Assignments were 
made using the DEPT sequence with secondary pulses at 90° and 
135°. High resolution mass spectra were recorded on a Finnigan 
MAT 900 XLT spectrometer using the electrospray (ES) positive ion 
mode at the EPSRC National Mass Spectrometry Service Centre, 
University of Wales, Swansea, or on a Finnigan MAT 900 XLI 
spectrometer or a I(ratos MS50TC spectrometer at the School of 
Chemistry, University of Edinburgh. Optical rotations were per-
formed on an Optical Activity POLAAR 20 polarimeter. 
4.1.1. (R)-Methyl 2-benzyloxymethyl-2-(4-methoxybenzylamino)-
3-oxobutcinoate (11) 
To a stirred solution of (COCI)2 (1.67 mL, 18.8 mmol) in CH202 
(40 mL) at -78 °C was added DMSO (2.70 mL, 37.6 mmol) dropwise 
over 3 mm. After stirring for 15 mm, a solution of the alcohol 1012, 
(3.34 g, 8.94 mmol) in CH202 (30 mL) was added via cannula over 
5 mm. The reaction mixture was stirred at -78 °C for I h and Et3N 
(5.23 mL, 37.6 mmol) was then added over I mm. The reaction 
mixture was stirred at -78 °C for I h, allowed to warm to -40°C 
over 2 h, and then quenched with saturated aqueous NH4CI 
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solution (40 mL). The aqueous layer was separated and extracted 
with CH202 (3x20mL) and the combined organic layers were 
dried (MgSO4) and concentrated in vacuo. Purification of the resi-
due by column chromatography (10% EtOAc/petro1-20% EtOAc/ 
petrol) gave the ketone 11 (2.39g, 72%) as a pale yellow solid. 
Rj=0.55 (30% EtOAc/hexane); mp 60-62'C; 	25 -12.7 (c 1.02, 
CHCI3); IR (CHCI3) 3347 (NH), 2952, 2836, 1741 (C=O), 1718 (C=O), 
1511,1245, 1178, 1033, 700 cm- 1 ; 	NMR (250 MHz, CDC13)  ô 7.39- 
7.28 (5H, m, ArH), 7.25 (2H, dm, 1=8.7 Hz, ArH), 6.85 (2H, dm, 
1=8.7 Hz, ArH), 4.59 (IH, d, 1= 12.4 Hz, CH2Ar), 4.53 (1H, d, 
1=12.4Hz, CH2Ar), 4.02 (IH, d,J=10.1 Hz, CH2Ar), 3.90 (1H, d,J= 
10.1 Hz, CH2Ar), 3.80 (3H, s, OCH3), 3.74 (3H, s, OCH3), 3.59 (1H, d, 
1=12.3 Hz, CH2OBn), 3.46 (1 H, d,J=12.3 Hz, CH2013n), 2.53 (1 H, br s, 
NH), 2.21 (3H, s, COCH3 ); 13C NMR (62.9 MHz, CDC13)  ô 203.3 (C), 
169.8 (C), 158.7 (C), 137.6 (C), 131.7 (C), 129.4 (2xCH), 128.4 (2xCH), 
127.8 (3xCH), 113.7 (2xCH), 74.9 (C), 73.5 (CH2 ), 68.1 (CH2), 55.3 
(Cl-I3), 52.7 (CH3), 46.7 (CH2), 25.7 (CH3); HRMS (ES) exact mass 
calcd for C21 H26N05 [M+H]: 372.1805, found: 372.1804. 
4.1.2. (R)-Ethyl (E)-3-fN-( I -benzyloxymethyl- I -carbornethoxy-2-
oxopropyl)-N-(4-methoxybenzyl)corbamoylJacrylate (8) 
To a stirred solution of mono-ethyl fumarate16 (858 mg, 
5.65 mmol) in CH202 (10 mL) at 0°C was added (COCI)2 (0.56 mL, 
6.40 mmol) followed by DMF (one drop). The resulting mixture was 
stirred for I hat room temperature, and then transferred via cannula 
to a solution of the amine 11 (1.33g. 3.60 mmol) and i-Pr2NEt 
(1.10 mL, 6.40 mmol) in CH202 00 mL) at 0 °C. The reaction mixture 
was stirred at 0°C for 10 min and then at room temperature for 18 h, 
when it was quenched with saturated aqueous NH4CI solution 
(20 mL). The aqueous layer was separated and extracted with CH202 
(3x20 mL), and the combined organic layers were dried (MgSO4), 
filtered and concentrated in vacuo. Purification of the residue by 
column chromatography (20% EtOAc/petrol) gave the amide 8 
(1.79 g, >99%) as a pale yellow oil. Rf=0.45 (30% EtOAc/hexane); [a ]25 
-18.2 (c 1.18, CHCI3); IR (film) 2953, 2837,1722 (C=O), 1658 (C=O), 
1513, 1408, 1294, 1248, 1175, 1032, 974, 822 cm 1 ; 1H NMR 
(360 MHz, CDC13)  6 7.35-7.27 (5H, in, ArH), 7.21 (1H, d, J=15.3 Hz, 
=CH), 7.14-7.11 (2H, m, ArH), 6.91 (2H, dm,J=8.8 Hz, ArH), 6.82(1 H, 
d, 1=15.3 Hz, =CH), 4.94 (IH, d, J=18.3 Hz, CH2Ar), 4.79 (1H, d, 
J=18.3 Hz, CH2Ar), 4.31 (IH, d, 1=11.9 Hz, CH2Ar), 4.27 (IH, d, 
1=11.9 Hz, CH2Ar), 4.18 (2H, q,J=7.1 Hz, OCH2CH3), 3.82 (3H, s, OCH3), 
3.80 (3H, s, OCH3), 3.76 (2H, br s, CH2013n), 2.43 (3H, s, CH3C=O), 1.25 
(3H, t,J=7.1 Hz, OCH2CH3); 13C NMR (62.9 MHz, CDC13)  6197.6 (C), 
168.0 (C), 167.5 (C), 165.2 (C), 158.9 (C), 136.5 (C), 133.3 (CH), 133.1 
(CH),129.7(C), 128.4 (2xCH), 127.9 (CH), 127.5 (2xCH), 127.1 (2xCH), 
114.1 (2xCH), 77.5 (C), 73.7 (CH2), 70.1 (CH2), 61.1 (CH2), 55.2 (CH3), 
52.9 (CH3), 48.9 (CH2), 27.9 (CH3), 14.0 (CH3); HRMS (ES) exact mass 
calcd for C27H32N08 [M+H]: 498.2122, found: 498.2123. 
4.1.3. (3aR,6R,6aS)-6-Benzyloxymethyl-5-(4-methoxybenzy!)-6a-
methyl-2,4-dioxohexahydrofuro[2,3-c]pyn-ole-6-carboxylic acid 
methyl ester (15) and (3aS,6R,6aR)-6-benzyloxymethyl-5-(4-
methoxybenzyl)-6a-methyl-2,4-dioxohexahydrofuro[2,3-c]pyrrole-
6-carboxylic acid methyl ester (16) 
A solution of ,13-unsaturated  amide 8(875mg, 1.76 mmol) and 
(Me3P)2NiCl2 (115 mg, 0.175 mmol) in THF (75 mL) was stirred at 
room temperature for 30 min and then cooled to -15 °C (ice/salt 
bath). Et2Zn (3.52 mL, I M solution in THF, 3.52 mmol) was then 
added over 0.5 mm. The reaction mixture was allowed to warm 
slowly to room temperature over 18 h, and then quenched carefully 
with saturated aqueous NH4C1 solution (50 mL) and extracted with 
EtOAc (3 x30 mL). The combined organic layers were dried (Mg504) 
and concentrated in vacuo. Purification of the residue by column 
chromatography (20% EtOAc/petrol-35% EtOAc/petrol) gave the 
double cyclization product 15 (354 mg, 42%) as a pale yellow oil, 
followed by the double cyclization product 16 (253 mg, 30%) as  
a white solid. Recrystallization of 16 from EtOAc/petrol gave col-
orless blocks that were suitable for X-ray crystallography. 
Data for IS: Rj=0.19 (30% EtOAc/CHCI3); [c] 5 -33.3 (c 1.02, 
CHCI3); IR (film) 2955, 1789 (C=O), 1733 (C=O), 1699 (C=O), 1612, 
1513, 1439, 1404, 1248, 1178, 1129, 736 cm- 1 ; 1H NMR (250 MHz, 
CDC13) 6 7.35-7.25 (5H, m, ArH), 7.12-7.08 (2H, m, ArH), 6.60 (2H, 
dm, J=8.7 Hz, ArH), 5.05 (1 H, d, 1=15.2 Hz, CH2Ar), 4.28 (1 H, d, 
1=15.2 Hz, CH2Ar), 3.91 (1 H, d, 1=11.5 Hz, CH20), 3.83 (1 H, d, 
1=10.4 Hz, CH20), 3.81 (1 H, d,J=11.5 Hz, CH20), 3.81 (3H, s, OCH3), 
3.74(3H, s, OCH3), 3.21 (I H, d,J=10.4 Hz, CH20), 3.05(IH, dd,J=9.3, 
1.5 Hz, CH2CH), 2.96 (1 H, dd, J=18.3, 1.5 Hz, CH2CH), 2.79 (1H, dd, 
1=18.3, 9.3 Hz, CH2CH), 1.61 (3H, s, CH3CO); 13C NMR (62.9 MHz, 
CDC13) 6173.5 (C), 172.9 (C), 166.9 (C), 158.9 (C), 136.7 (C), 130.0 
(2xCH), 129.4 (C), 128.5 (2xCH), 127.9 (CH), 127.3 (2xCH), 113.6 
(2xCH), 88.5 (C), 75.8 (C), 72.8 (Cl-I2), 67.7 (CH2), 55.2 (CH3), 52.8 
(CH3), 47.5 (CH), 45.1 (CH2), 30.7 (CH2), 19.4 (CH3); HRMS (ES) exact 
mass calcd for C25H28N07 [M+H]: 454.1860, found: 454.1856. 
Data for 16: Rj=0.08 (30% EtOAc/CHCI3); mp 105-106°C; [x] 5  
-17.9 (c 1.01, CHCI3); IR (film) 2952, 2870,1789 (C=O), 1743 (C=O), 
1703 (C=O), 1613, 1512, 1434, 1246, 1128, 739cm 1 ; 1 H NMR 
(250 MHz, CDC13) 6 7.34-7.28 (3H, m, ArH), 7.22-7.19 (2H, iii, ArH), 
7.09 (2H, dm,J=8.8 Hz, ArH), 6.78 (2H, d,J=8.8 Hz, ArH), 4.68 (1 H, d, 
1=15.2 Hz, CH2Ar), 4.37 (1 H, d, J=15.2 Hz, CH2Ar), 4.30 (1 H, d, J= 
11.7 Hz, CH2Ar), 4.23 (1 H, d, 1=11.7 Hz, CH2Ar), 3.90 (1H, d, 
1=10.2 Hz, CH2013n), 3.78 (3H, s, OC143), 3.71 (1H, d, 1=10.2 Hz, 
CH2013n), 3.64 (3H, s, OCH3), 3.03 (1 H, dd, J=9.7, 1.9 Hz, CH2CH), 
3.00 (1H, dd, J=18.3, 1.9 Hz, CH2CH), 2.84 (1H, dd, J=18.3, 9.7 Hz, 
CH2CH), 1.47 (3H, s, CH3CO); 13C NMR (62.9 MHz, CDC13)  6173.4 (C), 
173.2 (C), 169.2 (C), 158.7 (C), 137.1 (C), 129.2 (2xCH), 129.0 (C), 
128.3 (2xCH), 127.7 (3xCH), 113.6 (2xCH), 86.6 (C), 75.3 (C). 73.6 
(Cl-I2), 68.7 (CH2), 55.2 (CH3), 52.8 (CH3), 46.9 (CH), 45.1 (CH2), 30.9 
(CH2), 21.8 (CH3); HRMS (ES) exact mass calcd for C25H28N07 
[M-FH1: 454.1860, found: 454.1858. 
4.1.4. (3aR,6R,6aS)-6-Hydroxymethyl-5-(4-methoxybenzyl)-6a- 
methyl-2,4-dioxohexahydrofuro[2,3-c]pyrrole-6-carboxylic acid 
methyl ester (17) 
A mixture of benzyl ether 15(354mg, 0.78 mmol) and 10% Pd/C 
(99 mg, 0.093 mmol) in EtOH (5 mL) at room temperature was 
evacuated and flushed with H2 (three times) and then stirred vig-
orously under an atmosphere of H2 (1 atm, H2 balloon) at room 
temperature for 18 h. The reaction mixture was filtered through 
Celite and concentrated in vacuo. Purification of the residue by 
column chromatography (50% EtOAc/petrol) gave the alcohol 17 
(240 mg, 84%) as a white powder. Recrystallization of 17 from 
CH2Cl2/Et20 gave colorless blocks that were suitable for X-ray 
crystallography. Rj=0.52 (100% EtOAc); mp 144-146 C; [] -30.1 
(c 0.95, CHCI3); IR (CHC13) 3437 (OH), 2955, 2837, 2253, 1787 
(C=O), 1757 (C=O), 1692 (C=O), 1613, 1513, 1247, 1035. 951, 914, 
731 cm-1 ; 1H NMR (250 MHz, CDC13) 67.37 (2H, dm,J=8.6 Hz, ArH), 
6.87 (2H, dm, 1=8.6 Hz, ArH), 5.22 (1 H, d, 1=15.2 Hz, NC142), 4.24 
(IH, d,J=15.2 Hz, NCH2), 3.95 (1H, dd,J=13.0, 8.9 Hz, CH20H), 3.83 
(3H, s, OC143), 3.80 (3H, s, OCH3), 3.43 (IH, dd, 1=13.0, 5.5 Hz, 
CH20H), 3.04 (1H, dd, J-9.1, 1.7 Hz, CH2CH), 2.96 (1 H, dd, J=18.1, 
1.7 Hz, CH2CH), 2.85 (1 H, dd, 1=18.1, 9.1 Hz, CH2CH), 1.69 (3H, s, 
CH3CO); 13C NMR (62.9 MHz, CDC13)  6173.7 (C), 172.7 (C), 167.1 (C), 
159.5 (C), 129.6 (2xCH and C), 114.6 (2xCH), 88.3 (C), 77.3 (C), 60.9 
(CH2), 55.3 (CH3), 52.8 (CH3), 47.6 (CH), 44.9 (CH2), 30.5 (CH2), 19.8 
(CH3); HRMS (ES) exact mass calcd for C18l-125N207 [M+NH4]: 
381.1656, found: 381.1660. 
4.1.5. (3aR,6R,6aS)-6-Formyl-5-(4-methoxybenzy!)-6a-methyl-
2,4-dioxohexahydrofiiro[2,3-c]pyrrole-6-carboxylic acid methyl 
ester (18) 
To a solution of the alcohol 17 (30 mg, 0.082 mmol) in CH2Cl2 
(0.8 mL) at room temperature was added Dess-Martin periodinane 
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(43 mg, 0.099 mmol). The reaction mixture was stirred for 1.5 h, 
quenched with 1-120 (5 mL) and extracted with EtOAc (3x10 mL). 
The combined organic layers were dried (Na2SO4) and concentrated 
in vacuo to leave the aldehyde 18 as a pale yellow oil. This aldehyde 
was not very stable and was generally used immediately in the next 
step without purification. On one occasion, purification of a small 
amount of crude product by column chromatography (50% EtOAc/ 
petrol) was performed for characterization purposes. Rj-=0.34 (100% 
EtOAc); IR (CHC13) 2956, 1788 (C=O), 1760 (C=O), 1728 (C=O), 
1687 (C=O), 1513, 1438, 1246, 1176, 949 cm 1 ; 1H NMR (250 MHz, 
CDCI3) 5 9.47 (1 H, s, Cl-JO), 7.05 (2H, dm, J=8.7 Hz, ArH), 6.81 (2H, 
dm, J=8.7 Hz, ArH), 4.86 (1 H, d, 1=14.4 Hz, NCH2), 4.39 (1H, d, 
J=14.4 Hz, NCH2), 3.90 (3H, s, OCH3), 3.78 (3H, s, OCH3), 3.08 (1H, 
dd,J=9.7, 1.8 Hz, CH2CH), 2.99 (1 H, dd,J=18.4, 1.8 Hz, CH2CH), 2.85 
(11-1, dd, J=18.4, 9.7 Hz, CH2CH), 1.52 (3H, s, CH3CO); 13C NMR 
(62.9 MHz, CDCI3) 5195.5 (CH), 172.7 (C), 172.0 (C), 165.7 (C), 159.6 
(C), 131.1 (2xCH), 126.8 (C), 114.2 (2xCH), 87.3 (C), 79.0 (C), 55.2 
(CH3), 53.4 (CH), 46.8 (CH), 45.6 (CH2), 30.7 (CH2), 20.5 (CH3); 
LRMS (ES) 384 [M+Na]. 
4.1.6. (3aR,6R,6aS)-6-[(S)- ((S)-Cyclohex-2-eriy)hydroxymethylj-5-
(4-methoxybenzyl)-6a-methyl-2,4-dioxohexahydrofuro [2,3- 
c]pyrrole-6-carboxylic acid methyl ester (20) 
To a solution of cyclohexenyltributyltin (19)20  (ca. 85% pure by 
1H NMR analysis, 90 mg, 0.21 mmol) in THF (0.6 mL) at -78 °C was 
added ri-BuLi (130 iL, 1.6 M solution in hexanes, 0.21 mmol). After 
stirring at -78 °C for 1 h, ZnCl2 (420 iL, 0.5 M solution in THF, 
0.21 mmol) was added and stirring was continued at this temper-
ature for another I h. A solution of the unpurified aldehyde 18 from 
the above experiment (theoretically 0.082 mmol) in THF (0.4 mL) 
was then added via cannula, and after stirring for 3 h at -78 °C, the 
reaction was quenched with H20 (5 mL) and extracted with EtOAc 
(3x5 mL). The combined organic layers were dried (MgSO4) and 
concentrated in vacuo, and purification of the residue by column 
chromatography (50% EtOAc/petrol) gave the homoallylic alcohol 20 
(22.4 mg, 61% over two steps) as a white solid. Recrystallization 
from 20 from a mixture of EtOAc/hexane and acetone (a few drops) 
gave colorless needles that were suitable for X-ray diffraction. 
Rj=0.61 (100% EtOAc); mp 114-116'C; [c] 5 +3.0 (c 1.47, CHC13);  IR 
(CHC13) 3438 (OH), 2931, 2359, 1790 (C==O), 1755 (C==O), 1687 
(C=O), 1512,1440,1246,1175, 807 cm 1 ; 1H NMR (360 MHz, CDCI3) 
57.19 (2H, dm, J=8.7Hz, ArH), 6.84 (2H, dm, 1=8.7 Hz, ArH), 5.92 
(IH, dm,J=10.3 Hz, =CH), 5.68 (IH, dm,J= 10.3 Hz, =CH), 4.80 (1H, 
d, J=14.9 Hz, NCH2), 4.54 (1H, d, J=14.9 Hz, NCH2), 4.13 (1 H, t, 
J=7.1 Hz, CHOH), 3.78 (6H, s, 2xOCH3), 3.13 (1H, dd, J=6.8, 3.3 Hz, 
C1-I2CHC=O), 2.92 (IH, br s, OH), 2.82-2.80 (2H, m, CH2CHC=O), 
2.32 (1H, br s, CHCHOH), 2.02 (2H, br s, (CH2)3), 1.81 (3H, s, CH3CO), 
1.76-1.66 (2H, m, (CH2)3), 1.57-1.46 (IH, m, (CH2)3), 1.44-1.33 (IH, 
M, (CH2)3 ); 13C NMR (62.9 MHz, CDCI3) 5174.8 (C), 173.0 (C), 167.8 
(C), 158.3 (C), 131.8 (CH), 129.3 (C), 127.6 (2xCH), 125.2 (CH), 113.7 
(2xCH), 91.1 (C), 79.0 (C), 76.9 (CH), 55.2 (CH3), 52.4 (CH3), 47.9 
(CH2), 47.8 (CH), 38.3 (CH), 30.9 (CH2), 27.0 (CH2), 24.9 (CH2), 20.6 
(CH2), 19.6 (CH3); HRMS (ES) exact mass calcd for C24H33N207 
[M+NH4]: 461.2282, found: 461.2283. 
4.1.7. (2R,3S,4R)-2-[(S)-((S)-Cyclohex-2-enyl)hydroxymethyl]-3-
hydraxy-4-(2-hydroxyethyl)- 1 -(4-methoxyberizyl)-3-methyl-5-
oxopyrrolidine-2-carboxylic acid methyl ester (21 )12, 
To a solution of the lactorie 20 (19.3 mg, 0.043 mmol) in MeOH 
(0.6 mL) at room temperature was added NaBH4 (75 mg, 2.0 mmol) 
portionwise over 2 mm. The solution was stirred for 18 h, quenched 
with 1-120(4 mL) and extracted with EtOAc (3 x4 mL). The combined 
organic layers were dried (Na2SO4) and concentrated in vacuo. 
Purification of the residue by column chromatography (70% EtOAc/ 
petrol) gave the trio! 21 (11.7 mg, 60%) as a white foam. Rj=0.12 
(70% EtOAc/CHCI3); mp 83-84°C; [ct1 +3.5 (c 0.565, CHC13); IR  
(CHC13) 3331 (OH), 2925, 2853, 1752 (C=O), 1670 (C=O), 1512, 
1441, 1245, 1175, 1034, 801 cm 1; 1H NMR (250 MHz, CDCI3) 5 7.30 
(2H, dm, 1=8.8 Hz, ArH), 6.85 (2H, dm, 1=8.8 Hz, ArH), 5.97-5.91 
(1H, m, =CH), 5.65-5.60 (11-1, m, =CH), 4.77 (IH, d, 1=15.2 Hz, 
NCH2), 4.58 (1H, d, J=15.2 Hz, NCH2), 4.15 (IH, app t, J=6.3 Hz, 
CHOH), 3.87-3.81 (11-1, m, CH20H), 3.80-3.75 (1 H, m, CH20H), 3.79 
(3H, s, OCH3 ), 3.71 (3H, s, OCH3), 3.02 (1H, dd, 1=8.1, 4.8 Hz, 
CHC=O), 2.20 (IH, br s, CHCHOH), 2.01 (21-1, br s, (CH2)3 and/or 
CH2CH2OH), 1.93-1.78 (2H, m, (CH2)3 and/or CH2CH2OH), 1.76-1.65 
(4H, m, (CH2)3  and/or CH2CH20H), 1.64 (31-1, s, CH3CO), 1.54-1.41 
(2H, m, (CH2)3 and/or CH2CH2OH); 13C NMR (62.9 MHz, CDCI3) 
5178.5 (C), 169.7 (C), 158.2 (C), 132.9 (CH), 130.2 (C), 128.0 (2xCH), 
124.8 (CH), 113.7 (2xCH), 81.8 (C), 80.6 (C), 77.2 (CH), 61.7 (CH2), 
55.2 (CH3), 51.9 (CH), 51.3 (CH3), 47.8 (CH2 ), 38.6 (CH), 28.2 (CH2), 
26.8 (CH2), 25.0 (CH2), 21.2 (CH3), 20.6 (CH2); HRMS (ES) exact mass 
calcd for C24H33NO7Na [M+Na]: 470.2149, found: 470.2150. 
Interestingly, the NMR data we obtained for triol 21 (recorded 
above) displayed subtle but appreciable differences to those 
reported by Corey and co-workers for the same compound '12a  most 
notably in the 13C NMR chemical shifts. However, we have also 
obtained from Pattenden and co-workers copies of the NMR 
spectra for the same compound that was prepared in their total 
synthesis of salinosporamide A, 12d  and our 13C NMR data are a good 
match for theirs ('3C NMR spectrum supplied by Pattenden in 
Supplementary data). The most likely explanation for this obser-
vation is that the values of the 13C NMR chemical shifts for triol 21 
are concentration-dependent; both our and the Pattenden group's 
13C NMR spectra were run at relatively low concentration, whereas 
the Corey group's 13C NMR spectrum was run at relatively high 
concentration. Due to limited quantities of trio! 21, we were unable 
to verify this hypothesis. 
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The 14-addition of a nucleophile to an alkene conjugated to an electron-
withdrawing group is a fundamental reaction in organic chemistry, and 
numerous catalytic asymmetric variants (eq 1) of this process are now 
routinely employed in the synthesis of molecules of interest.' .2 The most 
common functional groups used to activate alkenes toward asymmetric 
conjugate additions include carbonyls, nitriles, sulfones, phosphonates, and 
nitro groups. We recently questioned whether other rarely considered yet 
common functional groups might also be employed in this capacity, and 
our attention focused on nitrogen-containing aromatic heterocycles. Given 
that heteroarenes such as oxazoles, thiazoles, pyridines, and others are 
ubiquitous in biologically active natural products, pharmaceuticals, and 
agrochemicals, the ability to functionalize these privileged structures 
through a diverse set of asymmetric conjugate additions of 2-alkenyl 
derivatives (eq 2) would open up broad-ranging applications. 
Catalytic asymmetric conjugate additions: 
R1 	 R' Nu 
EWGL2 
Nu EWG = COR, CN, S02R (1) 
catalyst 	 PO(OR)2, NO2 
Aromatic heterocycles as substrates? 





Although conjugate additions to 2-vinylheteroarenes (R', R2 = H in 
eq 2) are relatively common ,3 the corresponding reactions of substrates 
containing af3-substituent are much rarer, presumably for steric reasons.' 
Furthermore, the only report of a catalytic enantioselective variant is limited 
to poorly selective (:515% ee) Grignard additions to 4-alkenylpyridines.5  
Therefore, we recently initiated a program targeted at addressing these 
deficiencies, and in this communication, our preliminary findings involving 
highly enantioselective copper-catalyzed reductions6 of3,fi'-disubstituted 
2-alkenylheteroarenes are presented. 
The asymmetric copper-catalyzed conjugate reduction of activated 
alkenes is a well-established method for the synthesis of various useful 
chiral building blocks .6-10  Whether a nitrogen-containing heteroarene 
would provide sufficient activation to an adjacent alkene in an analogous 
reaction was, however, uncertain. In addition, it seemed likely that 
coordination of the Lewis basic nitrogen of the heteroarene to the copper 
catalyst would occur in such a process, and whether this interaction would 
be beneficial, inconsequential, or detrimental was not easy to predict. 
Our investigations began with a survey of chiral hisphosphines L1—L6 
using 2-alkenylbenzoxazole la as a test substrate (Table 1). Using 10 mol 
% of Cu(OAc)2 •H20, 10 mol % of ligand, and 4 equiv each of PhSiH3 
and t-BuOH in toluene at room temperature, biaryl-based ligands Li—IA 
proved competent in promoting conjugate reduction.'' With (R)-BINAP 
(Li), both conversion and enantioselectivity were only moderate. However, 
improved results were observed using (R)-MeO-BIPI-IEP (L2) and the 
Table 1. Ligand Optimization for the Asymmetric Reduction of laa 
\ 	
bisphosphine (10 mol %) 
/ 	N 	Me 	Cu(OAc)2 H20 (10 mol%) 
PhS1H3 (4 equiv) 
	
la 	 t-BuOH (4 equiv) 	 2a toluene, rt, 18h 
<0D 







(R)-BINAP (LI) 	(R)-MeO-BIPHEP (U) (S)-SEGPHOS (11.3) 
80% conversion, 70% ee 88% conversion, 86°/s ee 98% conversion, -91% ee 
Me 	 Me 
0PAr2 	
—4uH 
o 	, 	PAr2 	Fe PPh2 Pcy2 	Fe PPh2 P(t-Bu)2 
Ar = 3,54-Bu-4-MeOC6 1-12 (R,S)-PPF-PCy2 (11-5) 	(R,S)-PPF-Pt-Bu2 (L6) 
(S)-DTBM-SEGPHOS (IA) >99% conversion, 89% eeb  95% conversion, 87% ee 
>99% conversion, -80% ee5  
' Reactions were conducted using 0.20 nimol of la in toluene (I mL). 
Conversions were determined by CC analysis. Enantioseleclivities were 
determined by chiral HPLC analysis. Reactions complete after 2 h. 
SEGPHOS ligands L3 and IA, with 91% ee obtained using (S)-SEGPHOS 
(L3). The Josiphos ligands L5 and L6 were also effective, providing 2a 
in 89% and 87% ee, respectively. Of all the ligands, the highest reaction 
rates were observed with [A and L5 (reactions were complete in 2 h). 
However, the superior selectivity provided by L5 prompted us to select 
this ligand for further optimization and investigation of the reaction scope. 
Using 5 mol % each of Cu(OAc)2 H7O and L5, PhSiH3 (1.5 equiv), 
and t-BuOH (2.0 equiv) at an initial temperature of 0 °C, a range of,8.3'-
disubstituted 2-alkenylheteroarenes underwent conjugate reduction with 
generally excellent levels of enantioselection (Table 2)." In addition to 
benzoxazole (entries 1-4), other effective nitrogen-containing hetero-
arenes in this process included 5-phenyloxazole (entry 5), benzothiazole 
(entry 6), pyridine (entries 7-9), quinoline (entry 10), and pyrazine (entry 
11). Tolerated functionality at the 3-positions of the alkene included simple 
aliphatic groups, a phenyl group (entry 4), a benzyl group (entry 9), various 
oxygenated alkyl groups (entries 2, 3, 7-9, and 11), and a cyclopropane 
(entry 10). The process is tolerant of lower loadings of copper and ligand. 
For example, reduction of ig on a 1.0 mrnol scale using 2 mol % each of 
Cu(OA02 H20 and L5 provided 2g in 92% yield and 96% ee (entry 7, 
values in parentheses). 
Experiments to explore the origins of reactivity were then conducted. 
Reduction of 4-alkenylpyrid.ine 3 provided 4 in 60% yield and 94% ee, 
albeit in a slower reaction that was incomplete even after 4 days (eq 3). 
This result suggests that alkene reduction by copper hydride can occur 
without assistance of a directing effect from the nitrogen atom. In contrast, 
10386. J. AM. CHEM. SOC. 2009, 131, 10386-10387 	 10.1021/ja904365h CCC: $40.75 © 2009 American Chemical Society 
Table 2. Scope of Cu-Catalyzed Asymmetric Conjugate 
Reductiona 
'N 	R1 / _N ' 
L5 (5 mol %) 
Cu(OAc)2 H20 (5 mol %) 
PhSiH3  (1.5equiv) XR2 
la-Ilk t-BuOH (2.0 equiv) 
















N 	 Me 
11 	
f-oTBs N  
2a 90 93 
2b 67 94 
2c 88 95 
2d 95 87 
2e 93 90 
2f 86 95 
2g 90 (92)' >99 (96)' 
2h 81 98 
2i 90 97 
2j 90 96 
2k 89 96 
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"Reactions were conducted using 0.20 mmol of la-1k unless 
otherwise stated. "Isolated yield. Determined by chiral HPLC analysis. 
"Using 0.155 mmol of Id. 'Values in parentheses refer to a reaction 
conducted using 1.0 mmol of lg, 2 mol % Cu, and 2 mol % L5. 'Using 0.10 
mmol of lh and 2.0 equiv of PhSiH3. 
3-alkenylpyridine 5 was unreactive (eq 4), demonstrating the importance 
of conjugation of the alkene to a C=N moiety for reactivity. 
L5(5 mol %) A% 	 OTBS (3) I- 
Cu(OAc)2 H20 (5 mol%)I 4, 94% ee, 60%, 4 d 
me 	 t-BuOH (2.0 equiv)I 
PhSiH3 (1.5 equiv) i  
BS 	toluene, 0 'C to it 	i-i.'- 	No reaction 	(4) 
5 
In summary, copper-catalyzed asymmetric conjugate reductions of
disubstituted 2-alkenytheteroarenes are reported. In addition to serving as 
a further demonstration of the power of chiral copper hydride catalysis,6 
this work has shown nitrogen-containing aromatic heterocycles can provide 
effective activation of an adjacent alkene for highly enantioselective 
catalytic conjugate addition reactions. Extension of the general concept 
to other classes of asymmetric reactions should provide a range of useful 
tools for chemists working with heteroarenes. Future studies from our 
laboratory will be directed toward this goal. 
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